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Chronic obstructive pulmonary disease (COPD) is currently ranked as the fourth leading 
cause of death in the world, and is expected to be the third in 2020 (Mannino and Kiriz 2006). 
The disease is characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced chronic inflammatory response of the lungs and the airways 
to noxious particles or gases (GOLD 2015). Currently, none of the existing medications used 
to treat COPD have been shown to improve the long-term decline of lung function. Thus, 
COPD still represents a public health challenge with the urge for disease prevention and 
novel treatment options (GOLD 2015). 
A Brief History of COPD
More than 300 years ago, the symptoms of COPD have first been noticed and recorded by 
physicians and various names have been used for their description (Petty 2006). In 1679, 
the Swiss physician Bonet referred to COPD as ‘voluminous lungs’ (Bonet 1679). In 1769, the 
Italian anatomist Giovanni Morgagni reported 19 cases of ‘turgid’ lungs (Morgagni 1769). 
During the 19th century, the British physician Charles Badham described bronchiolitis and 
chronic bronchitis as disabling disorders (Badham 1814), and the French physician René 
Laennec added emphysema as a component of COPD (Laennec 1829). However, it was not 
before 1959, during a gathering of medical professionals during the Ciba Guest Symposium, 
that the definition and diagnosis of COPD as we know it today was defined (Fletcher et 
al. 1959), whereas the term COPD was first used in 1965 by Dr. William Briscoe during the 
9th Aspen Emphysema Conference (Briscoe and Nash 1965). Eleven years later, Dr. Charles 
Fletcher and his colleagues noticed that stopping tobacco smoking could help to slow 
down the progression of COPD, linking smoking to the development of COPD (Fletcher et 
al. 1977). Today, exposure to tobacco smoke is recognized as one of the leading risk factors 
for COPD.
Pathophysiology of COPD 
COPD is characterized by chronic inflammation and structural changes of particularly the 
small airways and the lung parenchyma, which may underlie the progressive and irreversible 
airflow limitation. The inflammation is caused by infiltration of different inflammatory cells, 
particularly neutrophils and macrophages, into the lung, that may be involved in the 
development of emphysema and airway remodeling (O’Donnell et al. 2006). Pulmonary 
emphysema is the destruction of alveolar tissue. This may cause reduced oxygen uptake 
and loss of elastic recoil due to a reduced number of alveolar attachments. The loss of 
tethering results in collapse of the small airways, leading to airflow limitation and reduced 
gas exchange (McDonough et al. 2011). Emphysema is importantly attributed to increased 
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activity of proteolytic enzymes released by inflammatory cells (McDonough et al. 2011). 
Next to emphysema, airway remodeling is another important structural feature of COPD. 
Airway remodeling in COPD is characterized by peribronchial fibrosis and increased airway 
smooth muscle mass, thickening the airway wall, as well as mucus gland hypertrophy and 
goblet cell hyperplasia that are involved in mucus hypersecretion in these patients (Burgel 
and Martin 2010). Since the topic of tissue remodelling in COPD is not the main focus of 
this thesis, we refer the reader to excellent recent reviews on this particular topic (Postma 
and Timens 2006; Salazar and Herrera 2011; Chilosi et al. 2012; Dournes and Laurent 2012; 
Portillo and Morera 2012; Hirota and Martin 2013; Bidan et al. 2015). 
Clinical diagnosis of COPD is vital, and should be considered for any patient who has COPD 
symptoms or a history of exposure to risk factors such as cigarette smoke (GOLD 2015). The 
most common diagnosis is spirometry. Spirometry is a test of pulmonary function which 
measures the forced expiratory volume in one second (FEV
1
) and the forced vital capacity 
(FVC). The FEV
1
 represents the volume of air that can be maximally breathed out in the first 
second of a breath, and FVC represents the volume of air that can be maximally breathed 
out in a single large breath (Kormos and Chick 2010). COPD is defined by a ratio of FEV
1
/
FVC < 0.7. The severity of COPD is divided in four different stages according to the FEV1 as 
% predicted (GOLD 2015). According to the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), stage 1 or mild COPD is defined by an FEV1 > 80%, stage 2 or moderate COPD 
by an FEV
1
 of 50-80%, stage 3 or severe COPD by an FEV
1
 of 30-50% and very severe COPD by 
an FEV
1
 < 30% (GOLD 2015). While FEV
1
 and FVC have generally been accepted as the most 
important lung function parameters for the diagnosis of COPD, airway hyperresponsiveness 
(AHR) is also present in many of the patients (Tashkin et al. 1996; Postma and Kerstjens 1998; 
van den Berge et al. 2012). AHR is a common feature of asthma, another obstructive lung 
disease, and defined by an exaggerated obstructive response of the airways to a variety of 
pharmacological, chemical and physical stimuli, including histamine, methacholine, AMP, 
sulphur dioxide, fog and cold air (Hargreave et al. 1985; Postma and Kerstjens 1998; Meurs 
et al. 2008). In COPD, AHR represents an important characteristic, and is well described in 
an epidemiological and clinical context with rather consistent results (Vestbo and Hansen 
2001; Hansen and Vestbo 2005; Scichilone et al. 2006; van den Berge et al. 2012). It has 
been reported that the AHR is associated with an accelerated decline in FEV
1
 (Campbell 
et al. 1985; Postma et al. 1986; Tashkin et al. 1996), and could even be an independent 
predictor of mortality in COPD patients (Hospers et al. 2000). Moreover, there is a strong 
association between accumulation of lung neutrophils and AHR (van den Berge et al. 2012). 
Increases in the production of reactive oxygen species (ROS) and a number of potent pro-
inflammatory cytokines are associated with its development (Postma et al. 1988; Chung 
2001). Glucocorticosteroids are a class of corticosteroids, which can reduce inflammation via 




are used to treat diseases associated with inflammation such as asthma (Rhen and Cidlowski 
2005). However, the majority of COPD patients show resistance to even high doses of inhaled 
glucocorticosteroids, indicating steroid resistance of the underlying inflammatory response 
(Barnes 2013). Inhaled glucocorticosteroids appear only to be effective in a subgroup of 
COPD patients with frequent exacerbations (GOLD 2015). Oxidative stress is an important 
cause of glucocorticosteroids resistance in COPD, as ROS can reduce the activity of histone 
deacetylase, therefore leading to imbalance of acetylation-deacetylation states of histones 
(Adenuga and Rahman 2007; Marwick et al. 2007; Barnes 2013). 
Airway smooth muscle in COPD
ASM plays a critical role in obstructive pulmonary diseases such as COPD, and is 
therefore believed to represent a suitable therapeutic target. Indeed, the most effective 
pharmacological strategy to improve the FEV
1
 of COPD patients is represented by a change 
in ASM tone by bronchodilators, such as β
2
-agonists and anticholinergics (GOLD 2015). The 
contraction of ASM is mediated by G-protein coupled receptors (GPCRs) (Billington and 
Penn 2003). GPCRs are the largest family of cell surface receptors, structurally characterized 
by seven transmembrane peptide chains (Kobilka 2007). Agonist binding induces a 
conformational change and subsequently dissociation of the G
α
 subunit from the G
βγ
 











(Kobilka 2007). In ASM cells, activation of bronchodilating 
GPCRs that couple to G
αs




-adrenoreceptors, leads to an increase of intracellular 
cAMP and activation of PKA, thereby causing an inhibitory phosphorylation of myosin 
light chain (MLC) kinase and a subsequent reduction in myosin phosphorylation. This 
will eventually reduce the interaction between actin and myosin filaments and results in 
bronchodilation (Montuschi et al. 2014). Recent studies demonstrate that Epac also reduces 
MLC phosphorylation, a process involving the small GTPases Rac, and induces relaxation of 
pre-contracted ASM (Roscioni et al. 2011b). In contrast, activation of bronchoconstrictive 
GPCRs that couple to G
αq
, such as histamine H1 receptors or muscarinic acetylcholine 
(M
3
) receptors, cause an increase in intracellular calcium and thereby increase myosin 
phosphorylation, which triggers ASM contraction and bronchoconstriction (Montuschi et 
al. 2014). 
Bronchodilators are widely used in the treatment of airflow limitation in COPD, reducing 
airflow obstruction and dynamic hyperinflation, and improving exercise performance (GOLD 
2015). By reducing airway smooth muscle (ASM) tone, bronchodilators can significantly 
improve FEV
1





-agonists) and anticholinergics, as well as combinations thereof, are commonly used 
as bronchodilators that provide effective symptomatic relief (Cazzola et al. 2011). While 
anticholinergics relax ASM by antagonism of M
3





-agonists exert their function upon interaction with and activation of the β
2
-












-proteins that subsequently activate 
adenylyl cyclases, which catalyze the conversion of adenosine triphosphate (ATP) into 
bioactive cyclic adenosine monophosphate (cAMP). The second messenger cAMP in turn 
activates protein kinase A (PKA), exchange protein directly activated by cAMP (Epac) and 
certain ion channels (Grandoch et al. 2010; Dekkers et al. 2013; Schmidt et al. 2013). cAMP 
signaling is terminated by phosphodiesterase (PDEs), which degrade cAMP into inactive 
5’AMP (Taskén and Aandahl 2004). Several intracellular proteins are phosphorylated by the 
cAMP-dependent PKA, leading to several therapeutic effects including the relaxation of ASM 
(Billington et al. 2013) (see also below), increased mucociliary clearance (Hasani et al. 2005), 
antagonism of pro-inflammatory transcription factors (such as NF-κB) (Oldenburger et al. 
2012) and induction of synthesis of the anti-inflammatory cytokines (such as interleukin 
(IL)-10) (Theron et al. 2013). 
Although β
2
-agonists, next to anticholinergics, are widely used in COPD patients as 
bronchodilators, they possess several undesirable side effects. Repeated and prolonged 
treatment of β
2
-agonists can cause desensitization of the β
2
-adrenoceptor, which is believed 
to be one of the main mechanisms of β
2
-agonists tolerance (Broadley 2006). Another 
side effects of β
2
-agonists is caused by activation of β-adrenoceptors in extrapulmonary 
peripheral organs, leading to muscular tremor or tachycardia (Broadley 2006; Montuschi et 
al. 2014). Therefore, for patients suffering cardiovascular diseases, β
2
-agonists always need 
to be administered with caution (Montuschi et al. 2014). 
Airway epithelium in COPD
The airway epithelium is a tight structural cell barrier that acts as a first line of defense against 
inhaled foreign materials. However, exposure to cigarette smoke reduces the epithelial 
barrier function (Oldenburger et al. 2014). In addition, airway epithelial cells are also actively 
involved in the development of COPD. Airway epithelial cells are one of the major sources of 
inflammatory and fibrotic mediators, such as tumor necrosis factor α (TNF-α), transforming 
growth factor-β (TGF-β), IL-8 and matrix metalloproteinases (MMPs), therefore contributing 
to small airways inflammation and fibrosis (Mio et al. 1997; Takizawa et al. 2001; Hellermann 
et al. 2002; Barnes 2009). Goblet cells, a special type of epithelial cells, produce excessive 
mucus in the presence of cigarette smoke, and are thereby believed to contribute to airflow 
limitation in COPD (Shao et al. 2004). Moreover, cigarette smoke induces cycles of injury and 
repair in the epithelium, leading to increase in epithelial permeability and a loss of epithelial 
barrier properties, which is another important feature of COPD (Puchelle et al. 2006; Olivera 




Inflammatory cells in COPD
As mentioned before, the pathophysiology of COPD involves several types of inflammatory 
cells, including macrophages, neutrophils and T-lymphocytes known to produce multiple 
inflammatory mediators (Barnes et al. 2003; Barnes 2004). Macrophages play a pivotal role 
in the pathophysiology of COPD (Barnes 2004). Thus, exposure to cigarette smoke or other 
inhaled irritants activates macrophages that orchestrate the inflammatory process in COPD 
upon secretion of IL-8, leukotriene (LT) B
4
 and proteolytic enzymes (especially MMP-9, MMP-
12) (Angelis et al. 2014). IL-8 and LTB
4
 attract neutrophils to the respiratory tract and lead 
to further airway inflammation (Barnes 2004). Release of MMPs causes elastolysis and thus 
contributes to the development of pulmonary emphysema (Barnes 2004). 
Neutrophilic inflammation is a prominent feature of COPD. Neutrophils are recognized as a 
first line of defense against microbial invasion (Amulic et al. 2012) and the most abundant 
inflammatory cell type present in the airways and lung parenchyma of COPD patients (Pesci 
et al. 1998; Pilette et al. 2007). Cigarette smoke and other pathogens trigger the release 
of IL-8 from various cells as mentioned above, promoting the recruitment of neutrophils. 
Degranulation of neutrophils leads to the release of mediators including neutrophil elastase 
and MMP-9, both implicated in tissue damage and emphysema in COPD (Owen 2008). 
Inhaled irritants (such as cigarette smoke and air pollutants) create further pro-inflammatory 
signals by inducing secondary necrosis through impairing the removal of apoptotic 
neutrophils (Hoenderdos and Condliffe 2013). Moreover, in addition to macrophages, 
neutrophils are one of the main sources of ROS produced during the development and 
progression of COPD (Noguera et al. 2001; Vaitkus et al. 2013). 
Besides macrophages and neutrophils, the lung parenchyma and airways of COPD 
patients are characterized by increased infiltration of T-lymphocytes (CD8+ and CD4+) 
(Saetta et al. 1998; Retamales et al. 2001), which correlates with the development of 
emphysema (Finkelstein et al. 1995; Majo et al. 2001) and the severity of airflow obstruction 
(O’Shaughnessy et al. 1997; Saetta et al. 1999). Although the mechanism of T-lymphocyte 
accumulation in the lungs of COPD patients is not fully understood, one study has indicated 
that T-lymphocytes of COPD patients have increased expression of the chemokine receptor 
CXCR3 (Saetta et al. 2002), thereby allowing the chemotaxis of T lymphocytes via CXCR3-
activating chemokines, such as CXCL10, which are released by bronchiolar epithelial cells 
(Spurrell et al. 2005). 
Cellular Processes Involved in COPD
Cigarette smoke
Since its identification as a risk factor about 40 years ago (Fletcher et al. 1977), tobacco smoke 
has been established as the most commonly encountered risk factor for the development 
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of COPD (GOLD 2015). Smoking cessation is the most effective intervention to influence 
the progression of COPD and to slow down the exaggerated decline in lung function. It has 
been reported that non-smokers experience a smaller prevalence of respiratory symptoms 
and lung function abnormalities, a lower annual rate of FEV
1
 decline, and a lower COPD rate 
than cigarette smokers (Kohansal et al. 2009). 
Cigarette smoke contains about 5300 identified components, including nicotine, acrolein, 
formaldehyde and acetaldehyde as well as lipopolysaccharide (LPS) (Rodgman and Perfetti 
2013), which can actively participate in the process of airway inflammation via the release 
of (pro-)inflammatory cytokines and mucus hypersecretion (Borchers et al. 1999; de Jonge 
and Ulloa 2007; Facchinetti et al. 2007; Haswell et al. 2010; Lee et al. 2012). 
Next to the above mentioned chemical components, cigarette smoke is also a rich source 
of ROS that are responsible for several types of airway damage induced by oxidative stress 
(Church and Pryor 1985; Barnes et al. 2003; Domej et al. 2014). Cigarette smoke is reported 
to induce the intracellular level of ROS in various lung cells such as epithelial cells (Tang et 
al. 2011) and ASM cells (Wylam et al. 2015). The increased levels of ROS and oxidative stress 
in the cells subsequently activate several pro-inflammatory transcriptional factors, such as 
nuclear factor (NF)-κB, and eventually results in the production of various inflammatory 
mediators including IL-8 (Evans et al. 2003; Kirkham and Barnes 2013). Indeed, treatment with 
cigarette smoke or cigarette smoke extract (CSE) dose-dependently increases the release of 
IL-8 from cultured ASM cells by increasing NF-κB activity (Tang et al. 2011; Oldenburger et 
al. 2012; Pera et al. 2012; Chen et al. 2014). 
Oxidative stress
Oxidative stress, which is a result from an anti-oxidant/oxidant imbalance, is the physiological 
damage that occurs in the presence of ROS (Domej et al. 2014). Compared to other organs, 
ROS seem to exert profound effects in the lung due to its direct and constant exposure to an 
environment with a higher oxygen load (Kinnula and Crapo 2003). Consequently, the lung 
has sophisticated defense mechanisms against oxidative stress, including nuclear factor 
erythroid 2-related factor 2 (Nrf2), the “master regulator” of antioxidant response (Comhair 
and Erzurum 2010). Nrf2 is a nuclear factor that controls anti-oxidative responses of cells 
(Itoh et al. 1997). During the resting state, the activity of Nrf2 is suppressed by binding to 
Keap1, preventing its nuclear translocation. Under oxidative stress, Keap1 dissociates from 
Nrf2, thereby allowing its nuclear translocation (Kobayashi et al. 2004). Subsequently, Nrf2-












Figure 1. Nrf2 activation. During the resting state, the activity of Nrf2 is suppressed by Keap1 upon 
prevention of its nuclear translocation. Imbalance between ROS and anti-oxidants induces tissue 
damage and dysfunction. Under oxidative stress, Keap1 dissociates from Nrf2 thereby allowing its 
nuclear translocation. Subsequently, Nrf2-induced anti-oxidative elements start to alleviate oxidative 
stress responses. 
Currently, researchers put more and more focus on oxidative stress, as it is believed to play 
an important and central role in the pathogenesis of COPD (Barnes 2004; Kirkham and 
Barnes 2013) (Figure 2). COPD patients fail to maintain the anti-oxidant/oxidant balance 
due to either the dysfunction of those anti-oxidative stress mechanisms or due to inhalation 
of excessive ROS (e.g. via cigarette smoke) (Barnes 2004; Kirkham and Barnes 2013). ROS 
derived from environmental pollution, cigarette smoke and/or inflammatory cells, such as 
neutrophils, cause an increase in pulmonary oxidative stress and thereby contribute to the 
development and progression of COPD (Barnes 2004; Rahman and Adcock 2006; van Eeden 
and Sin 2013; Domej et al. 2014) (Figure 2). Moreover, studies have shown that cigarette 
smoke can cause mitochondrial dysfunction, thereby inducing ROS production in ASM 
cells (Aravamudan et al. 2014; Wiegman et al. 2015) and epithelial cells (van der Toorn et al. 
2009). Excessive pulmonary ROS production leads to the activation of the pro-inflammatory 
transcription factors, such as NF-κB and activator protein-1 (AP-1) (Morgan and Liu 2011). 
Subsequently, the activated pro-inflammatory transcription factors lead to the up-
regulation of adhesion molecules and increased release of pro-inflammatory mediators 
such as IL-6, IL-8, TNF-α (Mittal et al. 2014). Activation of the NF-κB can be activated by 
excessive ROS production in airway epithelial (Li et al. 2013) and ASM cells (Luo et al. 2009), 
thereby resulting in an increased secretion of IL-8 (Oenema et al. 2010; Oldenburger et al. 















Figure 2. Oxidative stress in COPD. ROS derived from cigarette smoke and environmental pollution 
cause an increase in pulmonary oxidative stress and thereby contribute to the development and 
progression of COPD, leading to airway inflammation, airflow limitation and remodeling. Inflammatory 
cells such as neutrophils, produce excessive ROS, therefore further increasing the oxidative stress. 
Oxidative stress is also implicated in fibrosis in a variety of organs, including the lungs 
(Cheresh et al. 2013). TGF-β is the most potent and ubiquitous pro-fibrogenic cytokine 
and its expression is increased in COPD (Liebhart and Dobek 2009; Mak et al. 2009). 
Evidence indicates that ROS play a key role in TGF-β-induced fibrosis by activating ASM 
cells, endothelial cells, airway epithelial cells and fibroblasts (Liu and Gaston Pravia 2010). 
While TGF-β is able to increase intracellular ROS production, ROS can also activate latent 
TGF-β and induce TGF-β gene expression, thereby creating a vicious circle (Koli et al. 2008; 
Liu and Gaston Pravia 2010). In support of a pro-fibrotic role for ROS, studies showed that 
exogenous antioxidants could attenuate the development of fibrosis (Liu and Gaston Pravia 
2010), suggesting the possibility of using an anti-oxidant compound as a novel treatment 
for fibrosis. 
Besides inflammation and fibrosis, ROS can also trigger the peroxidative breakdown of 
lipids, a process implicated in increased airway epithelial permeability (Bromberg et al. 
1991; Boardman et al. 2004; Rahman 2005; Rahman and Adcock 2006; Shintani et al. 2015). 
The major product of the lipid oxidation reaction, malondialdehyde (MDA), is also one of 
the most reactive electrophile species that causes further toxic stress to the cells (Farmer 
and Davoine 2007; Ayala et al. 2014). Moreover, studies indicate that oxidative stress is an 
important cause of glucocorticosteroid resistance in COPD, as ROS alter histone deacetylase 
functioning, causing reduced suppression of pro-inflammatory genes by corticosteroids, 




least, there is evidence suggesting that oxidative stress directly increase ASM contractility, 
which might contribute to the symptoms of COPD (Hulsmann et al. 1994; Rahman 2009; 
Berair et al. 2013).
Hydrogen sulfide
In addition to the gaseous neurotransmitter nitric oxide and carbon monoxide, hydrogen 
sulfide (H
2
S) has been added to the list of important gaseous biological mediators. H
2
S is 
synthesized in the cytoplasm from L-cysteine, a process involving several enzymes such 
as cystathionine-β synthetase (CBS), cystathionine-γ lyase, cysteine aminotransferase, 
3-mercaptopyruvate sulphurtransferase and cysteine lyase (Whiteman and Moore 2009; Li 
et al. 2011). 
Exogenous H
2
S seems to exert anti-inflammatory effects by downregulating pro-
inflammatory cytokines, including IL-8, IL-6 and IL-1 β, and upregulating anti-inflammatory 
cytokines, such as IL-10, in rodent models of lung injury, induced by either tobacco smoke 
(Esechie et al. 2008) or oleic acid (Li et al. 2008). Besides anti-inflammatory properties, 
exogenous H
2
S also showed bronchodilatory effects by reducing AHR induced by tobacco 
smoke in rodent models (Chen et al. 2009; Chen et al. 2011; Han et al. 2011). 
Some argue that the therapeutic effects of H
2
S is (at least partly) attributed to its anti-oxidative 
capacities (Chen et al. 2008; Esechie et al. 2008; Whiteman et al. 2010; Perry et al. 2011; Faller 
et al. 2012; Han et al. 2015b). In support, the anti-inflammatory and bronchodilatory effects 
of H
2
S are associated with anti-oxidative properties, measured by increased Nrf2 expression 
and glutathione/oxidized glutathione ratio in the lungs (Han et al. 2011). In accordance, H
2
S 
was reported to activate Nrf2 by inhibition of Keap1 via formation of the C226–C613 disulfide 
bond on Keap1 protein in mouse embryonic fibroblasts (Hourihan et al. 2013). In contrast, 
H
2
S possesses a high redox potential that may provoke pro-inflammatory responses. Studies 
showed that oxidative stress originating from activated neutrophils converts H
2
S to sulfite 
(Mitsuhashi et al. 2005), which is considered an inflammatory mediator in airway diseases 
(Ratthé et al. 2002; Mitsuhashi et al. 2004). These findings may explain the fact that H
2
S was 
also found to induce the secretion of pro-inflammatory cytokines ( e.g. IL-1β, IL-6, TNF-α) in 
other studies (Zhi et al. 2007; Bhatia et al. 2008). Currently, the usage of H
2
S or its donors as 
potential treatments for COPD is still under debate. 
LPS-induced Guinea Pig Models of COPD
For ethical reasons and limited availability of human tissue, animal models are frequently 
used to study the pathogenesis of COPD. COPD is closely related to the structure of the 
lung, therefore a good animal model should have pulmonary structure similar to that of 
humans (Wright et al. 2008). While none of present animal models can perfectly reproduce 
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the pathophysiology of human COPD, rats, mice and guinea pigs are able to mimic specific 
symptoms of the disease, including infiltration of inflammatory cells such as neutrophils, 
cytokine production, emphysema, airway remodeling and the development of AHR (Wright 
et al. 2008; Han et al. 2016; Oliveira et al. 2016). As we mentioned above, cigarette smoke 
is the major risk factor for the development of COPD (GOLD 2015), and is therefore used in 
many COPD studies (Wright et al. 2008). LPS is a component of the gram-negative bacterial 
cell wall (Kulp and Kuehn 2010), and represents an active component in cigarette smoke 
(Hasday et al. 1999). The complex mechanisms underlying the LPS-induced inflammation 
in the lung are not fully studied. In guinea pigs and rats, several studies have shown that 
LPS induces COPD-like symptoms, including AHR, inflammation and airway remodeling, 
by binding to cell surface pattern recognition receptors encompassing toll-like receptor 4, 
CD14, LPS-binding protein, and myeloid differentiation-2 (Brass et al. 2003; Brass et al. 2004; 
Savov et al. 2005; Brass et al. 2007; Pace et al. 2015). Upon activation of those receptors, LPS 
induces the production of pro-inflammatory cytokines such as IL-8 in the airways, which 
leads to the influx and activation of inflammatory cells such as neutrophils (Fricker et al. 
2014). 
Although most current studies are using mice or rats as animal model for COPD, in this 
thesis we used a guinea pig model. Guinea pigs have also been used as small animal species 
in preclinical studies related to asthma and COPD (Canning 2003). In contrast to mice and 
rats, pulmonary biological mediators and anatomy in guinea pigs are quite similar to that 
of humans (Canning 2003; Canning and Chou 2008), leading to the fact that experimental 
interventions in the lung are comparable (Canning 2003; Canning and Chou 2008). Guinea 
pigs give a fast inflammatory reaction upon exposure of LPS. There was a significant influx 
of neutrophils, along with other inflammatory cells, into the airways 24 hours after exposure 
of LPS (Toward and Broadley 2000; Toward et al. 2004; Smit et al. 2013). Although often 
underestimated in clinical assessment, AHR is an important characteristic of COPD (van den 
Berge et al. 2012) that associates with accelerated lung function decline (Postma et al. 1986; 
Tashkin et al. 1996). There is a strong association between AHR and accumulation of lung 
neutrophils (van den Berge et al. 2012). Similar to those clinical findings, exposing guinea 
pigs with LPS acutely or chronically has been shown to induce significant AHR (Toward and 
Broadley 2000; Toward et al. 2004; Kaneko et al. 2007; Smit et al. 2013). Intranasally  applied 
or inhaled LPS mimicked pathologic and inflammatory changes in guinea pigs that are also 
observed in human subjects with COPD and LPS-treated guinea pig are therefore used as 
in vivo models for COPD (Toward and Broadley 2000; Toward and Broadley 2002; Toward 
et al. 2004; Kaneko et al. 2007; Pera et al. 2011; Baarsma et al. 2013; Smit et al. 2013; Pera 
et al. 2014). In this thesis, we used as an acute guinea pig model of COPD using a single 
exposure to LPS. Earlier studies from our group as well as of others have shown that the 




Smit et al. 2013), a feature that correlates strongly with clinical outcomes (Stockley 2006; 
Gernez et al. 2010; Hoenderdos and Condliffe 2013), and AHR (Toward and Broadley 2000; 
Smit et al. 2013). 
Novel Therapeutic Avenues for COPD
Sul compounds
As we mentioned above, the COPD is characterized by persistent and progressive 
airflow limitation and featured with an enhanced chronic airway inflammation (GOLD 
2015). However, the current medications are not always effective and fail to reduce the 
progression of COPD (Barnes 2013). Therefore, studies for novel medicines are necessary. 
Recently, a series of novel compounds (named as Sul compounds) were synthesized. They 
have shown to protect cells form oxidative stress induced by hypothermia and rewarming 
(Patent: WO2014098586 A1, Van et al. 2014). Moreover, preliminary studies suggested 
that Sul compounds might activate cystathionine β synthase, a main enzyme for cellular 
endogenous H
2
S production (Dugbartey et al. 2014). As both the anti-oxidative property 
and H
2
S would beneficially affect the pathophysiology of COPD, these Sul compounds may 
represent potential novel treatments of obstructive lung disorders such as COPD. 
A-kinase anchoring proteins
Compartmentalization of cellular signaling is a common strategy used to ensure the 
accuracy and efficiency of cellular responses (McCormick and Baillie 2014). Over the past 
years, it is generally accepted that spatial-temporal mechanisms regulate cAMP pools 
within individual cells. Several studies indicated that the communication between β
2
-
adrenoreceptor, cAMP effectors, PDEs and other downstream targets are coordinated 
by A-kinase anchoring proteins (AKAPs) (Figure 3) (Logue and Scott 2010; Dekkers et al. 
2013). AKAPs are a group of scaffolding proteins with the ability to associate with PKA via 
a short α-helical structure. Members of the AKAP superfamily act as targeting devices that 
assemble a large variety of structural and signaling molecules and thereby help those 
signaling elements to localize to different cellular microdomains (Scott and Santana 2010; 
Logue and Scott 2010). Recently our group was the first to publish that dysfunction of AKAP 
complexes contributes to features of COPD (Oldenburger et al. 2014; Poppinga et al. 2015). 
Thus, disruption of the interaction between AKAPs and PKA further increases inflammatory 
processes and loss of epithelial barrier function induced by cigarette smoke (Oldenburger 
et al. 2014; Poppinga et al. 2015). In addition, the expression of several AKAPs, including 
AKAP5 and AKAP12, is lower in lung tissue of COPD patients and in ASM cells exposed to 
cigarette smoke. Each AKAP is featured with a amphipathic helix domain responsible for 
PKA RII subunit binding (Carr et al. 1992). St-Ht31 is a stearated form of a peptide containing 
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the amphipathic helix domain (human thyroid AKAP), which allows it to competitively 
inhibit the interaction of PKA RII subunits with AKAPs (Carr et al. 1992) (Figure 3). Currently, 
st-Ht31 is used to study the role of PKA-AKAP complexes in several biological processes, 
including in the lung (Poppinga et al. 2014; Han et al. 2015a). The following section briefly 























Figure 3. Compartmentalization of cAMP signaling by A-kinase anchoring proteins (AKAPs). 
After activation of β2-adrenoceptors by their appropriate ligands, adenylyl cyclase (AC) is stimulated 
leading to the generation of cyclic adenosine monophosphate (cAMP) and activation of cAMP 
effectors, such as protein kinase A (PKA). Phosphodiesterases (PDEs) decrease the cellular cAMP level 
by cleavage to 5’AMP. By binding PKA, PDEs, AC and other proteins, AKAPs help to form localized cAMP 
pools. AKAPs organize the anchoring of PKA in the vicinity of such cAMP pools, thus controlling its 
maintenance in space and time. All AKAPs are featured with a amphipathic helix domain responsible 
for PKA RII subunit binding. The synthetic peptide st-Ht31 mimics this amphipathic helix domain 
(human thyroid AKAP) and thereby competitively inhibits the interaction of PKA RII subunits with 
other AKAPs.
In 2001, Huang and coworkers suggested that the compartmentalization of cAMP signaling 
at the inner apical membrane surface allows cells to selectively activate the apical functions 
needed for the protective response to physical luminal stimuli (Huang et al. 2001). Later 




phosphodiesterases (PDE)4D, the main PDE expressed in the lungs, which limit cAMP effects 
to short distances from the apical membrane by subcellular localization of PKA (Barnes et 
al. 2005). Recently, a study indicated that anchoring of PKA to AKAPs is critical for cAMP 
modulation of the cystic fibrosis transmembrane conductance regulator (CFTR) in airway 
epithelial cells (Monterisi et al. 2012). Indeed, our previous studies also demonstrate that 
AKAP5, AKAP9 and AKAP12 are expressed in human bronchial epithelial (HBE) cells, and 
that exposure of HBE cells to CSE resulted in an alteration of AKAP expression accompanied 
with a loss of barrier function (Oldenburger et al. 2014). Importantly, disruption of AKAP-
PKA interactions by st-Ht31 prevented the CSE-induced reduction of E-cadherin and 
AKAP9 protein expression and subsequent loss of barrier function, suggesting that AKAP 
complexes contribute to the maintenance of epithelial barrier. 
As ASM also expresses several AKAPs (e.g. AKAP5) (Horvat et al. 2012; Poppinga et al. 2015), 
recruitment of PDE and PKA to a distinct subset of AKAPs might bear the potential to control 
cellular cAMP pools in ASM as well. The importance of the cellular cAMP homeostasis in 
ASM has been shown in studies on the “β-agonist paradox”. Overexpression of the β
2
-
adrenoceptor (McGraw et al. 2003) or adenylate cyclase (AC) subtype 5 (Wang et al. 2011) 
leads to AHR, instead of the anticipated reduction of both as both are involved in relaxing 
ASM. Due to these studies and several others it has become clear that the intracellular cAMP 
gradient in human ASM is spatially controlled by PDEs (Billington and Hall 2012). Although 
representing a minor component of the lung PDE pool, it has been shown that inhibition 
of PDE4D5 by rolipram augmented isoproterenol-induced cAMP production, suggesting 
that this PDE subtype plays a key role as physiological regulator of β
2
-adrenoreceptor-
induced cAMP elevations (Billington et al. 2008). Furthermore, research has shown that 
PDE4D deficient mice neither respond to cholinergic stimulation nor develop AHR after 
exposure to antigen, presumably due to their inability to decrease-cellular cAMP (Hansen 
et al. 2000). Due to the intrinsic property of plasticity, ASM cells not only contract but also 
have the ability to produce inflammatory mediators (Halayko and Amrani 2003; Wright et al. 
2013). It has been shown that cAMP-mobilizing agents, including β-agonists, reduce CSE-
induced IL-8 release in ASM cells (Oldenburger et al. 2012). Thus, subtle alterations in spatio-
temporal regulation of cellular cAMP might profoundly change diverse cellular responses 
of ASM beyond relaxation. It is tempting to speculate that AKAP might contribute to the 
distinct functional responses of ASM. Recent studies demonstrate that disruption of AKAP-
PKA complexes in ASM changed only cAMP elevations close to the membrane, leaving 
global cAMP production unaffected (Horvat et al. 2012), as well augments CSE-induced 
IL-8 release, a process involving signaling to extracellular signal-regulated kinases 1 and 2 
(ERK1/2) (Poppinga et al. 2015). 
Besides inducing ASM relaxation and inhibiting cytokine release from ASM cells, activation 
of the cAMP effectors PKA and Epac also inhibit growth factor-induced DNA synthesis in 
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ASM cells, a process involving ERK1/2 and p70S6 kinase (Roscioni et al. 2011a; Roscioni et al. 
2011b). Activation of PKA and Epac also prevents the development of the  growth factor-
induced hypocontractile ASM phenotype (Roscioni et al. 2011a; Roscioni et al. 2011b), 
demonstrating that cAMP signaling also regulates phenotypic plasticity of ASM cells. The 
involvement of PKA-AKAP complexes have not yet been studied in the regulation of ASM 
cell plasticity. However, studies indicate that PKA-AKAP complexes regulate processes that 
are important for the regulation of the cell cycle in ASM (Collas et al. 1999; Indolfi et al. 2001; 
Landsverk et al. 2001; Alfthan et al. 2004; Laulajainen et al. 2008; Smith et al. 2010; Gao et al. 
2012). Therefore, AKAP-PKA interactions may be important in regulating processes as ASM 
tone, ASM proliferation and cytokine release from ASM and are thus interesting targets for 
novel therapies of COPD. 
Scope of the Thesis
The objective of this thesis is to investigate possible novel targets for the treatment of COPD. 
Special focus lies on the involvement of PKA-AKAP complexes and oxidative stress. Using in 
vitro, ex vivo and in vivo approaches, we explored the therapeutic potential and underlying 
molecular mechanisms of several novel compounds (Sul compounds) for the treatment of 
COPD. The contribution of PKA-AKAP complexes to ASM responses have been studied by 
using the peptide st-Ht31, known to interfere with the binding of PKA to AKAP proteins.
In Chapter 2, we summarize the potential of novel targets and tools to study these, including 
anti-inflammatory drugs, inhibitors of PDEs as well as kinase inhibitors for the treatment of 
asthma and COPD. We discussed the potential role of PKA-AKAP complexes in modulating 
the effect of drugs used to treat obstructive lung diseases, and we suggest that AKAPs may 
be a novel therapeutic target acting downstream of GPCRs to treat COPD. 
Since ASM plays a critical role in obstructive pulmonary diseases including COPD, ASM 
therefore represents a very suitable therapeutic target. ASM can contribute to the progress 
of airflow limitation by inducing increased airway narrowing, which may involve remodeling 
of the ASM characterized by hyperplasia and hypertrophy (Chung 2005). β
2
-Agonists are 
important bronchodilators via elevation of cellular cAMP levels and subsequent activation 
of the downstream effectors PKA and Epac (Cazzola et al. 2011; Oldenburger et al. 2012). 
AKAPs coordinate responses driven by either PKA and/or Epac (Grandoch et al. 2010), and 
have recently been shown to be expressed in the airways (Horvat et al. 2012; Poppinga et 
al. 2015). Using st-Ht31, we studied the role of the PKA-AKAP complexes in phenotypic 
plasticity of ASM. (Chapter 3). The effect of st-Ht31 on markers of the proliferative ASM 
phenotype, such as DNA synthesis and activation of cell cycle proteins, was studied in 
cultured human ASM cells. Since AKAP8 is known to interact with cell cycle proteins such as 




presence of st-Ht31. In addition, the effect of st-Ht31 on the expression of the contractile 
proteins α-smooth muscle actin and calponin, markers for the contractile ASM phenotype, 
was studied in ASM cells. The expression of α-smooth muscle actin and the proliferative 
marker PCNA (proliferating cell nuclear antigen) were also studied in intact human tracheal 
smooth muscle strips following overnight treatment with st-Ht31. Lastly, the effect of this 
overnight treatment with st-Ht31 on methacholine-induced contractility was studied in the 
human tracheal smooth muscle strips. 
A series of highly sophisticated, strictly regulated molecular mechanisms are required to 
maintain the cell cycle progression, including cyclins and Rb (Bertoli et al. 2013; Dick and 
Rubin 2013; Zitouni et al. 2014). Dysfunction of this process could lead to the development 
of diseases like cancer as well as COPD (Sundar et al. 2011; Sperka et al. 2012). Cellular 
signaling compartmentalization is considered a common strategy to ensure the accuracy 
and efficiency of cellular signaling in cell cycle regulation (McCormick and Baillie 2014). In 
Chapter 4, we reviewed the recent knowledge about the role of AKAPs in the regulation and 
progression of the cell cycle in a pathophysiological context. 
Although many COPD patients are treated with anti-inflammatory corticosteroids, 
most patients respond poorly to these drugs due to low sensitivity, urging better anti-
inflammatory treatment (Barnes et al. 2002; Broadley 2006). A series of novel compounds 
(Sul-90, Sul-121, Sul-127 and Sul-136) have shown promising cell protective effects from 
oxidative stress (Van der Graaf et al. 2014). In Chapter 5, we screened these compounds 
based on their pharmacological potential as novel treatment options for COPD, with a 
special focus on their potential anti-inflammatory effects on cultured ASM cells and relaxing 
properties on pre-contracted ASM strips. We used the most promising compound (Sul-
121) in Chapter 6 to explore its protective role on neutrophilia and AHR in an LPS-induced 
guinea pig model of COPD. Using a combination of in vivo and in vitro studies, we studied 
the molecular mechanisms involved in the effects of Sul-121 on LPS and CSE-induced 
inflammatory processes. The effect of Sul-121 on CSE-induced IL-8 release, ROS production, 
H
2
S levels, and the activation of the anti-oxidative response factor Nrf2 was evaluated. 
All results and findings are summarized and discussed in Chapter 7 and a future perspective 
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Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent 
respiratory diseases characterized by airway inflammation, airway obstruction and airway 
hyperresponsiveness. Whilst current therapies, such as β-agonists and glucocorticoids, may 
be effective at reducing symptoms, they do not reduce disease progression. Thus, there is 
a need to identify new therapeutic targets. In this review, we summarize the potential of 
novel targets or tools, including anti-inflammatories, phosphodiesterase inhibitors, kinase 
inhibitors, transient receptor potential channels, vitamin D and protease inhibitors, for the 
treatment of asthma and COPD. 
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2
Introduction 
Obstructive airway diseases, including asthma and chronic obstructive pulmonary disease 
(COPD), represent a major health problem worldwide. According to the World Health 
Organization (WHO), asthma is the most common chronic disease among children (WHO 
2013), and it is predicted that COPD will become the third leading cause of death worldwide 
by 2030 (Mannino and Buist 2007; Miles et al. 2012). 
The common pathophysiological components of asthma and COPD are airway inflammation, 
airway obstruction and airway hyperresponsiveness (AHR); the differences are mainly 
related to the cellular and molecular features of inflammation and the reversibility of airflow 
obstruction. Airway inflammation in allergic asthma is usually eosinophilic, whereas COPD 
is associated with predominantly neutrophilic inflammation. However, some non-allergic 
endotypes of asthma, such as exercise-induced, aspirin-sensitive and infection-induced 
asthma, may present with little to no eosinophilic inflammation. Severe, steroid-resistant 
and obesity related asthma endotypes are frequently associated with a neutrophilic 
inflammatory profile [reviewed in (Lötvall et al. 2011)]. Physiologically, asthma is typically 
characterized by reversible AHR, whereas COPD is characterized by airflow limitation that is 
not fully reversible and is usually progressive. 
Whilst current asthma therapies, namely β-agonists and glucocorticoids, reduce airway 
inflammation, reverse bronchoconstriction and improve quality of life in the majority of 
patients, these treatments have little or no effect on the structural alterations associated 
with the disease. Furthermore, there remains a considerable population of people for whom 
these treatments are ineffective and thus their asthma is poorly controlled. Similarly, current 
treatments for COPD have limited efficacy in terms of inhibiting chronic inflammation and 
do not reverse the disease process or prevent its progression. Hence, there is a clear need 
to increase our understanding of disease processes, identify novel targets and develop new 
therapies. In this review, we provide an update on existing treatments and highlight novel 
emerging targets and treatments for asthma and COPD. 
Novel Anti-Inflammatory Drugs for the Treatment of Allergic Asthma 
Anti-inflammatory therapies for allergic asthma were introduced in the mid-20th century, 
and inhaled corticosteroids have been the primary therapy for asthma for the past 35 
years (Chu and Drazen 2005). In recent decades, research has focused on more specific 
targeting of the asthmatic inflammatory response, with the advent of anti-leukotriene and 





The inflammatory response to respiratory allergen exposure is characterized by eosinophilic 
infiltration of the airways driven by increased expression of Th2 cytokines [interleukin 
(IL)-4, IL-5, IL-13 and in more severe cases IL-17 and IL-22] (Chu and Drazen 2005). In the 
lung, eosinophils release a potent combination of inflammatory mediators, cytokines, 
chemokines and basic proteins that are thought to not only exacerbate the inflammatory 
response to allergen, but also contribute to the structural changes to the airway wall 
known as airway remodeling. These processes in combination lead to the lung dysfunction 
that defines allergic asthma (Efraim and Levi-Schaffer 2008). It is well-established that IL-5 
promotes the maturation and release of eosinophils from the bone marrow, as well as the 
secretion of mediators and survival in the tissue (Garcia et al. 2013). Although early efforts to 
target IL-5 met with only limited success (Kips et al. 2003; O’Byrne 2007; Garcia et al. 2013), 
more recent clinical trials on the anti-IL-5 antibody mesolizumab showed a positive effect of 
this intervention, as mesolizumab treatment significantly reduced asthma exacerbations in 
patients with severe eosinophilic asthma (Nair et al. 2009; Pavord et al. 2012).
Other Th2 cytokines have recently been targeted as novel anti-inflammatory therapies for 
allergic asthma. IL-4 and IL-13 are typical Th2 cytokines that play important roles in the B 
cell switch to IgE synthesis, eosinophil accumulation in the lung, goblet cell hyperplasia 
and enhanced airway smooth muscle (ASM) contractility (Walsh 2013), and are therefore 
promising targets for therapeutic intervention. Dupilumab (SAR231893/REGN668) is a 
human monoclonal antibody targeting the IL-4Rα/IL-13Rα receptor complex; a randomized, 
double-blind, placebo-controlled, parallel-group phase 2A study was recently completed 
to assess the impact of this therapy in moderate-to-severe asthmatics. Subcutaneous 
injections of dupilumab for 12 weeks led to significant improvements in asthma control 
and lung function, as well as a reduction in Th2 inflammatory markers (Wenzel et al. 
2013). Targeting IL-13 signaling alone, however, may be less promising. An early study 
using lebrikizumab, a humanized anti-IL-13 antibody, showed significantly improved lung 
function in patients with high pretreatment levels of serum periostin (Zeskind 2011), which 
is a systemic indicator of Th2/IL-13 activity and airway eosinophilia in asthmatics (Jia et al. 
2012). However, a follow-up study did not find significant improvements in lung function in 
treated asthmatics compared to controls, even when patients were stratified according to 
serum periostin levels (Noonan et al. 2013). This lack of consensus may have been due to a 
briefer treatment period (12 weeks vs 6 months of treatment) and continued corticosteroid 
use by patients in the latter study. Further investigations are certainly warranted to clarify 
the role of anti-inflammatory therapies for patients with the allergic endotypes of asthma. 
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Statins
Statins are a family of 3 hydroxy-3methylglutaryl coenzyme A reductase (HMG-CoA 
reductase) inhibitors that have been used clinically as cholesterol-lowering drugs; however, 
recent evidence from in vitro studies (Wang et al. 2011b; Zeki et al. 2012) and in mouse models 
of allergic airway disease (Huang et al. 2013a) has demonstrated that these compounds also 
have potent anti-inflammatory effects. It has been suggested that the addition of a statin to 
maintenance corticosteroid therapy in asthmatics might be beneficial, but human studies 
have provided mixed results (Walker and Edwards 2013). Encouragingly, recently reported 
clinical trials focusing on severe asthmatics showed that the addition of a statin to standard 
inhaler controller therapy led to improved asthma symptoms, fewer exacerbations and 
reduced corticosteroid use (Zeki et al. 2013; Tse et al. 2013). Further investigations into the 
mechanism of action of the corticosteroid/statin combination revealed that this treatment 
increases the induction of T regulatory cells in asthmatics, suggesting an enhanced ability 
to suppress airway inflammation in these patients (Maneechotesuwan et al. 2013). 
Macrolides
Macrolides represent another drug class with a long history of use that has only recently 
been explored as a novel asthma therapy. Macrolides are antibiotics used to treat infections 
caused by Gram-positive bacteria and act by inhibiting protein synthesis in target 
microorganisms. When used in a mouse model of allergic airways disease, the macrolide 
azithromycin attenuated expression of IL-13 and IL-5 and reduced mucus production in 
the lung (Beigelman et al. 2009). This success has been translated to the clinic with the 
publication of a number of clinical trials showing that short-term (three weeks) macrolide 
therapy improved some aspects of lung function, symptoms and quality of life in asthmatic 
patients (Reiter et al. 2013). When given for a longer period of time along with corticosteroids, 
azithromycin treatment did not lead to a significant improvement in lung function in the 
entire cohort, but patients with non-eosinophilic asthma saw better outcomes with this 
therapy, suggesting that macrolides may be of interest in treating this particular asthma 
phenotype (Brusselle et al. 2013). 
Novel Anti-Inflammatory Drugs for the Treatment of COPD
Inflammation in COPD is characteristically distinct from other lung diseases and is less 
responsive to inhaled glucocorticoids compared to asthma. In acute exacerbations of 
COPD (AECOPD), which can be triggered by bacterial or viral infections, lung inflammation 
is dramatically increased (Bathoorn et al. 2008). It is crucial to understand the underlying 
contributions of different cell types, for example increased neutrophils and macrophages, 
and how these contribute to complicated cytokine and chemokine profiles seen in patients 
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with COPD and commonly occurring AECOPD. Given the complexity of the inflammatory 
response in COPD, there have been two main approaches to improving patient quality of life. 
The first is to adopt a broad anti-inflammatory approach and the second is to specifically target 
individual components of the inflammatory cascade which differ in specific COPD patients.
Patient biopsies and sputum samples have identified increased numbers of many 
inflammatory cells, including macrophages, neutrophils, T and B cells. Activation of these 
cell types contributes to increased levels of cytokines and chemokines which are detected 
in the sputum, bronchoalveolar lavage fluid (BALF) and systemically in blood samples; these 
include IL-1α and IL-1β (Botelho et al. 2011), tumor necrosis factor (TNF)α (Keatings et al. 
1996), IL-5 (Schild et al. 2011) and (Molfino et al. 2012), IL-6 (Agustí et al. 2012) and (Celli et al. 
2012), IL-8 (Keatings et al. 1996), IL-17 (Zhang et al. 2013), IL-18 (Kawayama et al. 2012) and 
granulocyte macrophage-colony stimulating factor (GM-CSF) (Saha et al. 2009). 
In addition to these cytokines and chemokines, there is reduced expression of histone 
deacetylase 2 (HDAC2), which in normal patients maintains steroid sensitivity and in COPD 
patients is believed to be a key component in steroid insensitivity (Ito et al. 2005). There is 
also evidence of increased expression of epidermal growth factor receptors (Anagnostis et 
al. 2013) and leukotriene B4 (LTB4) (Keatings et al. 1996). Given these diverse factors and 
their potential complex interplay, it is perhaps not surprising that it is difficult to achieve a 
therapeutic benefit regarding inflammation in COPD.
Cigarette smoke is a major contributor to COPD and has been shown to skew the immune 
response in patients with COPD [reviewed in (Stämpfli and Anderson 2009)]. Cigarette 
smoke exposure in animals, primarily rodents, can cause inflammation directly and/or 
indirectly by inducing oxidative stress [reviewed in (Vlahos and Bozinovski 2014)]. Short-term 
exposure models induce glucocorticoid-resistant inflammation whereas long-term models 
induce emphysematous changes. It is worth noting that minor changes in the smoke 
exposure protocol can influence the outcome and may coincide with the heterogeneity of 
inflammation in COPD.
In the following sections, we review IL-8 and IL-1β inhibitors as potential novel anti-
inflammatory treatments for COPD. 
Interleukin-8 antibodies – from promising pre-clinical assessments to failed clinical trials
IL-8 is a chemotactic mediator involved in recruiting neutrophils to the lung. Concentrations 
of IL-8 are increased in both sputum and BALF from COPD patients (Keatings et al. 1996). 
The development of a monoclonal antibody recognizing IL-8 was characterized in vitro in 
human neutrophils by blocking IL-8 binding (Yang et al. 1999). This was also confirmed 
in an in vivo model of IL-8 driven skin inflammation in rabbits, whereby administration of 
the IL-8 antibody decreased neutrophil recruitment and subsequent inflammation (Yang 
et al. 1999). Despite promising pre-clinical evidence, a phase 2 clinical trial assessing the 
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effects of the monoclonal antibody recognizing IL-8 (ABX-IL8) showed very limited clinical 
improvements in patients symptoms with COPD (Mahler et al. 2004). 
Interleukin 1α antibodies – promising pre-clinical evidence
In some patients, IL-1α and IL-1β are increased in sputum and BAL samples. Pre-clinical 
evidence using cigarette smoke exposed mouse models has shown a critical role of IL-1α 
in the initiation of neutrophilic inflammation and that signaling through IL-1R1 is a key 
driver in the production of other pro-inflammatory cytokines such as TNFα and matrix 
metalloproteinase-9 (MMP-9) (Botelho et al. 2011). In IL-1α knockout mice and in naïve 
mice treated with short-term cigarette smoke and an IL-1α antibody, this neutrophilic 
inflammation was decreased. This is promising pre-clinical evidence; however it is crucial 
that clinical trials involving these IL-1α targeting antibodies are given to patients with 
increased levels of IL-1α. 
Given the complexity and heterogeneity of inflammation in COPD patients, and the 
relatively limited success with broad spectrum anti-inflammatory agents, the overarching 
goal for treating this underlying inflammation is to endotype/phenotype patients to ensure 
that anti-inflammatory drugs will specifically target patient needs.
G-Protein-Coupled Receptors in Asthma and COPD
Currently, β
2
-adrenoreceptor agonists and muscarinic receptor antagonists are the two 
main types of bronchodilators that provide effective symptomatic relief for the treatment of 
airway constriction (Meurs et al. 2013). These receptors are members of the G-protein coupled 
receptor (GPCR) family. GPCRs are a large family of cell surface receptors, characterized by 
the presence of seven membrane-spanning peptide chains. Agonist binding induces a 
conformational change and subsequently dissociation of the α subunit from the βγ dimer. 













-receptors activate the 
enzyme adenylyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) 
into cyclic adenosine monophosphate (cAMP). This in turn activates protein kinase A (PKA) 
and exchange protein directly activated by cAMP (Epac) (Schmidt et al. 2013). Via this 
signaling cascade, several intracellular proteins become phosphorylated, leading to the 
relaxation of ASM, increased mucociliary clearance, decreased microvascular leakage and 
inhibition of mediator release from mast cells and basophils (Nelson 1995). When the G
q
-
coupled muscarinic M3 receptor (M3R) is triggered, phospholipase C (PLC) is subsequently 
activated. PLC can release inositol 1,4,5-triphosphate (IP
3
) and thereby increase the levels of 
intracellular calcium, as shown in Figure 1. Thus, by antagonizing M3R, the contraction of 
the ASM is prevented. 
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Figure 1. Muscarinic M3 receptor – β2-adrenoceptor cross-talk in airway smooth muscle.
Activation of muscarinic M3-receptors by acetylcholine causes protein kinase C (PKC)-mediated β
2
-
adrenoceptor uncoupling, thereby attenuating β-agonist-induced relaxation of airway smooth muscle, 
presumably by phosphorylation of the third intracellular loop of the receptor. AC = adenylylcyclase, IP
3
 
= inositol 1,4,5-trisphosphate, PLC = phospholipase C. 
Therefore, it is not surprising that β
2
-adrenoreceptor agonists and muscarinic receptor 
antagonists are the mainstay therapies for COPD patients. In asthma, however, muscarinic 
receptor antagonists are less effective and therapeutic management relies mainly on 
treatment with β
2
-adrenoreceptor agonists in combination with inhaled glucocorticoids 
(Dekkers et al. 2013). The next section will provide an overview of new developments in 
targeting GPCRs for the treatment of asthma and COPD. 
New developments for once-daily treatment
The pharmaceutical industry has shown considerable interest in the development of 
inhaled bronchodilators with a long duration of action, i.e. >24 h, to strive for a once-daily 
treatment regime. This is an important development, as inadequate adherence to inhaled 
therapy is a major cause of poor clinical outcomes in the treatment of asthma and COPD 
(Tamura and Ohta 2007; Cazzola and Matera 2009). Several long-acting β
2
-adrenoceptor 
agonists (LABA) are being studied, including carmoterol, indacaterol and vilanterol [for a 
comprehensive review see (Cazzola et al. 2011)].
Olodaterol (Boehringer Ingelheim) was pharmacologically characterized in preclinical 
models in 2010 (Bouyssou et al. 2010a). Two 48-week Phase III studies demonstrated that 
olodaterol, in addition to standard therapy, provides a statistically significant improvement 
in lung function vs. standard therapy alone in COPD patients. These outcomes led to 
olodaterol becoming the first once-daily LABA approved for maintenance therapy in COPD 
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patients (Gibb and Yang 2013). Whilst studies to unravel the effectiveness of olodaterol in 
asthmatic patients are ongoing, its bronchoprotective effects have been demonstrated in a 
guinea pig model of allergic asthma (Smit et al. 2014). 
Tiotropium is a long-acting muscarinic receptor antagonist (LAMA) that has been available 
for over a decade, and is widely accepted for the treatment of COPD (Yohannes et al. 2013). 
Glycopyrronium was recently approved as once-daily maintenance treatment for patients 
with moderate-to-severe COPD. Treatment with this LAMA leads to fast and sustained 
improvements in lung function, health status and exercise endurance, as well as reduced 
risk of exacerbations, to a comparable level as seen with tiotropium (van Noord et al. 2010; 
Yu et al. 2011). Although anticholinergics are not a mainstay therapy for asthma, a recent 
publication by Kerstjens et al. (Kerstjens et al. 2011) demonstrated improved lung function 
in patients with severe uncontrolled asthma. 
A-kinase anchoring proteins as modulators of GPCR downstream signaling
Whilst activation of GPCRs can trigger a cascade of signaling events via the second 
messenger cAMP, transmission of this signal is conveyed by effector proteins such as Epac 
and PKA. The communication between receptors, cAMP effectors, and other downstream 
targets are coordinated by A-kinase anchoring proteins (AKAPs) (Figure 2) (Wong and Scott 
2004; Dekkers et al. 2013). AKAPs are scaffolding proteins known to associate with PKA via 
a short α-helical structure (Kritzer et al. 2012). AKAPs act as targeting devices that assemble 
a large variety of structural and signaling molecules and thereby support their targeting to 
different microdomains in cells (Wong and Scott 2004). Dysfunction of AKAP complexes 
has been implicated in a wide variety of diseases, such as cancer (Troger et al. 2012; Scott 
et al. 2013). The following sections briefly describe how AKAPs modulate the downstream 
signaling of GPCRs in ASM cells. 
In particular, in the cardiac system, it has been reported that PDE4 can bind to mAKAP, AKAP5 
and AKAP9 (Dodge et al. 2001; Taskén et al. 2001; Lynch et al. 2005). As ASM seems to express 
several AKAPs (Horvat et al. 2012), recruitment of PDE, PKA and Epac to a distinct subset of 
AKAPs might bear the potential to control the cAMP pathway in the lung as well. Elevation 
of cAMP leads to the activation of mAKAP-bound PKA and subsequent phosphorylation and 
activation of PDE (Dodge-Kafka et al. 2005). Activated PDE4 then hydrolyzes local cAMP and 
thereby de-activates the mAKAP-bound PKA. As a result of locally decreased cAMP levels, 
the inhibitory effect of Epac on ERK5 is attenuated. Activated ERK5 then phosphorylates 
PDE4 and decreases its activity, allowing the local accumulation of cAMP. This action loop 
creates a unique negative feedback control to spatio-temporally compartmentalize cAMP 
signaling (Dodge et al. 2001; Dodge-Kafka et al. 2005). 
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Figure 2. Compartmentalization of cAMP signaling by A-kinase anchoring proteins (AKAPs). 




-agonists, adenylyl cyclase (AC) generates cAMP and 
thereby produce localized cAMP pools. AKAPs organize the anchoring of PKA in the vicinity of such 
cAMP pools, allowing for the control of its maintenance in space and time by the counterbalancing 
activities of AC and phosphodiesterases (PDEs). 
The importance of cellular cAMP homeostasis in ASM has been shown in studies on the 
“β-agonist paradox” by breaking the spatio-temporal compartmentalization of cAMP. 
Instead of relaxing ASM, overexpression of the β
2
-adrenoceptor (McGraw et al. 2003) or 
adenylate cyclase (AC) subtype 5 (Wang et al. 2011a) leads to AHR. It has become clear 
that the intracellular cAMP gradient in human ASM is spatially controlled by PDEs via cAMP 
hydrolyzation (Billington and Hall 2012). Although, being a minor component of the tissue 
PDE pool, using fluorescence resonance energy transfer (FRET) technique, others found 
that inhibition of PDE4 by rolipram augmented isoproterenol-induced cAMP production, 
suggesting that PDE4D5 plays a key role as a physiological regulator of β2AR-induced cAMP 
signaling within human ASM (Billington et al. 2008). Furthermore, research has shown that 
PDE4D deficient mice are neither responsive to cholinergic stimulation nor develop AHR 
after exposure to antigen, a process believed to relate to an inability to decrease-cellular 
cAMP in PDE4D deficient mice (Hansen et al. 2000). Due to the property of plasticity, 
ASM cells not only contract but also have the ability to produce inflammatory cytokines 
and chemokines, which can serve as an immune-modulator in the airway (Halayko and 
Amrani 2003; Wright et al. 2013). It has been shown that cAMP-mobilizing agents including 
β-agonists and PGE2 reduce TNFα-induced expression of eotaxin and RANTES (Pang 
and Knox 2000; Ammit et al. 2000). Thus, subtle alterations on the level of cellular cAMP 
might profoundly change cellular responses of ASM. It is tempting to speculate that AKAP 
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might contribute to the distinct functional responses of ASM. Indeed, a recent study by 
Penn and colleagues demonstrated that the AKAP-PKA complex disrupting peptides did 
not change global cAMP production in ASM but cAMP elevations close to the membrane 
compartments (Horvat et al. 2012). All this evidence implies that AKAPs might function as 
potential regulators during inflammatory responses of ASM by cAMP compartmentalization. 
In this sense, distinct AKAP complexes in ASM cells might rely on various molecular 
mechanisms to modulate GPCR downstream signaling pathways, and may be exploited as 
novel therapeutic targets for obstructive lung diseases.
Phosphodiesterase Inhibitors
Phosphodiesterases are a superfamily of enzymes involved in the regulation of cellular 
functions. Theophylline, a non-specific PDE inhibitor, has been used in the treatment 
of asthma and COPD for over 75 years as it promotes bronchodilation and inhibits 
inflammation. Despite its high oral bioavailability and anti-inflammatory, anti-proliferative 
and bronchodilator effects, its use has been hampered by its adverse effects. However, 
recent advancements in our understanding of PDE isoenzymes have led to renewed 
interest in PDE inhibitors as potential treatments for asthma and COPD. Both physiological 
and pharmacological studies have highlighted the important role of PDEs in the control of 
airway inflammation, airway function and remodeling. PDEs consist of 11 subfamilies (PDE1-
11) capable of hydrolyzing the second messenger molecules cAMP and cyclic guanosine 
monophosphate (cGMP) into their inactive forms, 5-AMP and 5-GMP, respectively, thus 
terminating their downstream activity. PDE-1, -2, -3, -10 and -11 hydrolyze both cAMP and 
cGMP, whereas PDE-4, -7 and -8 are specific for cAMP and PDE-5, -6, -9 are specific for cGMP 
(Bingham et al. 2006). Since PDEs regulate the breakdown of cAMP and cGMP, the inhibition 
of PDEs results in an elevation in cAMP and cGMP and thus regulates ASM relaxation, 
proliferation and immunomodulatory functions. Whilst many of the PDE isoforms are 
expressed in the lung, PDE4 is the major therapeutic target in respiratory diseases (Méhats 
et al. 2003). Increased understanding of the PDE superfamily has allowed the development 
of more targeted approaches, including rolipram, cilomilast and roflumilast (PDE4 inhibitors) 
and RPL554 (a dual PDE3/PDE4 inhibitor). 
Targeting phosphodiesterases as a treatment for asthma 
PDEs have been implicated in the pathogenesis of asthma as they can regulate airway tone, 
airway hyperplasia and airway remodeling (Torphy et al. 1993; Burgess et al. 2006). Recently, 
in vitro studies have demonstrated deregulation of the cAMP-PDE pathway in asthma with 
elevated PDE activity and lower cAMP levels in ASM cells from asthmatic subjects compared 
with cells from non-asthmatic subjects (Trian et al. 2011). Furthermore, PDE4D, the dominant 
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PDE4 expressed on ASM cells (Méhats et al. 2003; Niimi et al. 2012), has been implicated as 
an asthma susceptibility gene (Himes et al. 2009). Recently, both preclinical and clinical 
studies have examined the potential of PDE inhibitors for the treatment of asthma. 
Preclinical studies have highlighted the potential for isoenzyme-specific PDE inhibitors for 
the treatment of bronchoconstriction in both rodent and human airways. For example, the 
PDE4 inhibitor roflumilast decreases ovalbumin (OVA)-induced contraction in the guinea 
pig trachea as well as large and small airway contraction in ventilated rats and guinea pigs 
(Bundschuh et al. 2001). Similarly, inhibition of both PDE3 and PDE4 decreases leukotriene 
C4-induced contraction in human airways (Rabe et al. 1993; Schmidt et al. 2000; Bundschuh 
et al. 2001). Thus, targeting PDEs may be beneficial to reduce the increased bronchomotor 
tone associated with asthma. In addition, in vitro studies have highlighted the potential of 
PDE inhibitors to reduce ASM proliferation, migration and extracellular matrix deposition 
as well as inflammatory mediators (Goncharova et al. 2003; Burgess et al. 2006; Burgess 
et al. 2006). Recently, Mata and colleagues reported that the PDE4 inhibitor roflumilast 
decreases respiratory syncytial virus infection in bronchial epithelial cells and reduces the 
expression of both the mucin gene MUC5AC and inflammatory mediators (Mata et al. 2013). 
Similarly, Kobayashi and colleagues reported that ASP3258 (3-[4-(3-chlorophenyl)-1-ethyl-7-
methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl] propanoic acid), a PDE4 inhibitor, reduces 
eosinophilia in a chronic OVA-induced murine model of asthma (Kobayashi et al. 2012). 
Clinical studies have shown promising effects of PDE4 inhibitors for the treatment of asthma, 
such as improvements in forced expiratory volume in 1 s (FEV1), inhibition of the late phase 
response and a reduction in inflammatory cell numbers. Gauvreau and colleagues recently 
showed that roflumilast inhibits the allergen-induced late phase response, eosinophilia 
and neutrophilia in a trial that included 25 subjects with mild allergic asthma (Gauvreau et 
al. 2011). However, despite some promising results, PDE4 inhibitors also exhibit unwanted 
adverse effects, including nausea, diarrhea and headaches and thus they are not currently 
approved for the clinical treatment of asthma. 
Targeting phosphodiesterases as a treatment for COPD
The selective PDE4 inhibitor cilomilast has been shown to have anti-inflammatory 
properties and some clinical efficacy, including the prevention of exacerbations in COPD 
patients (Rennard et al. 2008). However, despite showing some beneficial effects, its use 
has been limited due to severe adverse effects. Recently, the PDE4 inhibitor roflumilast was 
approved for use in the treatment of COPD by both the European Medicines Agency and 
the US Food and Drugs Administration (FDA). In vitro studies showed promising results for 
the use of roflumilast in the treatment of COPD. Roflumilast reduces cytokine release from 
a range of inflammatory cells in vitro, suggesting that it may be beneficial in targeting the 
influx of inflammatory cells associated with COPD. Furthermore, in animal models of COPD, 
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roflumilast reduced smoke-induced emphysema (Martorana et al. 2005) as well as the 
influx of neutrophils in the BALF (Martorana et al. 2008). In addition, roflumilast decreased 
the expression of MUC5AC in cultured epithelial cells (Mata et al. 2013) and improved cilia 
motility in vivo (Milara et al. 2012), suggesting that it may improve mucociliary clearance.
The first large randomized clinical trial of roflumilast in COPD studied 1411 patients treated 
with either roflumilast (250 μg or 500 μg) or placebo for 24 weeks showed that roflumilast 
improved post-bronchodilator FEV1 and quality of life and decreased exacerbations 
(Rabe et al. 2005). However, while more recent studies have also shown roflumilast to 
reduce the frequency of exacerbations in patients with COPD (Chong et al. 2011; Yu et al. 
2014), the effects on quality of life and FEV1 have been inconclusive. A Cochrane review 
of 29 randomized control trials reported that PDE4 inhibitors reduced the frequency of 
exacerbations; however, they also reported little effect on quality of life or symptom scores 
(Chong et al. 2011). Whilst further long term studies are required to fully investigate the 
effects of PDE4 inhibitors on lung function, issues regarding safety have been raised with 
many patients experiencing adverse effects including gastrointestinal and psychiatric 
effects. However, there is ongoing development of more potent PDE4 inhibitors such as 
GSK256066, which may have a reduced likelihood of causing vomiting (Nials et al. 2011).
Targeting TRP Channels
The transient receptor potential (TRP) family of ion channels are cation-selective 
transmembrane proteins which show a preference for Ca2+ ions (Caterina et al. 1997; 
Ramsey et al. 2006). The TRP family of proteins consists of 28 members in six subfamilies 
(TRPC, TRPV, TRPM, TRPA, TRPP and TRPML) based on sequence homology (Clapham 2003). 
They are known as cellular sensors as they respond to changes in the local environment 
(Clapham 2003). Whilst expression of TRP channels has been mainly demonstrated in 
sensory nerve cells, they have also been identified in a range of cell types associated with 
respiratory diseases (Peier et al. 2002; Story et al. 2003; Bandell et al. 2004; Jia et al. 2004; 
Kunert-Keil et al. 2006; Bautista et al. 2006; Yang et al. 2006; Alvarez et al. 2006; Dietrich et al. 
2006; Grant et al. 2007; Grant et al. 2007; Nassenstein et al. 2008; Prasad et al. 2008; Banner 
et al. 2011; Li et al. 2011; Jang et al. 2012). TRPA1, TRPV1, TRPC6 and TRPV4 are expressed 
on ASM (Jia et al. 2004; Kunert-Keil et al. 2006; Banner et al. 2011; Jang et al. 2012) and 
inflammatory cells, including neutrophils (Heiner et al. 2003; Li et al. 2003; McMeekin et 
al. 2006; Banner et al. 2011), CD8+ T cells (Prasad et al. 2008; Banner et al. 2011) and airway 
macrophages (Liedtke et al. 2000; Finney-Hayward et al. 2010; Banner et al. 2011). Therefore, 
they represent novel therapeutic targets for the treatment of asthma and COPD. 
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TRP channels as targets for asthma
TRP channels are increasingly being linked to key features of the asthma phenotype. Here, 
we summarize the emerging roles of two members of the TRP family (TRPA1 and TRPV1) in 
bronchoconstriction, allergic airway inflammation and AHR. 
TRPA1 has been reported to be expressed in asthma-relevant cell types such as CD4+ T cells, 
CD8+ T cells, B cells and mast cells (Prasad et al. 2008; Banner et al. 2011); activation of these 
receptors has been linked to the symptoms of asthma. For example, studies have shown 
that environmental irritants that usually cause asthma-like symptoms also activate TRPA1 in 
the airways (Deering-Rice et al. 2011; Shapiro et al. 2013). 
TRPA1 has been associated with the characteristic bronchoconstriction of the late asthmatic 
response (LAR). Raemdonck et al. demonstrated that administration of a TRPA1 antagonist 
in a rodent model of allergic asthma attenuated the LAR. In this same study, the authors also 
deduced a role for airway sensory nerves, a central reflex component and a parasympathetic 
cholinergic constrictor response. Following from this, it could be concluded that allergen 
challenge activates TRPA1 channels present on airway sensory nerves which triggers a 
neuronal response, resulting in bronchoconstriction (Raemdonck et al. 2012). Other studies 
have also indicated a role for TRPA1 in the control of airway tone. Andre et al. reported 
that activation of TRPA1 channels on isolated guinea pig bronchus results in constriction, 
which is secondary to the release of neuropeptides via local axons (Andrè et al. 2008). Hox 
et al. investigated the increased incidence of AHR in swimmers using a mouse model of 
hypochlorite exposure. Exposure to hypochlorite induced AHR, which was abolished 
in TRPA1 deficient mice (Hox et al. 2013). Similarly, TRPA1 deficient mice have reduced 
inflammation and AHR when exposed to OVA (Caceres et al. 2009). Conversely, Spiess et 
al. have recently shown that exposure to acrolein (a known TRPA1 agonist) resulted in a 
decreased inflammatory response in a murine allergic asthma model (Spiess et al. 2013). 
Studies exploring the role of TRPV1 in AHR and allergic inflammation have produced 
conflicting results. Contraction of isolated guinea pig ASM by TRPV1 agonists was 
demonstrated to involve the release of sensory neuropeptides from finite stores in nerve 
endings which consequently act upon neurokinin receptors on ASM, resulting in contraction 
(Belvisi et al. 1992). Rehman et al. reported that TRPV1 modulation inhibits inflammation, AHR 
and airway remodeling in their IL-13 driven murine model (Rehman et al. 2013). However, 
other studies have indicated a protective role for TRPV1 in allergic inflammation (Mori et al. 
2011) and others report no part played by TRPV1 in features of allergic asthma (Caceres et 
al. 2009; Raemdonck et al. 2012). However, it is currently unclear whether TRPV1 is involved 
in bronchospasm in humans and if its action is altered in diseases such as asthma. 
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In conclusion, the roles of TRP channels in asthma continue to be identified (briefly 
summarized in Figure 3). Further study into their mechanisms of action within this disease 
will hopefully result in therapeutic targeting of these channels and the development of 
novel treatments for asthma. 
Figure 3. The role of TRP channels in Asthma. 
TRP channels as targets for COPD
Many direct activators of TRP channels, including arachidonic acid derivatives, lowered 
airway pH, increased temperature and altered airway osmolarity are present in the diseased 
airway, which makes them promising targets for the treatment of COPD. Seven genetic 
variants of the TRPV4 gene are associated with developing COPD (Zhu et al. 2009), and 
expression of the TRPV1 channel is upregulated following exposure to inhaled pollutants 
in the rat bronchus (Costa et al. 2010), suggesting that TRP proteins may play an important 
role in the pathogenesis and susceptibility to COPD. The roles of four TRP channels (TRPA1, 
TRPV1, TRPC6 and TRPV4) in lung inflammation, bronchoconstriction and cough associated 
with COPD are outlined in this section. 
A defining feature of COPD is lung inflammation, caused by increased numbers of 
macrophages, neutrophils and CD8+ T lymphocytes (Keatings et al. 1996; Keatings et al. 
1997). It has recently been demonstrated that TRPC6 plays a modulatory role in neutrophil 
migration as migration to CXCL2 in bone-marrow derived neutrophils is attenuated in 
TRPC6−/− mice (Damann et al. 2009). Cigarette smoke, the primary causative agent of 
COPD (Sethi and Rochester 2000), contains many stimuli that activate the TRPA1 ion 
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channel (Gylling et al. 1991; Bautista et al. 2006; Facchinetti et al. 2007; Andrè et al. 2008; 
Lin et al. 2010), and TRPA1 plays a major role in the early phase of bronchial inflammation 
to cigarette smoke (Bautista et al. 2006). A further role for TRPA1 in COPD has also been 
found in human fibroblasts epithelial and smooth muscle cells where cigarette smoke 
induces cells to release IL-8, and, in mice, KC (IL-8 murine mimetic) in a non-sensory nerve 
driven mechanism (Nassini et al. 2010). TRPV1 has also been implicated in the inflammatory 
processes associated with COPD, where attenuation of neutrophil influx and cytokine 
release was achieved by pretreatment with a TRPV1 agonist, through desensitization of 
the receptor (Tsuji et al. 2010). In addition, airway neutrophilia was significantly reduced 
following exposure to cigarette smoke in TRPV1−/− mice compared to wild type controls 
(Baxter et al. 2012). However, there is no evidence as of yet to implicate TRPV4 in COPD-
associated inflammation as relatively little is known and further investigation is required. 
COPD is characterized by progressive, irreversible airway obstruction, and a number of TRP 
channels have been associated with bronchoconstriction. TRPV1 agonists are known to cause 
bronchoconstriction in humans, probably through a central reflex as bronchoconstriction 
is inhibited by ipratropium bromide (Fuller et al. 1985), as well as in animals (Lalloo et al. 
1995). In animals, this has been is caused by neurogenic inflammation and activation of a 
central reflex. The guinea pig trachea contracts in response to TRPV1 through the release of 
the neuropeptides substance P and neurokinin A, which activate neurokinin receptors on 
ASM (Belvisi et al. 1992). TRPA1 agonists have also been found to cause bronchoconstriction 
secondary to release of neuropeptides (Andrè et al. 2008). In contrast, TRPV4 agonists have 
been shown to cause direct activation of ASM (Jia et al. 2004). It has been shown that a 
selective TRPV4 agonist causes ASM contraction in the absence of a reflex arc (Bonvini et 
al. 2013). 
Cough is a troublesome symptom and is currently the most common complaint for which 
patients visit a doctor in the UK (Barnes 2000). Cough is normally a protective reflex which 
clears the lungs of harmful particles (Nasra and Belvisi 2009) and during disease the cough 
response can become excessive leading to chronic cough (cough which lasts over 8 weeks) 
because of hypersensitivity of the neuronal pathways responsible (Young and Smith 2011). 
This is a problem, lowering the quality of life for sufferers [149] and causing damage to the 
airway mucosa (Canning 2006). Chronic non-productive cough can affect up to 7% of the 
population at any one time (Ford et al. 2006) and is a characteristic symptom in patients 
with COPD, caused by activation of airway sensory nerves (Nasra and Belvisi 2009). The 
role of TRPV1 has been extensively characterized in sensory nerves, and TRPV1-expressing 
nerves innervate the entire respiratory tract (Watanabe et al. 2006). TRPV1 agonists are 
well-documented to cause cough, and in COPD there is increased cough sensitivity to 
capsaicin (O’Connell et al. 1996; Doherty et al. 2000; Higenbottam 2002). Animal models 
have shown that exposure to cigarette smoke causes hypersensitivity to TRPV1 agonist 
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inhalation (Karlsson et al. 1991; Lewis et al. 2007; Maher and Belvisi 2010; Grace and Belvisi 
2011). Similarly, TRPA1 channels have been shown to cause cough in both guinea pigs and 
humans (Birrell et al. 2009), and recently it has been shown that TRPV4 agonists can also 
activate airway sensory nerves directly to cause cough (Belvisi et al. 2013). 
To conclude, a role for a number of TRP channels has been outlined regarding the 
inflammation, bronchoconstriction and chronic cough associated with the pathogenesis 
of COPD (briefly summarized in Figure 4). Taken together with the fact that many direct 
activators of TRP channels are present in the diseased airways, we suggest that TRP channels 
are emerging as promising new targets for the treatment of COPD. 
Figure 4. The role of TRP channels in COPD. 
Kinases
Kinases are key regulators of normal cellular functions, through the site-specific 
phosphorylation of a downstream substrate. As kinases are involved in diverse regulations 
of various cellular functions, they have become an obvious target for rational drug design 
for diseases such as asthma and COPD. In this section, we will briefly discuss the roles of 
various kinases that have been linked to the pathogenesis of asthma and COPD, including 
mitogen activated protein kinase (MAPK; e.g. extra cellular signal-regulated kinase/ERK, 
c-Jun N-terminal kinase/JNK and p38), tyrosine kinases, Ras human ortholog (Rho)/Rho 
kinase (ROCK), protein kinase A (PKA), protein kinase C (PKC), phosphoinositide 3 kinase 




Activation of the MAPK signaling cascade is associated with differentiation, proliferation, 
activation, degranulation and migration of various cell types such as immune cells, 
airway epithelial cells and ASM (Duan and Wong 2006), thus making MAPK an important 
therapeutic target for asthma. To support this, in the in vitro setting, SB239063, a p38 MAPK 
inhibitor, has been found to induce apoptosis in eosinophils isolated and cultured from the 
BALF of guinea pigs. In addition, in in vivo models, SB239063 inhibits OVA- or leukotriene 
D4-induced eosinophilia (Underwood et al. 2000) as well as airway inflammation and 
remodeling in OVA-sensitized and ozone challenged mice (Liang et al. 2013). ERK1/2 has 
been found to be elevated in asthmatic mice in comparison to naïve control mice. U0126, 
a specific ERK1/2 inhibitor, significantly inhibits the infiltration of inflammatory cells and 
various cytokines in the BALF of OVA-challenged mice. In addition, U0126 treatment also 
inhibits eosinophils, goblet cell hyperplasia and vascular cell adhesion molecules (VCAM-1) 
and reduces AHR to methacholine challenge (Duan et al. 2004). 
Another MAPK implicated in asthma is JNK, as inhibition of JNK with SP600125 has 
been found to reduce CXCL10 mRNA expression (Alrashdan et al. 2012). CXCL10/IP10 
is responsible for mast cell migration toward ASM cells. In vivo studies in Brown Norway 
rats has shown that SP600125 inhibits the allergen-induced infiltration of inflammatory 
cells, including macrophages, lymphocytes, neutrophils and eosinophils; however, it did 
not affect eosinophils or T cell accumulation in lung tissue, nor did it reduce the mRNA 
expression of various allergen-induced cytokines such as IL-1β, IL-4 and IL-5. Furthermore, 
this intervention did not affect allergen-induced AHR. In light of these effects, the utility of 
JNK inhibitors in the treatment of asthma is limited (Eynott et al. 2004). 
Phosphatidylinositol 3-kinase (PI3K) activation leads to various cellular functions such as 
cell growth, proliferation, survival and migration. Recent insight into the PI3K pathway has 
revealed that it is associated with numerous inflammatory processes such as activation and 
recruitment of inflammatory mediators and cells along with airway remodeling and steroid 
insensitivity (Finan and Thomas 2004; Ito et al. 2007). This has led to the evaluation of various 
PI3K inhibitors as potential therapeutic options in asthma. Wortmannin, a PI3K inhibitor, 
significantly reduces the in vitro release of eosinophil cationic protein and eosinophil 
peroxidase from eosinophils and myeloperoxidase from neutrophils in asthmatics, 
suggesting a role in eosinophil and neutrophil degranulation (Kämpe et al. 2012). LY294002 
and TG100-115, additional PI3K inhibitors, significantly inhibit inflammatory cell infiltration 
and the expression of inflammatory mediators (IL-5, 13 and eotaxin) in the BALF of OVA-
challenged Balb/C mice, as well as eosinophilia, goblet cell hyperplasia and AHR (Duan et 
al. 2005). Furthermore, the PI3K isoforms p110α, p110β and p110δ are present in ASM cells 
(Krymskaya et al. 1999; Moir et al. 2011; Ge et al. 2012), and both wortmannin and LY294002 
have been found to decrease AHR in a murine model of OVA-induced asthma (Duan et al. 
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2005). Taken together, these data provide promising evidence that PI3K inhibitors could 
emerge as potential therapeutic options for asthma. 
Rho associated coiled coil-containing protein kinase (ROCK) is one of the most studied 
downstream signaling molecules of the monomeric GTP-binding protein RhoA. The major 
physiological functions of the Rho/ROCK axis include contraction, migration and proliferation; 
this pathway has been implicated in the pathogenesis of asthma (Wettschureck and 
Offermanns 2002; Kume 2008; Schaafsma et al. 2008). For example, targeting the Rho/ROCK 
axis inhibits inflammation and airway contraction. Y-27632, a ROCK inhibitor, suppresses the 
release of inflammatory cytokines from activated T cells (Aihara et al. 2004) and reverses the 
carbachol-mediated contraction of rabbit tracheal and human bronchial smooth muscle 
cells via the inhibition of calcium sensitization ex vivo (Yoshii et al. 1999). Furthermore, in an 
in vivo model of allergic asthma, Y-27632 improved AHR to contractile stimuli in response 
to allergen or viral challenge and also reduced airway eosinophilia (Hashimoto et al. 2002; 
Henry et al. 2005; Schaafsma et al. 2006). Similarly, another ROCK inhibitor, fasudil (HA-1077), 
has been shown to inhibit allergen-induced airway inflammation, hyperreactivity and 
hyperresponsiveness in an OVA-driven murine model of allergic asthma (Taki et al. 2007; 
Wu et al. 2009). 
Kinases in COPD
Current forms of therapy for COPD are relatively ineffective, however, in more recently 
kinase inhibitors have been suggested as potential treatments. This is because a variety of 
extracellular stimuli such as Toll receptor ligands (e.g. lipopolysaccharide) and cytokines, 
which are thought to contribute to the progression of COPD, activate kinase pathways such 
as p38 MAPKs, PI3K, Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
and Rho kinase, resulting in downstream activation of transcription factors such as NF-κB 
and increasing pro-inflammatory mediators. In recent years drugs which target specific 
isoforms of these kinases have been developed and their use in in vitro and in vivo models 
has enhanced our understanding of the roles of these kinases in COPD. 
The p38 MAPK family (α, β, γ, δ) is activated by cellular stress, regulates the expression of 
inflammatory cytokines and has been implicated in the induction and maintenance of 
airway inflammation in COPD. For example, levels of phosphorylated (active) p38 are greater 
in alveolar macrophages from COPD lungs compared with those from non-COPD control 
smokers and non-smokers (Renda et al. 2008). In addition, phosphorylated p38 is also 
increased in sputum from COPD patients and correlates with both CXCL8 and decreased 
lung function (Huang et al. 2013b). Further support for the role of p38 was recently shown 
in an in vivo transgenic mouse model study where it accelerated the rate of LPS + cigarette 
smoke induced emphysema (Amano et al. 2014). Similarly, in another murine inflammatory 
model of COPD inhibition of p38 using the α-isoform selective inhibitor SD-282 reduced 
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the increased number of tobacco smoke-induced macrophages and neutrophils back 
to baseline (Medicherla et al. 2008). Thus, p38 appears to play a pivitol role in the airway 
inflammation associated with COPD, hence making it a potential target for therapeutic 
intervention. 
Several oral p38 inhibitors, such as losmapimod and PH797804, have undergone phase 
II clinical trials for the treatment of COPD however, their findings are variable. Singh and 
colleagues reported that orally administered SB681323 reduced p38 MAPK signaling and 
suppressed TNFα production in a small clinical pharmacological study of 17 COPD patients 
(Singh et al. 2010). In a study by Lomas et al. oral administration of the p38 inhibitors 
losmapimod (GW856553) for 12-weeks significantly reduced plasma fibrinogen levels [a 
biomarker for COPD (Duvoix et al. 2013)] but had no effect on sputum neutrophil levels 
or lung function (Lomas et al. 2012). Similarly, in a recent multicentre clinical trial study 
Watz and colleagues reported that despite being well tolerated losmapimod (2.5, 7.5 or 15 
mg) treatment for 24 weeks had no effect on exercise tolerance in patients with COPD as 
demonstrated using the 6-min walk test (Watz et al. 2014). In contrast, in a 6-week clinical 
trial PH797804 improved dyspnea and lung function in moderate to severe COPD patients 
(MacNee et al. 2013), thus PH797804 shows great promise. However, whilst there may be 
some beneficial effects of p38 inhibitors further longer term-studies are required. One of 
the major limiting problems reported in clinical studies using oral p38 inhibitors is adverse 
effects therefore drugs which are directly delivered to lung via inhalation, such as PF-
03715455 may prove beneficial (Millan et al. 2011). 
Another kinase to be considered is JAK. In COPD several cytokines and inflammatory 
mediators signal via the JAK/STAT pathway and therefore inhibition of JAK may provide 
another therapeutic target. Whilst oral JAK inhibitors such as tofacitinib have shown 
promise in other diseases, such as ulcerative colitis and rheumatoid arthritis (Fleischmann 
et al. 2012a; Fleischmann et al. 2012b; Sandborn et al. 2012; Kawalec et al. 2013), their effects 
on COPD have not been investigated. 
PI3K is another important kinase in COPD as PI3Ks generate second messengers that 
regulate several cellular events involved in inflammation and PI3K activity is increased in 
the peripheral lungs of people with COPD (To et al. 2010). PI3K-δ and -γ are likely to be the 
most important isoforms as they play an important role in inflammation associated with 
COPD. PI3K-δ is increased in macrophages from people with COPD compared with smokers 
with normal lung function (Marwick et al. 2010). In addition, p110δ isoform expression is 
higher on ASM from the lungs of patients with COPD compared with those without COPD 
(Ge et al. 2012). The PI3K-γ isoform is expressed predominantly on leukocytes and knockout 
of the PI3K-γ gene inhibits neutrophil migration in mice (Medina-Tato et al. 2007). Whilst 
non-selective PI3K inhibitors have a high toxicity and therefore have had limited success, 
there are several novel PI3K isoform specific inhibitors in development. Although none of 
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these are currently undergoing clinical trial for COPD they are beginning to emerge in in 
vitro and in vivo studies. Aerosol administration of the dual PI3K-γ/δ inhibitor TG100-115 
has been used in a preclinical mouse model study of LPS- and smoke-induced pulmonary 
inflammation. In this study by Doukas et al., TG100-115 reduced pulmonary neutrophilia and 
restored corticosteroid insensitivity in mice (Doukas et al. 2009). Theophylline has recently 
re-emerged into the arena as a treatment for COPD as when it is given at a low-dose it acts 
as an inhibitor of PI3Kδ (To et al. 2010). Currently, clinical trials examining the effectiveness 
of low-dose theophylline are under way. 
Kinase inhibitors in asthma & COPD – adverse effects 
On a cautionary note kinases modulate a number of key cellular functions, thus a global 
inhibition of a particular kinase via systemic delivery is likely to produce adverse events, for 
example various protein kinase inhibitors currently used as anticancer agents are associated 
with several major adverse events such as hypertension, anemia and other hematological 
disorders (Sodergren et al. 2014). Since kinases are inhibitors of enzymes belonging to 
cytochrome P450 superfamily in particular CYP1A2, 2C9, 2D6, and 3A4, their systemic use 
may result into the potential interaction with concomitant medication and may produce 
unwanted effects (Wang et al. 2014). In order to bypass this issue a localized delivery of 
these agents at a very low dose should be considered to target patients with asthma or 
COPD. Inhalation therapy rather than oral administration should also be considered. 
Nevertheless the positive impact of kinase therapy in in vitro and in vivo studies has led 
to the development of various molecules that are currently undergoing clinical trials for 
their efficacy in human asthma and COPD. Some of these molecules and their stages of 
development are shown in Table 1.
Vitamin D
Whilst vitamin D and its receptors are known for their role in bone mineralization and 
calcium homeostasis, there is growing evidence that vitamin D deficiency may contribute 
to respiratory diseases. Here, we discuss the role of vitamin D in asthma and COPD. 
Vitamin D in asthma 
Recently, it has been suggested that vitamin D deficiency has contributed to the rise in 
asthma and allergy. The current hypothesis is that Westernization has led to human 
populations spending more time indoors, resulting in less sun exposure and hence vitamin 
D deficiency (Litonjua and Weiss 2007). Epidemiological studies show that low serum 
vitamin D levels are associated with adverse asthma outcomes, including worse asthma 
control (Chinellato et al. 2011), increased corticosteroid use (Brehm et al. 2009; Gupta et 
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al. 2011) and increased asthma exacerbations (Brehm et al. 2009; Brehm et al. 2010). Much 
of the data from these observational studies support the hypothesis that higher vitamin D 
levels lead to better asthma outcomes. 
Table 1. Clinical development of kinase inhibitors for the treatment of asthma and COPD. (Source: 
ClinicalTrials.gov). 
Disease Kinase Drug name Sponsor Trial phase Title
Asthma p38 MAPK – Imperial College 
London
Unknown
PI3K IPI-145 Infinity Pharmaceuticals 2 Phase 2a, Efficacy and Safety 







AB Science 2 Efficacy of Oral AB1010 in Adult 
Patients with Severe Persistent 
Corticosteroid Dependent 
Asthma
COPD p38 MAPK Losmapimod Cambridge University 
Hospitals NHS 
Foundation Trust
2 Losmapimod in Chronic 
Obstructive Pulmonary 
Disease Patients Stratified by 
Fibrinogen. (EVOLUTION)
PH797804 Pfizer 2 A Phase II, study to evaluate 
the efficacy and safety of PH-
797804 in adults with moderate 
to severe Chronic Obstructive 
Pulmonary Disease (COPD) (study 
completed)
PF03715455 Pfizer 1 Single Dose Lipopolysaccharide 
(LPS) Study In Healthy Volunteers
PI3K Low-dose 
theophylline
Hospital Son Espases 3 Low-dose Theophylline as anti-
inflammatory enhancer in severe 
chronic obstructive pulmonary 
disease (ASSET)
Birth cohort studies investigating the associations between vitamin D status and asthma 
and allergy outcomes in children have however revealed conflicting results. While there 
have been studies showing that a lower dietary intake of vitamin D during pregnancy 
leads to an increased risk of wheeze (Camargo et al. 2007; Devereux et al. 2007) and asthma 
development in children (Erkkola et al. 2009), a Finnish study has also demonstrated 
an increased prevalence of asthma and atopy in adults who had received vitamin D 
supplementation during the first year of life (Hyppönen et al. 2004). Vitamin D status 
was assessed using food questionnaires rather than directly measuring serum 25(OH) D 
concentrations and may not provide an accurate representation of vitamin D status since 
this excludes vitamin D synthesized from sun exposure, a major determinant of vitamin D 
status. Studies that directly measure maternal serum vitamin D status are conflicting with 
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one study showing no association with risk of childhood asthma, wheeze and atopy (Pike et 
al. 2012), and another showing an increased risk of asthma in children at 9 years of age (Gale 
et al. 2008). As such, there has yet to be convincing data that vitamin D influences asthma 
and allergy outcomes. However, vitamin D deficiency in humans is often an indirect marker 
of confounding factors such as nutritional status and physical fitness, making it difficult 
to determine a causal association between vitamin D status and chronic lung disease. 
Therefore, in order to study the causal pathways between vitamin D and disease outcomes, 
in vitro and in vivo models are invaluable tools. 
In vitro studies using human ASM cells obtained from asthmatic and normal subjects have 
demonstrated that 1,25-dihydroxy vitamin D, the active metabolite of vitamin D, inhibits ASM 
cell proliferation by preventing cell cycle progression (Damera et al. 2009). These findings 
support a study showing increased ASM mass in vitamin D-deficient children with severe 
asthma (Gupta et al. 2011), and suggests that vitamin D may have a role in airway remodeling. 
However, this has yet to be demonstrated in in vivo studies. The immunomodulatory 
functions of vitamin D have, however, been well-studied using mouse models of allergic 
asthma. One study found that vitamin D deficiency enhanced the capacity of airway 
draining lymph nodes to secrete Th2 cytokines in both male and female mice. Eosinophil 
and neutrophil numbers, as well as bacterial levels, were increased in the BALF of male mice, 
and vitamin D supplementation reversed these effects (Gorman et al. 2013). Other mouse 
studies have shown that 1,25-dihydroxy vitamin D supplementation inhibits eosinophil and 
lymphocyte recruitment into the airway lumen, reduces IL-4 production from T cells and 
impairs T cell migration, thus damping the inflammatory response (Topilski et al. 2004). It has 
also been found that early treatment with 1,25-dihydroxy vitamin D results in enhanced Th2 
cytokine (IL-4 and IL-13) and IgE production, but IL-5 release and eosinophilia are inhibited 
when 1,25-dihydroxy vitamin D is administered at a later stage (Matheu et al. 2003). Despite 
different findings regarding T cell responses in different experimental protocols, the data 
from mouse models of asthma suggest that vitamin D supplementation may be beneficial 
for the treatment of established disease. Whether vitamin D supplementation can prevent 
disease onset still needs to be determined. 
Vitamin D can also act as an adjuvant for other therapies. Administration of 1,25-dihydroxy 
vitamin D with allergen immunotherapy enhanced the beneficial effects of immunotherapy 
in a mouse model of asthma (Taher et al. 2008). Xystrakis et al. demonstrated that the 
addition of vitamin D and dexamethasone to CD4+ regulatory T cell cultures from steroid-
resistant asthmatic patients enhanced IL-10 synthesis to levels comparable to steroid-
sensitive patients treated with dexamethasone alone. Furthermore, vitamin D overcame 
dexamethasone-induced downregulation of glucocorticoid receptor expression by CD4+ 
T cells (Xystrakis et al. 2006). In a separate study, addition of vitamin D to an experimental 
in vitro model of steroid resistance resulted in the suppression of T cell proliferation when 
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dexamethasone on its own did not inhibit cell proliferation (Searing et al. 2010). Together, 
these data provide evidence that vitamin D could enhance the anti-inflammatory effects of 
glucocorticoids and potentially be used as a therapy in severe asthma for patients who are 
steroid-insensitive. 
Vitamin D and COPD 
Vitamin D deficiency is also common in patients with COPD (Janssens et al. 2010; Persson 
et al. 2012). In a study by Janssens et al., serum 25-hydroxy vitamin D, the circulating form 
of vitamin D, correlated with lung function in patients with COPD. Certain genetic variants 
of the vitamin D binding protein (VDBP), the major carrier protein for vitamin D that binds 
circulating 25-hydroxy vitamin D and 1,25-dihydroxy vitamin D with high affinity, are risk 
factors for COPD (Janssens et al. 2010). Recent studies investigating the effects of vitamin 
D supplementation on COPD patients have primarily focused on the role of vitamin D 
in improving muscle strength in COPD patients. While a Belgian study demonstrated 
improvements in inspiratory muscle strength and maximal oxygen uptake following vitamin 
D supplementation (Hornikx et al. 2012), another study which supplemented patients with 
higher doses of vitamin D showed no effect in physical performance (Bjerk et al. 2013). A 
positive association between dietary vitamin D intake and FEV1, FEV1/FVC and a negative 
association with COPD incidence has also been shown (Shaheen et al. 2011). In the same 
study serum 25(OH) D levels were positively associated with COPD prevalence but not FEV1 
and FVC. These data further confirm that analysis of vitamin D intake from the diet is not 
an ideal indication of vitamin D status and that associations should be interpreted with 
caution in COPD due to the link between vitamin D and musculoskeletal abnormalities in 
COPD. Despite an association between vitamin D and COPD studies investigating the role 
of vitamin D and COPD using in vitro and in vivo models are lacking, and the majority of the 
available data are from cross-sectional human studies. 
Alveolar macrophages obtained from a population with a high risk of COPD showed 
increased macrophage activation and higher levels of VDBP in the airways (Wood et al. 
2011). In this population, the GC2 variant of VDBP, which is less able to activate macrophages, 
was protective against COPD. Macrophage accumulation and activation in the lung causes 
the release of neutrophil chemoattractants which may contribute to lung damage in COPD. 
Another variant of the VDBP gene, rs7041, was predictive of vitamin D deficiency, which 
in turn was associated with reduced lung function (Janssens et al. 2010; Wood et al. 2011). 
Vitamin D levels have been shown to correlate with lung function in a large population 
based study (Black and Scragg 2005); this was also demonstrated in a mouse model of 
vitamin D deficiency (Zosky et al. 2011). In this study, vitamin D-deficient juvenile mice not 
only had reduced lung function, but also had altered lung structure and smaller lungs (Zosky 
et al. 2011). Reduced lung function has also been reported in a vitamin D receptor (VDR) 
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knockout mouse model (Sundar et al. 2011). VDR deletion also led to chronic inflammation 
and immune dysregulation, which ultimately resulted in a COPD phenotype in this model. 
Given these data, it is tempting to speculate that vitamin D deficiency may be a risk factor 
for COPD. The strong evidence for a genetic susceptibility to COPD with variants of the VDBP 
genes warrants further investigation into the functional mechanisms of VDBP. In vitro and in 
vivo studies will certainly be useful for determining how VDBP and vitamin D contribute to 
inflammation and altered lung structure and, ultimately, if vitamin D supplementation will 
be beneficial. 
Matrix Metalloproteinases as Targets in Asthma and COPD 
Matrix metalloproteinases (MMPs) are a family of zinc endopeptidases capable of degrading 
most components of the extracellular matrix. They exist in balance with their endogenous 
inhibitors, tissue inhibitors of MMPs (TIMPs). A disruption of this balance is a key event in 
the development of pulmonary diseases such as asthma and COPD where elevated levels 
of MMPs have been reported. Thus, targeting the MMPs may be an alternative therapeutic 
strategy. 
MMPs and asthma 
MMPs have been implicated in asthma, and recent studies have highlighted polymorphisms 
in MMP genes which may contribute to a predisposition to asthma (Jiménez-Morales et al. 
2013). Altered levels of MMPs have also been reported; for example, MMP-9 is increased 
in the lung tissues as well as sputum, BALF and serum from asthmatic subjects when 
compared with healthy subjects (Hoshino et al. 1998; Cataldo et al. 2000; Mattos et al. 2002; 
Ko et al. 2005; Hong et al. 2012). Other MMPs, including MMPs -1, -2, -7, -10, -12 and -19, have 
also been implicated in asthma. There is strong evidence for a role for MMP-12 in asthma as 
mice deficient in MMP-12 exhibit a reduction in inflammation following allergen challenge. 
Interestingly, MMP-12 regulates airway remodeling through its capacity to degrade a wide 
range of ECM proteins including elastin, type IV collagen, fibronectin and gelatin. Similarly, 
MMP-10 has also been implicated in asthma exacerbations as it is induced by respiratory 
syncytial virus in human nasal epithelial cells (Hirakawa et al. 2013). Thus, there is evidence 
of elevated MMP levels in asthma which may contribute to airway remodeling. 
Broad spectrum MMP inhibitors such as tetracyclines have been investigated as potential 
treatments for asthma, although the results are not clear-cut. Tetracyclines work by directly 
binding to the Ca2+ and Zn2+ ions in the active site of MMPs, thus rendering the MMP inactive. 
Doxycycline, a broad spectrum MMP inhibitor, has been found to decrease allergen-induced 
eosinophilic inflammation and AHR in an OVA-driven mouse model of asthma by reducing 
the proteolytic activity of MMP-9 when administered by aerosol (Gueders et al. 2008). In 
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addition, this intervention reduced MMP-9 mRNA as well as airway inflammation and AHR 
in a mouse model of toluene diisocyanate-induced asthma (Lee et al. 2004). In contrast, 
doxycycline had no effect in a cat model of Ascaris suum-induced asthma (Leemans et al. 
2012). In addition, the broad spectrum MMP inhibitor R94138 reduced the development 
of allergic inflammation in a mouse model, and inhibition of MMP-12 led to a significant 
reduction in the early and late airway responses in a sheep model of asthma (Li et al. 2009; 
Mukhopadhyay et al. 2010). It has been suggested that other MMPs may have a protective 
role in asthma, since MMP-8 deficiency promotes allergen-induced airway inflammation 
and MMP-8 deficient mice exhibit AHR (Gueders et al. 2005). 
Whilst in vivo studies have found that broad spectrum inhibitors may be beneficial, their 
clinical use remains unclear. Clinical trials with MMP inhibitors for other diseases have 
been disappointing, partially due to the off-target effects observed with broad spectrum 
inhibition. More targeted approaches may provide therapeutic benefit with reduced 
adverse effects. 
MMPs and COPD 
Initially, emphysema was believed to be driven by neutrophil elastase; however, it is now 
accepted that MMPs, including -1, -2, -7, -9 and -12, produced by both inflammatory and 
structural cells in the lung, also play a significant role in the alveolar destruction. Studies have 
shown elevated levels of MMPs -1, -2, -9, and -12 in COPD (Segura-Valdez et al. 2000; Culpitt 
et al. 2005; Demedts et al. 2006; D’Armiento et al. 2013), with sputum and exhaled breath 
condensate levels of MMP-9 further increased during exacerbations (Mercer et al. 2005; 
Kwiatkowska et al. 2012). MMP-12 has been implicated in the pathogenesis of COPD with 
expression of the common serine variant at codon 357 of the MMP-12 gene associated with 
clinical manifestations of the disease (Mukhopadhyay et al. 2010). Furthermore, elevated 
levels of MMP-12 have been reported in many (Demedts et al. 2006; Ilumets et al. 2007) but 
not all (Imai et al. 2001) studies of COPD. 
There is increasing evidence that elevated MMP levels may cause alveolar destruction 
and inflammation and that inhibition may be an effective strategy to treat COPD. Chronic 
exposure of mice to cigarette smoke induces alveolar airspace enlargement and alveolar 
destruction as well as expression of MMPs, including MMP-1, MMP-9 and MMP-12 (Lavigne 
and Eppihimer 2005; Vlahos et al. 2006; Churg et al. 2007a; Churg et al. 2007b; Xu et al. 2011; 
Bezerra et al. 2011; Geraghty et al. 2011). Overexpression of collagenase or MMP-9 induces 
emphysema (D’Armiento et al. 1992; Foronjy et al. 2008), whereas in mouse models of smoke-
induced emphysema, treatment with the broad spectrum metalloproteinase inhibitors 
RS113456 or PKF242-484 prevented neutrophil infiltration (Churg et al. 2001; Morris et al. 
2008). Recent studies have investigated the roles of specific MMPs. Elevated MMP-1 has 
been implicated in the alveolar disruption associated with COPD, as expression of human 
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MMP-1 in a transgenic mouse model caused disruption of alveolar walls, coalescence of 
alveolar spaces and pulmonary emphysema in mice (Shiomi et al. 2003). MMP-12 induces 
alveolar destruction and degradation of elastin in COPD and MMP-12 deletion or inhibition 
(via MMP408) prevents inflammation and emphysema in mouse models of COPD (Li et al. 
2009). Thus, evidence from animal models suggests that targeting MMPs may be beneficial 
for the treatment of COPD. 
The effectiveness of MMP inhibitors as a treatment for COPD in humans remains unknown 
as few clinical trials have been conducted. In a recent clinical trial of 55 patients with stable 
moderate-to-severe COPD, treatment with AZD1236, a selective MMP-9/MMP-12 inhibitor 
was examined. Whilst treatment for 6 weeks was well-tolerated, there was little effect on 
clinical outcomes (Dahl et al. 2012); thus, further studies are required. 
Overall, given the body of evidence supporting a role for MMPs in emphysema, further 
research into MMP inhibitors as a possible treatment for COPD is justified. 
Combination Therapies in the Treatment of Asthma and COPD
New developments for combination therapy 
The bronchodilating effectiveness of β
2
-adrenoreceptor agonists is influenced by functional 
antagonism by bronchoconstricting agents. Thus, studies in human (Raffestin et al. 1985; 
Van Amsterdam et al. 1990) and animal (Torphy et al. 1985; Van Amsterdam et al. 1989) 
ASM preparations have demonstrated that the potency and efficacy of β
2
-adrenoreceptor 
agonists are gradually reduced in the presence of increasing concentrations of contractile 
stimuli, including muscarinic receptor antagonists and histamine. This reduced β
2
-adrenergic 
responsiveness may be due to cross-talk between G
q
-coupled muscarinic M3 or histamine 




-adrenoceptors (Figure 1). This provides a strong rationale 
for combination treatment with β
2
-adrenoreceptor agonists and muscarinic receptor 
antagonists, as muscarinic receptor antagonists both attenuate bronchoconstriction 
and potentiate β
2
-adrenoreceptor agonist-induced bronchodilation by relieving the 
cholinergic restraint on β
2
-adrenoceptor function. Therefore, several long acting LABA + 
LAMA combinations are under development, as well as bi-functional molecules that link a 
muscarinic receptor antagonist and β
2
-adrenoreceptor agonist (MABA). 
Several studies have demonstrated its safety and tolerability profile (Dahl et al. 2013b; Dahl 
et al. 2013a) as well as a significant improvements in dyspnea and health status (Mahler et 
al. 2014). Furthermore, a once-daily fixed-dose combination of olodaterol and tiotropium 
is being studied in the TOviTO Phase III clinical trial program (Boehringer Ingelheim 2013). 
In preliminary studies, this combination has already demonstrated synergistic effects on 
bronchodilation (Bouyssou et al. 2010b), as well as anti-proliferative effects (Costa et al. 
2013) and anti-inflammatory effects (Profita et al. 2012; Costa et al. 2012). 
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Another approach to combining β
2
-adrenoreceptor agonists and muscarinic receptor 
antagonists can be found in single molecules, which possess activity at both muscarinic 
receptors and β
2
-adrenergic receptors. GlaxoSmithKline and Theravance have synthesized 
GSK961081, a MABA representing the combination of tiotropium and salmeterol. In a 4-week 
phase IIb 4 clinical trial, GSK961081 appeared to be well-tolerated and bronchodilator 
efficacy was comparable to tiotropium + salmeterol (Bateman et al. 2013; Wielders et al. 
2013). Taken together, this evidence suggests that MABA molecules are a potential new 
therapeutic approach for the treatment of COPD. 
A novel combined corticosteroid/bronchodilator 
Combined formulations of LABAs and inhaled corticosteroids (ICS) in a single inhaler have 
been put forward in the last decade as an improved therapy for allergic asthma since this 
drug combination has been found to confer synergistic effects in terms of controlling 
airway inflammation and improving lung function. Importantly, providing therapy in 
a single inhaler has also been shown to improve patient compliance (Cates and Karner 
2013). Recently, a new combined formulation has been developed that allows for once-
daily dosing, combining the corticosteroid fluticasone furoate (FF) and the long-acting 
β-agonist vilanterol (VI). A one-year safety study of FF/VI in asthma patients showed that 
this intervention is well-tolerated (Busse et al. 2013). In another study in moderate-to-severe 
asthmatics, FF/VI significantly improved lung function compared to treatment with the 
single drugs alone (O’Byrne et al. 2014). FF/VI was also found to be effective in inhibiting 
the early and late asthmatic responses to allergen challenge (Oliver et al. 2013), supporting 
the use of this therapy for the treatment of allergic asthma. Additionally, this drug was 
approved by the FDA in May 2013 for the treatment of COPD. Clinical trials on the use of FF/
VI for the treatment of COPD showed a reduced incidence of exacerbations with long-term 
treatment (Bollmeier and Prosser 2014). 
Anti-leukotrienes as add-on therapy for asthma
Several recent studies have assessed targeting leukotrienes, which are well-known lipid 
mediators of allergic inflammation, as further add-on therapy. Approaches have included 
adding a novel 5-lipoxygenase-activating protein inhibitor (GSK2190915) or an established 
leukotriene receptor antagonist (montelukast) to either inhaled corticosteroids alone 
or a combination corticosteroid/long-acting β-agonist (Snowise et al. 2013). Although 
these two studies did not find a statistically significant benefit of inhibiting leukotrienes 
in terms of the primary outcome (improvement in FEV1), targeting this pathway did have 
a positive effect on asthma symptoms and reduced the need for short-acting β-agonist 
rescue therapy. A recent study by Gao et al. investigated the impact of anti-leukotriene add-
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on therapy on lung structure in moderate-to-severe asthmatics using high-resolution CT 
scans after 24 weeks of treatment with salmeterol/fluticasone (SFC) plus montelukast (SFC 
+ M) or SFC plus placebo. Although the addition of montelukast treatment did not have 
a beneficial effect in terms of reducing airway wall thickness, SFC + M triple combination 
therapy did reduce air trapping, suggesting that interfering with leukotriene signaling may 
have a beneficial effect on the physiology of the small airways (Gao et al. 2013).
Anticholinergic drugs as add-on therapy for COPD 
Combined therapy with an anticholinergic agent such as tiotropium and either a long-
acting β-agonist alone or along with combined corticosteroid/long-acting β-agonist 
therapy has been recently evaluated for the treatment of COPD. In a study by Hoshino et 
al., tiotropium + salmeterol + fluticasone propionate treatment for 16 weeks was associated 
with reduced airway wall thickening, improved lung function and reduced symptoms 
compared to treatment with tiotropium, salmeterol or salmeterol + fluticasone propionate 
(Hoshino and Ohtawa 2013). These results were corroborated by Maltais et al. who found 
significant improvements in lung function in COPD patients after four weeks of treatment; 
however, there was no significant improvement in exercise endurance with the addition of 
tiotropium to salmeterol + fluticasone propionate (Maltais et al. 2013). 
Targeting the small airways 
Small airway dysfunction is a feature of both allergic asthma and COPD; however, few 
inhaled drug formulations are designed to reach the distal parts of the lung. However, 
with the advent of extrafine particle corticosteroids, inflammation in these areas of the 
lung can now be addressed. Asthma patients who were switched from conventional 
combined corticosteroid/long-acting β-agonist therapy to an extrafine formulation of 
beclomethasone/formoterol showed improvements in asthma symptom scores and blood 
eosinophils as well as a reduction in air trapping, indicating a positive effect on the small 
airways with the extrafine formulation (Popov et al. 2013). In another study on patients with 
stable asthma, extrafine ciclesonide given as an add-on therapy led to a reduction in indices 
of peripheral lung inflammation and significantly improved symptom scores (Nakaji et al. 
2013). Targeting the small airways in COPD has also led to improved symptom scores and 
small airways function, despite no change in FEV1 (Timmins et al. 2014). 
Future Directions
In this review, we have highlighted some of the potential targets that are emerging for 
the treatment of asthma and COPD. However, due to space limitations, other potential 
candidates for future treatments such as Toll-like receptors, bitter taste receptors and the 
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receptor for advanced glycation end products (RAGE) should also be considered [reviewed 
in (Bezemer et al. 2012; Sukkar et al. 2012; Drake et al. 2012; Liggett 2013)]. 
Whilst significant advances in our understanding of the cellular and molecular mechanisms 
involved in the pathogenesis of asthma and COPD have allowed for the identification of 
novel therapeutic targets, few new pharmaceutical agents have been developed for clinical 
treatment. Asthma and COPD are multifaceted diseases and, therefore, it is unlikely that 
a single treatment will be optimal; thus, further investigations into potential combination 
therapies are needed. In order to develop new therapeutic interventions, we not only need 
to fully understand the multifaceted action of potential drug targets, but also improve drug 
delivery systems such that therapeutic agents are delivered to these targets. One potential 
delivery system is the use of nanotechnology and nanoparticles [refer to (Vij 2011)]. 
Whilst the use of nanoparticles in the treatment of lung health may be controversial, with 
arguments that they may aggravate pulmonary diseases, there may also be advantages. 
Nanotechnology allows for more targeted drug delivery and controllable release of the 
drug by protecting the drug from inactivation or degradation upon administration, thus 
potentially minimizing adverse reactions (Da Silva et al. 2013). Experimental models of 
asthma have shown greater treatment responses with drugs encapsulated in nanoparticles 
when compared to the drug alone (John et al. 2003; Matsuo et al. 2009; Kenyon et al. 2013). 
Similarly, nanocarrier drug delivery is also beneficial in the treatment of COPD models 
(Geiser et al. 2013). However, further studies are required as some reports have suggested 
nanoparticles themselves may have adverse effects on the lung (Gwinn and Vallyathan 
2006; Hussain et al. 2011). 
Overall, in vitro and in vivo studies have identified multiple potential drug targets which may 
lead to the development of the next generation of treatments for asthma and COPD. 
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With the ability of switching between a proliferative and a contractile phenotype, airway 
smooth muscle (ASM) cells play an important role in the progression of airway diseases 
such as asthma and chronic obstructive pulmonary disease (COPD). This capacity underpins, 
in part, airway remodeling in asthma as well as COPD, with patients very often exhibiting 
ASM hypertrophy associated with hypercontractility. A-kinase anchoring proteins (AKAPs) 
provide a molecular platform to ensure that signaling effectors are appropriately targeted 
to facilitate intracellular signal transduction. A unifying feature of AKAPs is their ability to 
anchor protein kinase A (PKA) in proximity to its substrates near membrane structures. 
Several studies indicate that interruption of AKAP-PKA function leads to cellular dysfunction. 
As stearated (st)-Ht31, a peptide that disrupts the interaction of AKAP and PKA, affects a 
variety of cellular functions, including cardiac muscle contraction and cell cycle progression, 
we studied here whether st-Ht31 alters airway smooth muscle function. We report that 
treatment of ASM cells with st-Ht31 enhances proliferative markers such as DNA synthesis, 
cyclin D expression as well as phosphorylation of retinoblastoma protein and p70S6 kinase, 
a process accompanied by a downregulation of AKAP8. Interestingly, st-Ht31 also promotes 
accumulation of contractile marker proteins, including α-smooth muscle actin (SMA) and 
calponin, presumably by regulating protein stability. Of note, treating intact human ASM 
strips with st-Ht31 simultaneously enhanced α-SMA abundance and muscle contraction, 
whilst concomitantly increasing abundance of the S phase marker proliferating cell nuclear 
antigen. 
Taken together, treating ASM with st-Ht31 leads to a simultaneous increase in markers of 
both a hypercontractile and a hyperproliferative phenotype in both ASM cells and intact 
ASM strips. Thus, AKAP-PKA interaction could play a critical role to maintain ASM normal 
function, therefore preventing progression of airways diseases such as asthma and COPD. 
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Introduction
Airway smooth muscle (ASM) cells have capacity for phenotypic plasticity and are able to 
switch between a more proliferative (and less contractile) or a more contractile (and less 
proliferative) phenotype in response to microenvironment changes in mitogens, growth 
factors such as transforming growth factor-β, and extracellular matrix composition (Halayko 
et al. 2008). Phenotypic plasticity of ASM plays an important role in the pathophysiology of 
obstructive pulmonary diseases, such as chronic obstructive pulmonary disease (COPD) and 
asthma, by enabling airway hypercontractility and increased ASM mass (Halayko et al. 2008), 
which contribute to airway narrowing and airflow limitation (Amrani and Panettieri 2003; 
Chung 2005). The hypercontractile phenotype is characterized by an increased expression 
of contractile proteins, such as α-smooth muscle actin (SMA) and calponin (Halayko et 
al. 2008). We have shown that cAMP regulates mitogen-induced phenotypic plasticity 
(Roscioni et al. 2011a; Roscioni et al. 2011c) and that activation of the cAMP effector protein 
kinase A (PKA) both prevents mitogen-induced proliferation by blunting the activation of 
ERK and p70S6K, as well as inhibiting mitogen-induced reduction in contractile protein 
expression in ASM strips (Roscioni 2011 and 2011).
A-kinase anchoring proteins (AKAPs) are scaffolding proteins that provide a molecular 
platform for other proteins to ensure that signaling effectors are appropriately targeted 
to different domains, thereby specifying and facilitating intracellular signal transduction 
(Wong and Scott 2004). Several AKAP isoforms have been identified that can differ in their 
cellular localization (Skroblin et al. 2010). A unifying feature of AKAPs is their ability to anchor 
the regulatory subunits of PKA in proximity to substrates via a conserved short α helical 
structure (Esseltine and Scott 2013). Besides PKA, each AKAP can bind several receptors, 
ion channels, protein kinases, phosphatases, small GTPases and phosphodiesterases to 
orchestrate formation of unique signaling complexes (Poppinga et al. 2014; Han et al. 
2015). AKAPs are important in compartmentalizing cAMP within the cellular context, thus 
providing spatio-temporal regulation of the cAMP pathway (Wong and Scott 2004). On this 
basis, AKAPs regulate a number of cellular responses including intracellular actin dynamics 
(Kim et al. 2013) and cell cycle progression (Han et al. 2015). All AKAPs bind to the regulatory 
subunits of PKA through a conserved short α helical structure (Pawson and Scott 1997), and 
based here on a cell permeable inhibitor peptide, stearated (st)-Ht31, was developed to 
block the interaction between all members of the AKAP family and PKA (Vijayaraghavan et 
al. 1997; Poppinga et al. 2014).
Cell cycle kinetics is controlled by various effectors, including p70S6 kinase (p70S6K), 
extracellular signal-regulated kinase (ERK), proliferating cell nuclear antigen (PCNA), cyclins, 
and retinoblastoma protein (Rb) (Leonardi et al. 1992; Karpova et al. 1997; Grewe et al. 1999; 
Bertoli et al. 2013; Dick and Rubin 2013). Of note, most of these effectors can interact with 
AKAPs (Han et al. 2015), and dysfunction of AKAPs is associated with cell cycle dysregulation 
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(Akakura et al. 2008; Pellagatti et al. 2010; Kong et al. 2013; Petrilli and Fernández-Valle 2015).
A number of AKAPs have been identified in ASM, including AKAP8 (aka AKAP95) (Horvat 
et al. 2012; Poppinga et al. 2015), which can interact with cyclin D1 (Arsenijevic et al. 2004). 
However, the a more general role for AKAPs in regulating cell cycle transit and contractility 
in ASM is yet to be defined. Using a unique a specific AKAP-PKA interaction disruptor, 
st-Ht31 (Skroblin et al. 2010), the current study explores the role of AKAPs in regulating 
airway smooth muscle contractility and proliferation. 
Methods 
Cell culture 
Human ASM cell cultures were generated from macroscopically healthy 3rd-5th generation 
bronchial segments obtained from three different donors undergoing lung resection surgery, 
and thereafter  low passage number primary cultures (P2-P3) were made senescence-
resistant by stable ectopic expression of human telomerase reverse transcriptase (hTERT) 
as described previously (Gosens et al. 2006). Cell cultures were maintained in DMEM (Life 
technologies, 11965-092) containing heat-inactivated fetal bovine serum (10% vol/vol), 
streptomycin (50 U/ml) and penicillin (50 mg/ml) in a humidified atmosphere at 37 °C in 
air/CO
2
 (95%:5% vol/vol). hTERT ASM cultures up to passage 30 were used. 
[3H]-Thymidine incorporation assay 
hTERT ASM cells were plated in 24-well plates at 20,000 cells/well. After growing to 
confluence, cells were serum deprived for 3 days and subsequently incubated with 50 
µM st-Ht31 (V8211, Promega) or vehicle for 4 h, then  incubated in the presence of [3H]-
thymidine (0.25 µCi·ml−1) for 24hr. After incubation, cells were washed twice with PBS at 
room temperature and subsequently with ice-cold 5% trichloroacetic acid on ice for 30 
min and the acid-insoluble fraction was dissolved in 1 ml NaOH (1 M). Incorporated [3H]-
thymidine was quantified by liquid-scintillation counting using a Beckam LS1701 β-counter 
as described previously (Roscioni et al. 2011a). 
Cell proliferation assay 
hTERT ASM cells were plated in 24-well plates at 20,000 cells/well and serum deprived for 
3 days. After incubation with 50 µM st-Ht31 or vehicle for 4 days, cells were washed twice 
with PBS and incubated with a 5% vol/vol AlamarBlue® (DAL1100, Thermo Fisher) in HBSS 
for about 45 min. AlamarBlue® is converted into its fluorescent form by mitochondrial 
cytochromes in viable cells. Therefore, the amount of fluorescence is proportional to the 
number of living cells. Proliferation was assessed by measuring fluorescence emission using 
a Wallac 1420 Victor 2TM (excitation: 570 nm, emission: 590 nm). 
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Fluorescence-activated cell sorting analysis 
To study the effect of st-Ht31 on cell cycle distribution, fluorescence-activated cell sorting 
(FACS) analysis was performed in the hTERT ASM cells. hTERT ASM cells were plated in 6-well 
plates at a concentration of 200,000 cells/well. After growing to confluence, cells were 
serum deprived for 3 days and subsequently treated with 50 µM st-Ht31 or vehicle for 24 h. 
After incubation, cells were detached by trypsin treatment and washed twice with warm 
PBS (37oC). Cells were then resuspended in ice-cold PBS and fixed by transferring into ice-
cold 70% ethanol. After centrifugation, the cell pellet was resuspended in PBS containing 10 
µg/ml propidium iodide, 20 mM EDTA, 0.05% Tween 20 and 50 µg/ml RNAse, and incubated 
at 4oC overnight. Cell cycle analysis was performed on a BD FACSCalibur (Becton, Dickinson 
and Company, BD, Franklin Lakes, NJ, USA). Fluorescence histograms were collected for at 
least 10,000 cells. The cell cycle distribution was analyzed using ModFit LT flow cytometry 
modelling software (ModFit LT, version 4.0.5). 
Western blot 
hTERT ASM cells were plated in 6-well plates at a concentration of 200,000 cells/well. After 
serum deprivation for 3 days, cells were treated with 50 µM st-Ht31 for 24 h. For α-SMA and 
calponin expression, cells were serum deprived for 1 day, followed by a 4 day treatment with 
50 µM st-Ht31. To study the possible mechanisms of st-Ht31 on α-SMA and calponin protein 
expressions, inhibitors (MG-132: 5 µM, ab141003, Abcam; cycloheximide: 5 mg/ml, 44189, 
BDH Biochemicals; actinomycin D: 1 µg/ml, A1410, Sigma; chloroquine diphosphate salt: 50 
µM, C6628, Sigma) were added for the final 24 h. After washing twice with ice-cold PBS, cells 
were lysed using 100 µl of RIPA buffer (composition: 50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% 





, 1 mM NaF, 1,06 mg/ml β-glycerolphosphate, 1 μg/ml apoprotein, 1 μg/ml leupeptin, 
and 1 μg/ml pepstatin A. The cell lysate was homogenized by passing through a 25-gauge 
needle for 10 times. Protein content was determined using the Pierce BCA protein assay. 
Equal amounts of protein were prepared for SDS-PAGE by adding 4X SDS loading buffer 
and ultrapure water, and separated on a 10% polyacrylamide gel and transferred to a 
nitrocellulose membrane, followed by  blocking with 1x Roti®-Block (A151, Carl Roth), and 
incubated overnight with primary antibodies (see Table 1). After washing, the membranes 
were incubated with horseradish peroxidase-labelled secondary antibodies (see Table 
1). Protein bands were visualized using Western Lightning® Plus-ECL (NEL104001EA, 
PerkinElmer) and quantified using ImageJ J 1.48v. Proteins were normalized to GAPDH, lamin 
AC or caveolin-1. These protein expressions were found unaltered under the experimental 
conditions (data not shown). 
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Table 1. Antibodies used for Western blot analysis
Protein of interest Primary antibody Secondary antibody
α-SMA 1:1000, A2547, Sigma 1:2000, A9044, Sigma
Calponin 1:1000, C2687, Sigma 1:5000, A9044, Sigma
PCNA 1:1000, sc-7907, Santa-Cruz 1:2000, A0545, Sigma
Pan-ubiquitin 1:1000, ab7780, Abcam 1:3000, A0545, Sigma
Cyclin D1 1:1000, #2926, Cell Signaling 1:1000, A9044, Sigma
Phosphorylated (p)-Rb  1:500, #9308, Cell Signaling 1:1000, A0545, Sigma
p-p70S6K 1:500, sc-7984-R, Santa-Cruz 1:2000, A0545, Sigma
p-ERK 1:2000, #9101S, Cell Signaling 1:5000, A0545, Sigma
Caveolin-1 1:1000, sc-894 (HRP conjugated), Santa-Cruz Not necessary
Lamin AC 1:1000, sc-7292, Santa-Cruz 1:2000, A9044, Sigma
GAPDH 1:2000, sc-47724, Santa-Cruz 1:8000,A9044, Sigma
Co-immunoprecipitation
For co-immunopreciptation (Co-IP), hTERT ASM cells were plated in 10 cm dishes. After 
grown to confluence, cells were serum deprived for 1 day and subsequently treated with 
50 µM st-Ht31 or vehicle for 4 days. After treatment, cells were lysed using Co-IP buffer 
(composition: 40 mM HEPES, 120 mM NaCl, 0.5% Triton-X-100, 10% glycerol and 1 mM 
EDTA), supplemented with 1 mM Na3VO4, 1 mM NaF, 1,06 mg/ml β-glycerolphosphate, 
1 μg/ml apoprotein, 1 μg/ml leupeptin and 1 μg/ml pepstatin A. Protein content was 
determined using the Pierce BCA protein assay. Equal amounts of protein (1 mg) were 
distributed in 2 incubation tubes. 2 µg anti-α-SMA (A2547, Sigma) or normal mouse IgG 
(used as control IgG, SC-2025, Santa-Cruz) were added to the cell lysates to incubate 
overnight at 4 ºC. Then, 50 μl protein A/G PLUS-Agarose beads (sc-2003, Santa-Cruz) were 
added per incubation tube and incubated for 4 h at 4 ºC. After washing for 5 times with Co-
IP buffer, beads were resuspended in 25 μl 4X SDS loading buffer and 25 μl Co-IP buffer. The 
degree of ubiquitination of proteins was detected using western blot analysis (see above 
for technical details). 
Immunofluorescence 
hTERT ASM cells were plated at a density of 20,000 cells per well on a 24-well plate with cover 
slips placed at the bottom of each well. For α-SMA expression, cells were serum deprived for 
1 day and subsequently treated with 50 µM st-Ht31 or vehicle for 4 days. For cyclin D1 and 
AKAP8, cells were serum deprived for 3 days and subsequently treated with 50 µM st-Ht31 
or vehicle for 24 h. After stimulation, cells were washed twice with PBS and fixed with 4% 
paraformaldehyde + 4% sucrose for 15 min, followed by 0.3% Triton X100 for 2 min at room 
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temperature. Cells were then blocked with a blocking buffer containing 5% bovine serum 
albumin (BSA) and 2% donkey serum at room temperature for 1 h. After fixing, cells were 
incubated overnight at 4°C with the primary antibody (α-SMA: 1:1000, A2547, Sigma; cyclin 
D1: 1:100, #2926, Cell Signaling; AKAP8: 1:50, sc-10766, Santa-Cruz) diluted in 1% BSA. The 
next day, after through wash, cells were incubated with the secondary antibody (anti-rabbit 
FITC, Green, 1:500, 65-6111, ThermoFisher) for 1 h at room temperature in a dark chamber. 
After a thorough wash, nuclei were stained with Hoechst (1:10,000, H3570, Invitrogen) for 
5–10 s, immediately followed by two quick and four 10-min washing steps with dd-H
2
O. 
Finally, cover slips were placed and attached on microscope slides using ProLong Gold 
antifade reagent (Invitrogen). Images were taken and analyzed using an Olympus AX70 
microscope equipped with digital image capture system (ColorView Soft System with 
Olympus U CMAD2 lens, Olympus Corporation, Tokyo, Japan). The background corrected 
fluorescence measurements were performed with Image J 1.48v (Burgess et al. 2010). 
mRNA isolation and real time PCR 
hTERT ASM cells were plated in 6-well plates at a concentration of 200,000 cells/well. After 
serum deprivation [1 day for actin alpha 2 (Acta2), calponin 1 (Cnn1), and 3 days for AKAP8], 
cells were treated with 50 µM st-Ht31 for 10 h. mRNA from hTERT ASM cells was extracted 
using a Nucleospin RNA II kit (Machery Nagel) and quantified using spectrophotometry 
(Nanodrop, ThermoScientific). 1 µg of mRNA was converted in cDNA by reverse transcriptase 
using Promega tools (Madison). cDNA was subjected to real-time PCR (RT-PCR) using a 
MyiQ™ Single-Color detection system (Bio-Rad Laboratories Inc. Life Science Group) and 
the specific primers (see Table 2). RT-qPCR was performed in duplicate using SYBR Green 
(Roche) with denaturation at 94 °C for 30 s, annealing at 59°C for 30 s and extension at 72°C 
for 30 s for 40 cycles followed by 10 min at 72 °C. The amount of target gene was normalized 
to ribosomal subunit 18 S (designated as ΔCT). Relative differences were determined using 
the equation 2−(ΔΔCt). 
Table 2. Primers used for RT-PCR











Human tracheal smooth muscle strips
Human tracheal tissue from anonymized lung transplantation donors was obtained from 
the Department of Cardiothoracic Surgery, University Medical Center Groningen. After 
dissection of the smooth muscle layer and careful removal of the mucosa and connective 
tissue, human tracheal smooth muscle strips of identical length and width were prepared 
as described previously (Roscioni et al. 2011c). Tissue strips were transferred to serum-free 
DMEM supplemented with sodium pyruvate (1 mM), non-essential amino acid mixture 
(1:100), gentamicin (45 µg/ml), penicillin (100 U/ml), streptomycin (100 µg/ml), amphotericin 
B (1.5 µg/ml), apo-transferrin (human, 5 µg/ml) and ascorbic acid (100 µM). The strips were 
incubated with 50 µM st-Ht31 or vehicle for 4 days in an Innova 4000 incubator shaker 
(37 °C, 55 rpm). After culture, strips were mounted in the organ bath for isometric tension 
measurements. 
Isometric contraction measurement
Isometric contraction experiments were performed essentially as described previously 
(Roscioni et al. 2011c). Briefly, ASM strips were mounted for isometric recording in 20-ml 
organ-baths, containing Krebs-Henseleit buffer at 37 °C. During a 90 min equilibration 
period with wash-outs every 30 min, resting tension was adjusted to 1 g, followed by 
pre-contractions with 10 µM methacholine. Following wash-out, maximal relaxation was 
established by the addition of 0.1 µM (-)-isoprenaline. Tension was readjusted to 1 g, followed 
by refreshing of the Krebs-Henseleit buffer twice. After another equilibration period of 30 min, 
cumulative concentration–response curves were constructed with methacholine (0.1 nM – 
1 mM). When maximal tension was reached, strips were washed several times and maximal 
relaxation was established using 10 µM (-)-isoprenaline. Contractions were expressed as 
percentage of maximal contraction induced by methacholine in basal strips, corrected for 
tissue weight. Curves were fitted using Prism 5.0. After the contraction protocol, strips were 
collected and tissue homogenates were prepared as previously described (Roscioni et al. 
2011c) for western blot measurement of α-SMA, calponin and PCNA. 
Statistics 
Data are expressed as means ± SEM of n individual experiments. Statistical significance of 
differences was evaluated by paired two tailed Student’s t-test using Prism 5 software. Non-
linear curve fit was performed in Prism 5.0, and curve comparison was done by extra sum-
of-squares F test using Prism 5.0 software. Differences were considered to be statistically 
significant when p<0.05. 
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Results 
Role of AKAPs in proliferation of ASM cells
Treatment for 1 day with st-Ht31 significantly increased [3H]-thymidine incorporation in ASM 
cells (Figure 1A), indicating that DNA synthesis was induced. However, st-Ht31 treatment 
for 4 days did not increase AlamarBlue® conversion (Figure 1B), demonstrating that the 
early increase in DNA synthesis did not result in an increase in cell number. We further 
assessed cell cycle distribution of propidium iodide stained ASM cells by flow cytometry 
and found that  st-Ht31 exposure had little effect, with only the suggestion of a small, but 
not statistically significant, change S phase cell number (Figure 1C). 
To further understand the paradoxical increase in DNA synthesis without cell cycle induction 
with st-Ht31 treatment, we next investigated the abundance and phosphorylation of cell 
cycle regulator proteins. Western blotting revealed that 1-day treatment with st-Ht31 
increased cyclin D1 abundance (Figure 1D), and this was confirmed microscopically by 
assessing immunofluorescence in fixed cell (Figure 1E). In addition, both Rb phosphorylation 
and phosphorylation of p70S6K were significantly increased in st-Ht31 treated hTERT ASM 
cells, whereas ERK phosphorylation was unaffected (Figures 1F-1H). 
AKAP8 expression and localization in ASM cells 
One day treatment with st-Ht31 decreased the fluorescent intensity of total AKAP8 in hTERT 
ASM cells compared to untreated cells (Figure 2A). The ratio of the distribution of AKAP8 
between nuclei and cytoplasm was not altered by st-Ht31, suggesting a treatment causes a 
general decrease in AKAP8 abundance (Figure 2A). In line with the changes on protein level, 
we found that 10 h treatment with st-Ht31 also significantly decreased the AKAP8 gene 
expression (Figure 2B). Next to AKAP8, we also measured the expression of AKAP5, 12 and 
Ezrin, which were not significantly altered by st-Ht31 (data not shown). 
Role of AKAPs in contractile protein expression in ASM cells
Four days of treatment with st-Ht31 induced a significant increase in both α-SMA and 
calponin protein in hTERT ASM cells as measured by western blot (Figure 3A). Increased 
α-SMA protein was also confirmed using microscopy to assess immunofluorescence of 
fixed cells (Figure 3C). The abundance of mRNA for Acta2 and Cnn1, which encode α-SMA 
and calponin, respectively, was measured after 10 h of treatment with st-Ht31. Although 
protein abundance of α-SMA and calponin increased, the mRNA abundance for Cnn1 was 
































































































































































































































Figure 1. The effects of st-Ht31 on proliferative markers. hTERT ASM cells were serum-deprived for 
3 days and treated with 50 µM st-Ht31. A: [3H]-thymidine was added 4 h after st-Ht31 and incorporated 
[3H]-thymidine was quantified 24 h later. N=15. B: After 4 days of treatment with st-Ht31, cell number 
was assessed using AlamarBlue®. N=5. C: FACS analysis was performed 24 h after st-Ht31 treatment. 
N=3. D-H: Protein expression of the indicated proteins was measured 24 h after st-Ht31 treatment 
using Western blot (D, F-H) or immunofluorescence (IF, E). N=4-9. *p<0.05 and **p<0.01 compared to 
basal (paired two tailed Student’s t-test). 
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Figure 2. The effects of st-Ht31 on AKAP8 expression and cellular localization. hTERT ASM 
cells were serum deprived for 3 days and treated with 50 µM st-Ht31 for 24 h. A: The expression and 
localization of AKAP8 were measured by immunofluorescence. Representative images are shown. 
Images were quantified by Image J 1.48v. N=4, *p<0.05, two tailed Student’s t-test. B: AKAP8 mRNA 
was measured using RT-PCR and normalized to ribosomal subunit 18 S (ΔCT). Relative differences 
were determined using the equation 2−(ΔΔCt). N=4. *p<0.05 and **p<0.01 compared to basal (paired 
two tailed Student’s t-test). 
To investigate the underpinnings of the differences in the effects of st-Ht31 on mRNA and 
proteins for α-SMA and calponin, we examined the effects of a number of pharmacologic 
inhibitors of transcription, translation and protein degradation. Blocking RNA synthesis 
using actinomycin D decreased basal α-SMA and calponin protein abundance (Figure 3E, 
Figure 4A). The presence of actinomycin D had no impact in st-Ht31-induced accumulation 
of α-SMA and calponin protein (Figure 3E, Figure 4A). Similarly, blocking protein translation 
using cycloheximide did not significantly affect the basal expression of either α-SMA or 
calponin, nor did it affect st-Ht31-induced α-SMA and calponin accumulation (Figure 3E, 
Figure 4B). Furthermore, blocking lysosomal degradation of proteins using chloroquine had 
no effect on basal or st-Ht31-induced α-SMA and calponin protein abundacne (Figure 3E, 
Figure 4D). Interestingly, though blocking proteasomal degradation of ubiquitin-conjugated 
proteins using MG-132 did not affect basal α-SMA protein and increased calponin protein 
(Figure 3E, Figure 4C), and though st-Ht31 did increase ubiquitination of α-SMA (Figure 
3D), MG-132 was without effect on the magnitude of st-Ht31 induced calponin or α-SMA 



















































































































































Figure 3. The effect of st-Ht3 on contractile markers. hTERT ASM cells were serum deprived for 1 
day and treated with 50 µM st-Ht31 for 4 days (A, C-E) or 1 h (B). Data expressed as means ± SEM of 
N experiments. A, C: Protein expression of α-SMA (A, C) and calponin (A) were measured by western 
blot (A) or immunofluorescence (IF, C). N=8. B: Acta2 and Cnn1 mRNA expression was measured using 
RT-PCR and normalized to ribosomal subunit 18 S (ΔCT). Relative differences were determined using 
the equation 2−(ΔΔCt). N=4. D: Cell lysates were first immunoprecipitated (IP) by using anti-α-SMA or 
normal IgG. The degree of protein ubiquitination was detected using an anti-ubiquitin (Ubi) antibody. 
E: 1 µg/ml actinomycin D, 5 mg/ml cycloheximide, 5 µM MG-132 and 50 µM chloroquine were added 
for the final 24 h of st-Ht31 treatment and protein expression of the indicated proteins was measured 
using Western blot. Representative blots are shown (quantifications are shown in Figure 4). *p<0.05 
and **p<0.01 compared to basal (paired two tailed Student’s t-test). 
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Figure 4. The involvement of post-transcriptional processes in the effect of st-Ht31 on α-SMA 
and calponin protein expression. hTERT ASM cells were serum deprived for 1 day and treated with 
50 µM st-Ht31 for 4 days. 1 µg/ml actinomycin D (A), 5 mg/ml cycloheximide (B), 5 µM MG-132 (C) and 
50 µM chloroquine (D) were added for the final 24 h and protein expression of α-SMA and calponin was 
tested using western blot. N=7. *p<0.05, **p<0.01 and ***p<0.001 (paired two tailed Student’s t-test). 
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Role of AKAPs in regulating contractility and proliferation in human ASM strips
To investigate the functional consequence of increased contractile protein abundance 
that we observed in cultured ASM cells, we next incubated human ASM strips with st-Ht31 
for 4 days then assessed methacholine-induced isometric contraction. Treatment with st-
Ht31 significantly increased contraction as evidenced by the significant 1.3-fold increase in 
maximal force (E
max














































































Figure 5. The effects of st-Ht31 on human tracheal strips. Isolated human tracheal strips were 
incubated with 50 µM st-Ht31 for 4 days. A: Methacholine-induced isometric contraction was 
measured. N=7-8. The expression of α-SMA (B) and PCNA (C) was determined in the tracheal strips. 
N=4-5, *p<0.05 (paired two tailed Student’s t-test) and ***p<0.001 (extra sum-of-squares F test) 
compared to basal.
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However, we did not observe any impact on sensitivity to methacholine (pD
2
-values 
5.28±0.18 and 5.36±0.18 for control and st-Ht31 treated, respectively). Notably, increased 
capacity to generate maximum force that was induced by st-Ht31 occurred with a 
concomitant increase in the abundance of α-SMA (Figure 5B). Interestingly, and in line with 
the findings in the cultured ASM cells that revealed st-Ht31-induced DNA synthesis, the 
abundance of PCNA was also increased by st-Ht31 treatment of human ASM tissue (Figure 
5C). 
Discussion 
AKAPs are a group of structurally diverse proteins, which act as scaffolds for a variety of 
structural and signaling molecules, thereby facilitating effective targeting of different 
cellular microdomains (Wong and Scott 2004; Poppinga et al. 2014). As indicated by their 
name, all AKAPs combine with the regulatory subunits of PKA through a short α helical 
structure to guide activity in different sub-cellular locales (Esseltine and Scott 2013). This 
functional feature was exploited in development of the st-Ht31 peptide, as it mimics the 
short α helical structure in AKAPs to block their interaction with PKA (Vijayaraghavan et al. 
1997). Since its development, st-Ht31 has been shown to alter a variety of cellular functions, 
including smooth muscle contraction and cell cycle progression (McConnell et al. 2009; 
Gao et al. 2012). 
ASM cells exhibit phenotype plasticity, which allows modulation contractile and proliferative 
functional capacity in response to changes in the surrounding microenvironment (Halayko 
et al. 2008). Prolonged exposure to mitogens concomitantly induces a hyperproliferative 
ASM phenotype, characterized by increased DNA synthesis and mitosis, as well as a 
hypocontractile ASM phenotype, characterized by a reduced contractility and reduced 
contractile protein abundance (Halayko et al. 2008; Simeone-Penney et al. 2008; Roscioni et 
al. 2011a; Roscioni et al. 2011c). On the other hand, other stimuli such as insulin or changes 
in laminin isoform profile can induce a hypoproliferative and hypercontractile phenotype 
(Ma et al. 1998; Gosens et al. 2003; Schaafsma et al. 2007; Halayko et al. 2008; Dekkers et 
al. 2009). Interestingly, we now demonstrate that interruption of the interaction between 
PKA and AKAPs using st-Ht31 simultaneously increases markers of a hyperproliferative (e.g. 
DNA synthesis, activation of cell cycle proteins and increased expression of the proliferative 
marker PCNA) and a hypercontractile phenotype (e.g. increased expression of contractile 
proteins and increased contractility) in cultured ASM cells and in intact ASM strips. 
Mitogen exposure of cells leads to phosphorylation and activation of p70S6K (Scott et 
al. 1996; Karpova et al. 1997; Grewe et al. 1999; Roscioni et al. 2011b), which promotes 
upregulation of the expression of a number of proteins, including cyclin D1 a critical cell 
cycle checkpoint determinant (Takuwa et al. 1999; Ravenhall et al. 2000; Chambard et al. 
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2007). We have demonstrated that p70S6K phosphorylation is reduced by activation of 
PKA (Roscioni et al. 2011a). Moreover, we have shown that PKA activity remains even after 
addition of st-Ht31 (Poppinga et al. 2015). Cyclin D1 can associate with pre-existing cyclin-
dependent kinases to phosphorylate target proteins, such as Rb, that further enable and 
modulates cell cycle progress into S phase (Lundberg and Weinberg 1998). We now show 
that disruption of AKAP-PKA using st-Ht31 enables enhanced DNA synthesis. In line with 
this observation, st-Ht31 increased cyclin D expression as well as the phosphorylation of 
Rb and p70S6K, which have roles in regulating DNA synthesis progression (Withers et al. 
1997; Takuwa et al. 1999). Furthermore, in intact ASM strips st-Ht31 treatment resulted in 
PCNA expression, a protein that is expressed during the S phase of the cell cycle (Leonardi 
et al. 1992). However, the increased DNA synthesis by st-Ht31 was not accompanied by an 
increase in cell number with prolonged treatment, suggesting that disruption of AKAP-ATP 
interaction is no sufficient in and of itself to induce cells to traverse S phase. In support, 
our FACS analysis in ASM cells showed that st-Ht31 had no significant impact on of the 
fraction of ASM cells in S phase. Taken together, these findings demonstrate that AKAP-PKA 
interaction is a modulator of early steps in DNA synthesis, likely by restraining the activation 
of p70S6K and expression of cyclin D1 and subsequent cell cycle proteins. In support, AKAPs, 
particularly AKAP8, interact with cyclins, including cyclin D1 (Eide et al. 1998; Arsenijevic et 
al. 2004; Qi et al. 2015; Han et al. 2015).
AKAP8 can reside in the nucleus, as confirmed by our studies, and is thought to be involved 
in DNA replication and expression of several genes associated with cell cycle regulation 
(Coghlan et al. 1994; Eide et al. 1998; Han et al. 2015). We now show that st-Ht31 reduced 
AKAP8 expression, with reduced protein in both the cytoplasm and the nucleus. On one 
hand, a AKAP8-cyclin D binding site has been identified that overlaps that for a CDK4 binding 
site, suggesting that nuclear AKAP8 may compete for cyclin D1 with CDK4 (Arsenijevic et al. 
2006). Therefore, downregulation of AKAP8 with st-Ht31 could be permissive for interaction 
of cyclin D1 with CDK4, thereby supporting Rb phosphorylation and early S phase activities. 
On the other hand, AKAP8 has been found to regulate M phase events of the cell cycle 
such as chromatin condensation, by interacting with DNA and associated proteins such 
as a condensin complex component, Eg7 (Collas et al. 1999; Steen et al. 2000) and histone 
deacetylase 3 (HDAC3) (Li et al. 2006). Based on this, and in light of our observations, we 
hypothesize that, in addition to disrupting the interactions between AKAPs and PKA, st-
Ht31-induced AKAP8 downregulation could contribute to disturbed cell cycle kinetics, that 
in our studies are revealed by increased proliferative markers but without increased cell 
number. 
Besides inducing markers of a hyperproliferative phenotype in cultured ASM cells, st-Ht31 
also increased the expression of the contractile proteins α-SMA and calponin, markers of 
a hypercontractile phenotype. An increase in α-SMA protein was also observed in intact 
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ASM strips treated with st-Ht31. An increased expression of contractile protein following 
4 days treatment with st-Ht31 was also associated with an increased contractile response 
towards methacholine. Of note, the involvement of AKAPs has previously also been shown 
in isoprenaline-induced cardiac contraction (McConnell et al. 2009). As already noted, 
the proliferative marker protein PCNA was also increased in st-Ht31 treated ASM strips, 
supporting the notion that st-Ht31 simultaneously induces markers of a hyperproliferative 
as well as a hypercontractile phenotype. 
In contrast to its effects on protein abundance, st-Ht31had little effect on mRNA for the 
calponin gene, Cnn1, and even decreased for abundance of mRNA from the α-SMA gene, 
Acta2. Therefore, the effects of st-Ht31 on α-SMA and calponin protein abundance appear to 
occur at a post-transcriptional or post-translational level. In support, the increase of α-SMA 
and calponin protein by st-Ht31 could not be prevented by blocking RNA synthesis using 
actinomycin D. Furthermore inhibition of protein translation using cycloheximide also did 
nto impact effects of st-Ht31. This suggests that st-Ht31 may affect protein stability, and 
indeed, AKAPs have recently been identified as factors involved in the ubiquitin-proteasome 
system (Rinaldi et al. 2015). Protein degradation via this system involves modification of 
the substrate protein by the covalent attachment of multiple ubiquitin molecules. The 
ubiquitin-tagged protein is eventually degraded through proteasomes (Ciechanover 2005). 
Using Co-IP we show that treatment with st-Ht31 increases ubiquitination of α-SMA protein, 
Nonetheless we also show that st-Ht31 also underpins accumulation of α-SMA protein, 
therefore, t-Ht31-induced ubiquitination of contractile proteins does not appear to lead 
to increased proteasomal degradation. This may suggest that st-Ht31 somehow inhibits 
proteasomal activity. In support, in our studies although basal abundance of calponin was 
increased by the proteasome inhibitor MG-132, it did not further increase the st-Ht31-
induced accumulation of calponin. Furthermore, increased ubiquitination of proteins has 
also been observed by the proteasome inhibitor MG-132 itself (Ding et al. 2007). Currently, 
whether a ubiquitin-tagged contractile protein remains functional is unknown, which we 
think deserves further confirmation. 
Taken together, treatment with st-Ht31 leads to a simultaneous increase in markers of a 
hypercontractile phenotype and those of a hyperproliferative phenotype in both ASM cells 
and intact strips. However, the increase in DNA synthesis and the activation of other cell 
cycle proteins (markers of a hyperproliferative phenotype) did not result in an increase 
in cell number. In contrast, the increase in contractile protein expression (marker of a 
hypercontractile phenotype) did lead to an increase in contractility, indicating the overall 
effect of disruption of AKAP-PKA interaction is the induction of a hypercontractile phenotype. 
Our observations could have major biological and drug development implications in 
obstructive respiratory disease, such as asthma and COPD, where there is both an increase in 
ASM mass and ASM contraction (Lambert et al. 1993; Chung 2005; Bentley and Hershenson 
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2008; Chung 2008). We recently demonstrated that the expression of several AKAPs in 
ASM and bronchial epithelial cells is differentially affected by cigarette smoke as well as in 
lung tissue of COPD patients (Oldenburger et al. 2014; Poppinga et al. 2015). In conclusion, 
AKAP-PKA interactions in ASM cells and intact ASM tissue simultaneously prevent the 
development of a hypercontractile phenotype, by restricting the expression of contractile 
proteins presumably by regulating proteasomal activity, as well as the development of a 
hyperproliferative phenotype, presumably by regulating the interaction of AKAP8 with 
cyclin D1. 
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Cell division relies on coordinated regulation of the cell cycle. A process including a well-
defined series of strictly regulated molecular mechanisms involving cyclin-dependent 
kinases, retinoblastoma protein and polo-like kinases. Dysfunctions in cell cycle 
regulation are associated with disease such as cancer, diabetes, and neurodegeneration. 
Compartmentalization of cellular signaling is a common strategy used to ensure the 
accuracy and efficiency of cellular responses. Compartmentalization of intracellular signaling 
is maintained by scaffolding proteins, such as A-kinase anchoring proteins (AKAPs). AKAPs 
are characterized by their ability to anchor the regulatory subunits of protein kinase A (PKA), 
and thereby achieve guidance to different cellular locations via various targeting domains. 
Next to PKA, AKAPs also associate with several other signaling elements including receptors, 
ion channels, protein kinases, phosphatases, small GTPases and phosphodiesterases. Taking 
the amount of possible AKAP signaling complexes and their diverse localization into 
account, it is rational to believe that such AKAP-based complexes regulate several critical 
cellular events of the cell cycle. In fact, several AKAPs are assigned as tumor suppressors due 
to their vital roles in cell cycle regulation. Here, we first briefly discuss the most important 
players of cell cycle progression. After that, we will review our recent knowledge of AKAPs 
linked to the regulation and progression of the cell cycle, with special focus on AKAP12, 
AKAP8 and Ezrin. At last, we will discuss this specific AKAP subset in relation to diseases with 
focus on a diverse subset of cancer. 
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Introduction
The growth of organisms is driven by cell division which relies on coordinated regulation 
of phases in cell cycle (Alberts et al. 2002). When the cell is quiescent it remains in the G1 
phase, however on initiation of cell division it progresses into the S-phase, during which DNA 
replication occurs followed by a separation of sister chromatids during the M-phase, which 
in turn is again separated in the pro-, meta-, ana- and telophase followed by cytokinesis 
where the actual cell division occurs. A series of strictly regulated molecular mechanisms are 
required to maintain the progression of the cell cycle including cyclin-dependent kinases 
(CDKs), retinoblastoma protein (Rb) and polo-like kinases (Plks) (Bertoli et al. 2013; Dick and 
Rubin 2013; Zitouni et al. 2014). In accordance, several diseases have been found to directly 
or indirectly relate to a defective regulation of the cell cycle, such as cancer, diabetes and 
neurodegeneration (Zhivotovsky and Orrenius 2010; Sperka et al. 2012). 
Importantly over the past years, it is accepted that compartmentalization of cellular signaling 
is a common strategy used to ensure the accuracy and efficiency of cellular responses 
(McCormick and Baillie 2014). Cellular compartmentalization of proteins involved in signal 
transduction is maintained by scaffolding proteins, such as A-kinase anchoring proteins 
(AKAPs), which are able to orientate a diverse subset of signaling effectors, such as protein 
kinase A (PKA), extracellular-signal-regulated kinase (ERK) and cyclins, towards selected 
substrates in specific cellular microdomains (Skroblin et al. 2010; Poppinga et al. 2014; Wang 
et al. 2014). AKAPs are characterized by their ability to anchor the regulatory subunits of PKA 
via a conserved short α helical structure, and thereby achieve guidance to different cellular 
locations via various targeting domains. PKA is a cAMP-dependent serine/threonine kinase 
and a very important player in many different cellular pathways. The involvement of PKA in 
the cell cycle progression is diversely regulated in different cell types. In Xenopus embryonic 
cells, PKA activity is low during the M phase but increases during M/G1 transition, (Grieco 
et al. 1994; Grieco et al. 1996), whereas in the human cancer cell line HeLa, PKA activity 
is increased during the M phase (Vandame et al. 2014). PKA negatively regulates the cell 
cycle progression upon activation of the small GTPase Rap1 and subsequent sequestration 
of Ras/MEK/ERk (Daaka et al. 1997; Schmitt and Stork 2000). Inhibition of the cell cycle 
progression by PKA can also be achieved upon upregulation of the CDK inhibitor p27Kip1 
(Indolfi et al. 2001). 
Next to PKA, AKAPs also associate with several other signaling elements including receptors, 
ion channels, protein kinases, phosphatases, small GTPases and phosphodiesterases 
(Skroblin et al. 2010; Poppinga et al. 2014; Deak and Klussmann 2015). Until now, over 
50 members of the AKAP family have been identified, and each AKAP can form a unique 
signaling complex in different microdomains in the cells (Skroblin et al. 2010; Troger et 
al. 2012; Esseltine and Scott 2013; Poppinga et al. 2014). With the large variety of AKAP 
signaling complexes at many different locations inside the cell, it is feasible that such AKAP-
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based complexes regulate several critical cellular events of the cell cycle. In fact, several 
AKAPs are assigned as tumor suppressors due to their vital roles in cell cycle regulation. 
Although the function of AKAP-PKA interactions in the cell cycle is not well understood, the 
role of some AKAPs being unveiled and will be described in this review. Here, we first briefly 
discuss the most important players of cell cycle progression. After that, we will review our 
recent knowledge of AKAPs linked to the regulation and progression of the cell cycle, with 
special focus on AKAP12, AKAP8 and Ezrin. In the final section, we will discuss this specific 
AKAP subset in relation to disease. 
Players of Cell Cycle Regulation 
The cell cycle is controlled by the activity of CDKs, which in turn are controlled by cyclins 
such as cyclin D/E (Yasutis and Kozminski 2013). Exposing cells to growth factors will elevate 
the amount of cyclins e.g. cyclin D1 in the cell through the Ras/Raf/MEK/ERK signaling 
cascade (Page et al. 1999; Ravenhall et al. 2000; Chambard et al. 2007), which can combine 
with pre-existing CDKs to activate or inactivate target proteins, such as Rb, to orchestrate 
the entry into the different phases of the cell cycle (Nigg 1995). The activity of cyclin-CDK 
complexes is tightly controlled, as check points, to fine-tune the cell cycle. For example, 
Plk1 activates cyclin B-CDK1 complex, during the prophase to initiate the G2/M transition 
(Toyoshima-Morimoto et al. 2001; Toyoshima-Morimoto et al. 2002). In addition, also the 
degradation of cyclins by ubiquitination allows cells to enter a next phase of the cell cycle. 
For example, human enhancer of invasion 10 (HEI10) functions as an E3 ubiquitin ligase 
to inhibit the progression into the M phase by decreasing the levels of cyclin B (Toby et 
al. 2003). In addition, the M phase is regulated by a series of complexes or enzymes that 
control chromosome segregation and condensation (e.g. condensin, histone H3 and Aurora 
B kinase) (Hendzel et al. 1997; Li et al. 2006; Wilkins et al. 2014). In Figure 1, the interactions 
between AKAPs and several key players in cell cycle regulation are summarized. 
AKAP12
AKAP12, originally called Gravin or AKAP250, was first recognized as an autoantigen in 
serum from myasthenia gravis patients (Gordon et al. 1992). Later, AKAP12 was found 
orthologous to a rodent protein, the Src-suppressed C Kinase Substrate (SSeCKS) (Lin et 
al. 1995). Since its discovery as an AKAP (Nauert et al. 1997), AKAP12 is probably one of the 
most studied AKAPs in the cell cycle regulation (Gelman 2010). Several reports indicate that 
AKAP12 generally regulates the cell cycle upon engagement of distinct cell cycle phases: 
1. Acting as a negative regulator during inappropriate cell cycle progression; 2. Helping to 
facilitate mitosis and cytokinesis (Nauert et al. 1997; Akakura and Gelman 2012). 
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Figure 1. A-kinase anchoring proteins regulate the cell cycle by spatial and temporal 
interaction with several key players. With the initiation of the G1 phase, Cyclin/CDK signaling is 
crucially mediated by several AKAPs, most notably AKAP5, AKAP8 and AKAP12. AKAPs can mediate 
this by controlling either the expression, nuclear translocation or activity of the cyclins and/or CDKs. 
During the S phase only the interaction of AKAP8 with the DNA replication complex is known. 
Throughout the different stages of the M phase AKAPs, again mainly AKAP8 and AKAP12, play a role 
in coordinating the initiation and finalizing of different stages from chromatin condensation until 
the cytokinesis that is at the very end. AKAP12 regulates the cell cycle by a) acting as a negative 
regulator during inappropriate cell cycle progression, and b) supporting mitosis and cytokinesis. As 
illustrated, AKAP12 decreases cyclin D expression via ERK. AKAP12 binds also to cyclin D1 to prevent 
its nuclear translocation. On the other hand, AKAP12 supports cytokinesis completion by controlling 
actin-myosin rings via scaffolding of PKC and actin. In addition, AKAP12 forms a complex with the 
mitotic kinase Plk1, known to activate the cyclin B-CDK1 complex during G2/M phase transition. As 
the only identified AKAP within nucleus, AKAP8 functions as a multivalent platform to anchoring 
different signaling elements to during cell cycle regulation. AKAP8 helps to recruit MCM2 to DNA and 
promotes thereby its replication during S phase. In the presence of growth factors, AKAP8 localizes to 
ERK-induced RSK1 in the nucleus to subsequently induce cell proliferation. Moreover, AKAP8 supports 
the delivery of cyclin D/E to CDKs and thereby facilitates cell cycle progression. During the M phase, 
AKAP8 recruits HDAC3 to the vicinity of chromatin and thereby initiates chromatin condensation. 
Subsequently, AKAP8 localizes the condensin complex to chromatin and initiates thereby chromatin 
condensation. Together with Merlin, Ezrin helps centrosome positioning and thereby guides mitotic 
spindle orientation during cell division. AKAP8 also decreases cyclin A expression by acting as a 
transcriptional repressor, and thereby reduces cell proliferation. AKAP5 modulates cell proliferation 
by affecting the expression of a specific CDK2 inhibitor p27kip1. Together with KSR-1, AKAP13 forms 
a scaffolding core, thereby allowing tuning of ERK signaling. Merlin controls cyclin B1 levels by HEI10 
localization. Merlin seems also to repress cyclin D1 expression through its interaction with a another 
tumor suppressor, PICT-1. For further details, abbreviations and references, see text. 
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AKAP12 as a negative regulator of the G1/S transition
AKAP12 regulates the cell cycle by reducing cyclin D1 expression presumably mediated via 
inhibition of ERK (Ravenhall et al. 2000; Chambard et al. 2007; Villanueva et al. 2007; Tao et al. 
2009). For example, Lin et al. reported in NIH 3T3 cells that induction of AKAP12 expression 
by tetracycline suppressed ERK2-dependent cyclin D1 expression and Rb phosphorylation, 
effects that coincided with a G1 arrest (Lin et al. 2000). Conversely, knock-down of AKAP12 
in a C6 rat glioma cells reversed dexamethasone-induced growth arrest, which was 
associated with elevated phosphorylation of ERK1/2 and expression of cyclin D1 (Liu et al. 
2009). Regulation of ERK might be mediated by controlling Src-focal adhesion kinase (FAK) 
complexes. AKAP12 sequesters Src through direct binding (Lin and Gelman 1997; Su et 
al. 2013), thereby disengaging Src-FAK complexes away from ERK (Gelman 2010; Akakura 
and Gelman 2012). Besides affecting the expression of cyclin D1, AKAP12 also sequesters 
cyclin D1, and thereby inhibits its nuclear translocation. In AKAP12-overexpressing NIH 
3T3 cells, the majority of cyclin D1 co-localized with AKAP12 in the cytoplasm, and nuclear 
cyclin D1 was reduced by about 70% compared to controls (Lin et al. 2000). In agreement, 
Burnworth et al. showed that cell-cell contact-induced AKAP12 expression sequesters 
cyclin D1 and prevents its nuclear translocation, resulting in growth arrest of glomerular 
parietal epithelial cells (Burnworth et al. 2012). AKAP12-mediated cyclin D1 sequestration 
is inhibited by protein kinase C (PKC) phosphorylation of AKAP12 (Lin and Gelman 2002) 
and short-term activation of PKC induced nuclear translocation of cyclin D1 even under 
AKAP12-overexpression (Figure 1) (Lin et al. 2000). 
AKAP12 important for the completion of cytokinesis
AKAP12 regulates cell cycle progression by facilitating the cytokinesis. In HeLa cells, Choi 
et al. found that knock-down of AKAP12 resulted in a profound rounding up of the cell 
morphology and multi-nucleated cells at later stages of cytokinesis compared to controls, 
leaving the anaphase and telophase of the cell cycle unchanged (Choi et al. 2008). Similarly, 
AKAP12-deficient mouse embryonic fibroblasts proliferated faster compared to wild type 
cells in early passages, but lost all proliferative capacity during later passages and showed 
significant Rb-dependent cell senescence and multi-nucleation (Akakura et al. 2010). 
AKAP12 is known to bind to PKC, thereby decreasing PKCα and δ activity (Akakura et al. 
2010; Guo et al. 2011). PKCα can lead to cell senescence by activation of p16INK4a/Rb 
(Takahashi et al. 2007), while PKCδ causes the downregulation of Lats1/Warts, a mitotic exit 
network kinase required for completion of cytokinesis (Yang et al. 2004; Iida et al. 2004). In 
addition, in HEK293 cells, AKAP12 was found to co-localize with actin near the actin-myosin 
contractile rings known to be important to complete cytokinesis (Figure 1) (Choi et al. 
2008). Reports have shown that PKC completes cytokinesis upon contraction of the actin-
myosin ring (Bement and Capco 1991; Saurin et al. 2008). AKAP12 might be involved in the 
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regulation of cytokinesis by controlling the contraction of actin-myosin rings by scaffolding 
PKC and actin. 
Recently, AKAP12 was also found to form a complex with a mitotic kinase Plk1 (Figure 1) 
(Canton and Scott 2013), known to activate the cyclin B-CDK1 complex during G2/M phase 
transition (Toyoshima-Morimoto et al. 2001; Toyoshima-Morimoto et al. 2002). Interestingly, 
phosphorylation of AKAP12 by CDK1 was required for the binding of Plk1 to AKAP12 (Fgure 
1). Taking together, AKAP12 may amplify the formation of cyclin B-CDK1 complexes due 
to its ability to function as a scaffolding protein for Plk1. As support, disruption of AKAP12-
Plk1 using a Plk1-binding deficient AKAP12 mutant decreased cell proliferation (Canton 
et al. 2012). Conclusively, AKAP12 may play an important role in cell cycle regulation and 
may thus represent a potential target for the treatment of cancer and other proliferation 
associated diseases. 
AKAP8
AKAP8, also known as AKAP95, is an AKAP that has been identified to reside in the nucleus, 
which leaves no surprise that AKAP8 is involved in DNA replication and the expression levels 
of several proteins that regulate the cell cycle (Figure 1) (Skroblin et al. 2010). 
AKAP8 in interphase
As outlined below, various studies suggest AKAP8 regulates the cell cycle through its 
interaction with different proteins during interphase, such as minichromosome maintenance 
protein 2 (MCM2), ribosomal S6 kinase 1 (RSK1) and cyclin D/E (Figure 1). Using a yeast two-
hybrid screening, one of the AKAP8-binding proteins identified in HeLa cells was MCM2, 
a component of the DNA pre-replication complex, which is in charge of DNA replication 
(Lei and Tye 2001; Eide et al. 2003). Disruption of the AKAP8-MCM2 interaction by GST-
AKAP8 peptides decreased or even abolished DNA replication. In S-phase nuclei, depletion 
of chromatin associated AKAP8 by partially removed MCM2 and inhibited the initiation 
and elongation phases of DNA replication (Eide et al. 2003), suggesting that AKAP8 plays a 
central role in controlling MCM2 function. 
Activation of RSK1 by ERK1/2 leads to its subsequent translocation to the nucleus, 
phosphorylation of downstream substrates and growth factor-induced proliferation (Anjum 
and Blenis 2008). In HeLa cells, Gao et al. discovered that an AKAP-PKA interaction inhibitor, 
stearated Ht31, reduced epidermal growth factor induced RSK1 nuclear translocation (Gao 
et al. 2012). Taken together these data indicate that AKAPs are involved in the nuclear 
retention of RSK1. Combining immuno-precipitation and liquid chromatography-mass 
spectrometer analyses, AKAP8 was indeed identified as the AKAP responsible for this 
nuclear retention of RSK1. Supportively, silencing of AKAP8 decreased nuclear RSK1 and 
increased cytosolic RSK1 (Figure 1) (Gao et al. 2012). 
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In Chinese hamster ovary cells, AKAP8 could co-immunoprecipitate with cyclin D 
(Arsenijevic et al. 2004) and cyclin E1 (Arsenijevic et al. 2006) (Figure 1). Interestingly, cyclin 
D/E were found to combine with either AKAP8 or CDK4, indicating a competition for 
cyclin binding (Arsenijevic et al. 2006). Interactions between AKAP8 and cyclin D/E were 
impaired upon overexpression of CDK4 in the cells (Arsenijevic et al. 2004; Arsenijevic et al. 
2006), suggesting that AKAP8 may help to deliver cyclin D/E to CDK4 to facilitate cell cycle 
progression. As cyclins require to be combined with a distinct subset of CDKs to exert a 
regulatory function on the cell cycle (Yasutis and Kozminski 2013), these findings provide 
another mechanism for AKAP8 to regulate the cell cycle. 
AKAP8 important for chromatin condensation
It is reported that AKAP8 helps to regulate chromatin condensation by interacting with the 
DNA and other proteins during the mitotic phase. In HeLa cells, Steen et al. found, by western 
blot analysis of the nuclear matrix and chromatin fractions prepared at different phases 
of the cell cycle, that AKAP8 redistributed from the nuclear matrix to the chromatin upon 
mitotic nuclear disassembly (Steen et al. 2000). Meanwhile, AKAP8 was found to directly 
interact with a human condensin complex component, Eg7, and thereby to support its 
recruitment to chromatin (Figure 1) (Collas et al. 1999; Steen et al. 2000). The data suggest 
that AKAP8 regulates the M phase by localizing the condensin complex to chromatin via its 
direct interaction with Eg7 during chromatin condensation. 
Chromatin condensation is initiated by the phosphorylation of histone H3 serine 10 by 
Aurora B kinase (Hendzel et al. 1997; Wilkins et al. 2014). This phosphorylation is regulated 
by AKAP8 during chromatin condensation. When cells enter the M phase, AKAP8 was found 
to recruit histone deacetylase 3 (HDAC3) to the vicinity of chromatin. The de-acetylation of 
histone H3 by HDAC3 resulted in a hypo-acetylated tail, which became a preferred substrate 
for Aurora B kinase, allowing phosphorylation of histone H3 at serine 10 (Li et al. 2006). In 
agreement, depletion of either AKAP8, or HDAC3, induced G2/M arrest and substantially 
increased cells with incomplete chromosomal condensation, chromosome segregation 
defection and tri- or multipolar mitoses (Figure 1) (Li et al. 2006). 
Although PKA has been implicated as negative regulator for proliferation in several cell 
types such as airway smooth muscle cells, vascular smooth muscle cells, NIH3T3 cells and 
adipocytes (Caretta and Mucignat-Caretta 2011; Hewer et al. 2011; Billington et al. 2013; 
Schmidt et al. 2013), other studies found that PKA activity relatively increased during the 
M phase (Grieco et al. 1996; Sheppard et al. 2014). Collas et al. found that Ht31, anti-AKAP8 
antibodies, the PKA inhibitors PKI or Rp-8-Br-cAMPS induced premature chromosome de-
condensation (Collas et al. 1999), suggesting that AKAP8-anchored PKA activity is essentially 
required for condensed chromatin maintenance during the M phase. Further studies 
indicated that PKA-AKAP8 anchoring requires phosphorylation of PKA regulatory subunit IIα 
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at threonine 54, as a PKA regulatory subunit IIα T54E mutant impaired in phosphorylation, 
inhibited interaction between PKA and chromatin-associated AKAP8 during the M phase 
(Landsverk et al. 2001). The cyclin B-CDK1 complex seems to be involved in this process, as 
it had been found to phosphorylate at threonine 54 of PKA RIIα during the M phase (Figure 
1) (Keryer et al. 1998). 
Ezrin
Identified as an AKAP (Dransfield et al. 1997), Ezrin is a member of the Ezrin, Radixin and 
Moesin protein family, this family crosslinks the membrane with its underlying actin 
cytoskeleton and helps to regulate a diverse subset of signaling routes (Fehon et al. 2010). 
Although many studies have related Ezrin with cancer metastasis and invasion (Meng et al. 
2010; Mak et al. 2012; Ren et al. 2012; Kong et al. 2013), data also suggested that Ezrin may 
play a role in cancer by regulating the cell cycle (Figure 1) (Rozenblatt-Rosen et al. 2002; 
Kishore et al. 2005; Hebert et al. 2012; Chen et al. 2013; Saito et al. 2013). 
Ezrin was found to direct mitotic spindle orientation during cell division (Hebert et al. 2012). 
Hebert et al. showed that Ezrin concentrated at certain areas of the plasma membrane to 
form a cap-like structure to help centrosome positioning, starting during G1 and reaching a 
peak by the S phase (Hebert et al. 2012). Interestingly, Ezrin acts in concert with the closely 
related neurofibromatosis type II (NF2) tumor suppressor Merlin to exert this function 
(Hebert et al. 2012), which was also identified as an AKAP (see below) (Figure 1) (Gronholm 
et al. 2003). In cells expressing Merlin short hairpin RNA, cortical Ezrin fails to form a cap-like 
structure, resulting in aberrantly oriented spindles and polarization (Hebert et al. 2012). 
Besides functioning as a cytoskeletal protein and cortical cue to direct mitotic spindle 
orientation, Ezrin seems to participate also in cell cycle regulation by acting as a 
transcriptional repressor. In endothelial cells, TNF-α induced a downregulation of cyclin A 
and decreased cell proliferation, which seemed to be mediated by the nuclear recruitment 
of an 84-kDa protein, that bound specifically to the cell cycle genes homology region in 
the cyclin A promoter (Kishore et al. 2002), which was later identified as Ezrin (Kishore et 
al. 2005). Conversely, endothelial cells transfected with dominant-negative Ezrin largely 
attenuated TNF-α-induced downregulation of cyclin A promoter activity and inhibition of 
proliferation. In a mouse hind limb ischemia model, transplantation of dominant-negative 
Ezrin–transfected endothelial cells improved blood flow recovery by increased endothelial 
cell proliferation (Kishore et al. 2005). It is known that cytoskeletal organization of Ezrin 
involves the Rho family of GTPases (Yamazaki et al. 2005). Interestingly, the same study also 
found that the TNF-α-induced Ezrin expression needed activation of RhoA kinase (Kishore 
et al. 2005). Supportively, similar effects of Ezrin were also discovered in another system, 
where fibroblast growth factor induced Ezrin expression resulted in growth arrest in the G1 
phase in rat chondrosarcoma cells (Rozenblatt-Rosen et al. 2002). 
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In cancer cells however, Ezrin seems to act differently as it plays a critical role during tumor 
progression by positively regulating the cell cycle progression. In tongue squamous cell 
carcinoma (SCC), high Ezrin expression correlated with an increased Ki-67 index, a marker 
for tumor proliferation and aggressiveness, although no obvious connection between the 
expression level of Ezrin and the tumor stage was observed in this study (Saito et al. 2013). 
Furthermore, Ezrin was found to be involved in cancer proliferation by affecting cell cycle 
distribution, as silencing of Ezrin decreased the S and G2/M fractions and the growth rate 
in human tongue SCC cell line HSC-3 (Saito et al. 2013). Similarly, in human lung cancer cell 
line 95D, Ezrin short hairpin RNA arrested the cells in G0/G1 phases, which lead to the delay 
of cell cycle progression and inhibited cell proliferation (Chen et al. 2013). 
Other AKAPs 
AKAP5
AKAP5, also known as AKAP79, has been reported to reduce cell proliferation by increasing 
the expression of p27kip1, a specific CDK2 inhibitor, in a PKA dependent way (Figure 1) 
(Indolfi et al. 2001). In line with this function, AKAP has been found in the nuclear fraction 
(Zhang et al. 1996). In rat aortic smooth muscle cells, Indolfi et al. found that overexpression 
of AKAP5 resulted in high cAMP-dependent signaling, a process most likely relying on the 
association of membrane-bound AKAP5 with PKA, as the cAMP signaling was diminished 
by co-expression of the PKA inhibitor PKI or a derivative of AKAP5 without the membrane-
anchoring domain. Enhanced transcriptional activity of the cAMP-dependent CRE promotor 
by AKAP5 were correlated with a high p27kip1 expression and low DNA synthesis level 
(Indolfi et al. 2001). Supportively, in a rat vascular injury model, site-specific gene transfection 
of AKAP5 after balloon injury significantly increased the p27kip1 level and inhibited neo-
intimal hyperplasia (Indolfi et al. 2001). 
AKAP13
Through the Raf/MEK/ERK cascade, the ERK pathway transduces signals from growth factor-
stimulated membrane receptors to growth factor-responsive targets in the cytosol and 
nucleus (Wan et al. 2004; Raman et al. 2007). It is already known that kinase suppressor 
of Ras (KSR) acts as a scaffolding protein to modulate the ERK signaling network (Figure 
1) (Therrien et al. 1996). Another study indicated that besides KSR, AKAP13, also known 
as AKAP-Lbc, is also involved in this signaling complex (Figure 1) (Smith et al. 2010). Using 
HEK293 cells and NIH3T3 fibroblasts, Smith et al. elucidated a molecular model, in which 
AKAP13 and KSR form a scaffolding core to localize Raf in the vicinity of MEK, allowing a 
signaling cascade from Raf, through MEK, to ERK1/2 (Smith et al. 2010). The growth factor 
induced Raf/MEK/ERK cascade happens during the G1/S transition (Ebisuya et al. 2005; 
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McCubrey et al. 2007), pointing towards AKAP13 playing a role during this transition. More 
importantly, this molecular model seems to suggest a reasonable explanation for the 
positive effects of PKA on the ERK cascade and cell proliferation (Dumaz and Marais 2005), 
as the function of this signaling complex was depended on the phosphorylation of Serine 
838 on KSR by an AKAP13 anchored PKA (Figure 1) (Smith et al. 2010). 
Merlin
As mentioned previously, Merlin is an AKAP that anchors different signaling proteins to 
actin cytoskeleton and involves in cell signaling during cell proliferation (Gronholm et 
al. 2003). Because the mutation of human Merlin gene is known to cause NF2, Merlin is 
also called neurofibromin 2 or schwannomin (Rouleau et al. 1993; Trofatter et al. 1993). As 
with Ezrin, it was found that cellular localization of Merlin was dependent on the cell cycle 
(Muranen et al. 2005). Merlin was found accumulated around the nucleus at the G2/M 
transition, but localized to mitotic spindles and the contractile ring during the M phase, 
and later more Merlin was found underneath the cortical membrane during the G1/S 
phases (Muranen et al. 2005). PKA phosphorylation coordinates a lot of Merlin’s functions 
as PKA phosphorylation of Merlin at serine 10 is required for its interaction with the actin 
cytoskeleton (Laulajainen et al. 2008). In addition, PKA phosphorylation of Merlin at serine 
518 causes a heterodimerization with Ezrin (Alfthan et al. 2004), directing mitotic spindle 
orientation during cell division (Hebert et al. 2012). The growth inhibition effects of Merlin 
are linked to its regulation of cyclin B or D1 (Figure 1). In a rat schwannoma cell line, Grönholm 
et al. found that Merlin expression is necessary for the subcellular localization of HEI10 
(Gronholm et al. 2006), a protein controlling the levels of cyclin B1 by acting as a divergent 
class of E3 ubiquitin ligase (Figure 1) (Toby et al. 2003). In addition, Merlin was suggested to 
repress cyclin D1 expression through its interaction with another tumor suppressor, protein 
interacting with carboxyl terminus 1 (PICT-1) in glioblastoma cells (Chen et al. 2011). 
Relation to Diseases
In the next section, we highlight some aspects of AKAP12, Ezrin and Merlin in a disease-
related context. We summarized the involvement of AKAPs in various diseases in Table 1. 
AKAP12 gene is mapped to 6q24-25.2, which is a hotspot for gene deletions during cancer 
progression (Gelman 2010; Gelman 2012). Downregulation of AKAP12 expression has been 
reported to cause abnormal cell cycle regulation, leading to pulmonary adenocarcinoma 
(Wikman et al. 2002), prostatic hyperplasia (Akakura et al. 2008), myelodysplastic syndrome 
(Pellagatti et al. 2010) and gastric carcinoma (Choi et al. 2004). Data indicate that gene 
silencing of the AKAP12 promoter through CpG island hypermethylation is responsible 
for the downregulation of AKAP12 in esophageal neoplastic progression (Jin et al. 2008), 
colon cancer (Mori et al. 2006) and gastric carcinoma (Choi et al. 2004), suggesting that 
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hypermethylation of the AKAP12 promoter may represent a potential indication for the 
early detection of a distinct subset of diseases. On the other hand, restoration of AKAP12 
expression might be beneficial in future treatment of cancer. Indeed, re-expression of 
AKAP12 in gastric cancer cells restored cell growth by inducing apoptosis (Choi et al. 2004). 
Similarly, re-expression of AKAP12 suppressed the ability of v-Src to induce cell growth and 
induced cell arrest in an AKAP12 deficient cell line (Lin and Gelman 1997). 
Table 1. AKAPs and diseases. For further details, see text.
AKAPs Diseases References
AKAP12 Pulmonary adenocarcinoma (Wikman et al. 2002)
Prostatic hyperplasia (Akakura et al. 2008)
Myelodysplastic syndrome (Pellagatti et al. 2010)
Esophageal neoplastic progression (Jin et al. 2008)
Colorectal cancer (Mori et al. 2006)
Gastric carcinoma (Choi et al. 2004)
Ezrin Uterine cervical cancer (Kong et al. 2013)
Uveal malignant melanoma (Makitie et al. 2001)
Tongue squamous cell carcinoma (Saito et al. 2013)
Hepatocellular carcinoma (Kang et al. 2010)
Brain astrocytoma (Mao et al. 2013)
Atypical endometrial hyperplasia (Ohtani et al. 2002)
Uterine endometrioid adenocarcinoma (Page et al. 1999)
Colorectal cancer (Leiphrakpam et al. 2014)
Lung cancer (Chen et al. 2013) 
Merlin Neurofibromatosis type II (Rouleau et al. 1993; Trofatter et al. 1993)
Melanoma (Morrison et al. 2001)
Mammary tumor (Hebert et al. 2012)
Osteosarcoma (Hebert et al. 2012)
Unlike AKAP12, Ezrin expression and increased malignancy seem to correlate in various 
human cancers, including uterine cervical cancer (Kong et al. 2013), uveal malignant 
melanoma (Makitie et al. 2001), tongue SCC (Saito et al. 2013), hepatocellular carcinoma 
(Kang et al. 2010), brain astrocytoma (Mao et al. 2013), and atypical endometrial hyperplasia 
and uterine endometrioid adenocarcinoma (Ohtani et al. 2002). This suggests that Ezrin 
expression could be a potential prognostic marker for these diseases. In accordance, Ezrin 
knockdown by silencing RNA decreased cell proliferation and survival rate in tongue SCC cell 
line (Saito et al. 2013), human lung cancer cell lines (Chen et al. 2013) and colorectal cancer 
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cell lines (Leiphrakpam et al. 2014). Moreover, inhibition of Ezrin expression seem to reduce 
the chemotherapy resistance of human lung cancer cells (Chen et al. 2013), suggesting a 
potential AKAP-related strategy for this disease. Notably, Ezrin phosphorylation is necessary 
for cancer cell proliferation. There is an increased Ezrin phosphorylation at threonine 567 in 
liver metastasis compared to the primary tumor. Interestingly, overexpression of T567D Ezrin, 
a phospho-mimicking Ezrin mutant, promoted the cancer cell proliferation (Leiphrakpam 
et al. 2014; Zhou et al. 2014), while an overexpression of wild-type Ezrin showed inhibitory 
effects on cell proliferation (Zhou et al. 2014). 
The most studied disease that relates to Merlin is NF2, as it is caused by mutations of 
the Merlin gene (Rouleau et al. 1993; Trofatter et al. 1993). Later studies suggested that 
the mechanism behind its tumor suppressor properties may also applies to other type 
of cancers (Morrison et al. 2001). The tumor suppression mechanism of Merlin is mainly 
associated with contact-mediated growth inhibition. At high cell density, Merlin was found 
hypo-phosphorylated and its growth-inhibitory activity was depended on interaction with 
the cytoplasmic tail of CD44 (Morrison et al. 2001). In addition, Merlin is also suggested to 
prevent centrosome amplification during tumorigenesis, as loss of Merlin fails to restrict 
Ezrin, leading to incorrect centrosome position and multipolar spindle formation in merlin-
deficient Caco2 cells, BT-549 mammary tumor cells and U2OS osteosarcoma cells (Hebert 
et al. 2012). For a comprehensive understanding of the role of Merlin in tumors, the authors 
recommend the latest review (Petrilli and Fernández-Valle 2015). 
Conclusion
In conclusion, there are several indications that AKAPs can regulate the cell cycle through 
either participating in signaling pathway by themselves or functioning as the scaffolding 
proteins that anchor and coordinate different signaling elements (Figure 1). 
This review has focused only on a few AKAPs, which have been shown to link cell cycle 
alterations and disease (Table 1). It is tempting to speculate that their balance could play an 
important role in other diseases through a yet to be defined mechanism. In this context it is 
worthwhile to mention that we have shown recently that cigarette smoke, a major cause not 
only for lung cancer but also for chronic obstructive pulmonary disease (COPD), provoked a 
decrease of AKAP12 and an increase of Ezrin expression in airway smooth muscle (Poppinga 
et al. 2015). Although both AKAP12 and Ezrin seem to inhibit proliferation, as outlined in 
detail above Ezrin seems to change its function in cancer. Thus, it would be interesting to 
study if Ezrin alters its function also in COPD. Taken together with what we have discussed 
above, it seems that understanding the balance of these AKAPs could be important to 









Figure 2. Balance between a distinct subset of AKAPs important for disease development. 
Expression of AKAP12 is decreased in various cancers and COPD. In cancers, Ezrin switched from an 
anti-proliferative to a pro-proliferative function. Cigarette smoke induced reduction of AKAP12 and 
elevation of Ezrin in airway smooth muscle, might represent a common link between cancer and 
CODP. For further details and references, see text. 
Several issues regarding to AKAPs in cell cycle regulation need to draw more attention. First, 
all AKAPs can bind to PKA, but the role of PKA in AKAP-mediated cell cycle regulation is still 
unclear. Second, some AKAPs were reported to interact with the same signaling partners 
(e.g. cyclin B), what could the mechanism be to coordinate different AKAPs to interact with 
the same signaling partner? In the case of PKA, AKAPs have varying affinities for the enzyme, 
which can be affected by the activation of PKA (Herberg et al. 2000; Zakhary et al. 2000). 
For example, Ezrin binds PKA (RII) only with low affinity (Jarnæss et al. 2008). Therefore, it is 
tempting to speculate that an AKAP with a higher affinity for PKA can compete with PKA 
binding to an AKAP with a lower affinity for PKA. However, this is thus far unstudied. There 
have been limited studies addressing the options of AKAPs affecting each other, however 
it has been published that AKAP5 and AKAP12 can form heterodimers (Gao et al. 2011). The 
authors showed that overexpression of AKAP12 in cells that endogenously express AKAP5, 
such as HEK293 or A431 cells, potentiates AKAP5-mediated phosphorylation of ERK1/2 in 
response to the β
2
-agonist isoprenaline. Interestingly, however, AKAP12 mediated recycling 
of the β
2
-adrenoceptor was unaffected upon AKAP5 overexpression (Gao et al. 2011). We 
have recently published a hypothetical model how AKAP5, AKAP12 and Ezrin can work 
in harmony to regulate that β
2
-adrenoceptor expression at the membrane (Poppinga 
et al. 2014). However, mechanisms involved in AKAP dimerization, and how such dimer 
formation is triggered by molecular cues still remain obscure. At last, studies referring to 
the roles of some AKAPs (e.g. AKAP8) in diseases are very limited. Nevertheless, further 
studies are necessary to help us gain more knowledge about the role of AKAPs in cell cycle 
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regulation, therefore providing new insights to perhaps develop AKAP-related therapies to 
treat diseases cause by abnormal cell cycle regulation. 
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Although chronic obstructive pulmonary disease (COPD patients are treated with 
(combinations of ) bronchodilators and anti-inflammatory glucocorticosteroids, many 
patients respond poorly to these drugs. Therefore there is a great need for novel therapy in 
this disease. Drugs that possesses both anti-inflammatory and bronchodilatory properties 
would yield an optimal treatment of COPD. In the present study, we explored the anti-
inflammatory and airway smooth muscle (ASM)-relaxing properties of 4 compounds that 
have shown anti-oxidative effects (Sul-90, Sul-121, Sul-127 and Sul-136), using in vitro 
models. 
We found that Sul-90 and Sul-121 (but not Sul-127 and Sul-136) dose-dependently 
prevented cigarette smoke extract (CSE)-induced release of interleukin-8 (IL-8) from human 
ASM cells, without significantly affecting basal IL-8 release. Moreover, Sul-90 and Sul-121 
(but not Sul-127 and Sul-136) both induced relaxation of pre-contracted bovine tracheal 
smooth muscle (BTSM) strips, which was unaffected by the nonselective β-adrenoceptor 
antagonist propranolol. In addition, Sul-121 relaxed BTSM strips at a concentration that did 
not affect cell viability, whereas Sul-90 only induced BTSM relaxation at a concentration that 
could decreases cell viability. 
In conclusion, Sul-121 represents a promising candidate for further screening in cell and 
animal models of COPD as it possesses the attractive combination of anti-inflammatory and 
(non-β
2
-adrenoceptor-mediated) ASM-relaxing properties without a detrimental effect on 
cell viability. Sul-121 may therefore present a novel compound for the treatment of COPD. 
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive 
airflow limitation and a chronic airway inflammation (GOLD 2015). COPD greatly reduces 
the quality of life of the patients and through its high morbidity and mortality COPD results 
in a significant clinical, economic and social burden (Mathers and Loncar 2006; Soriano and 
Rodríguez-Roisin 2011). In the western world, the main risk factor for COPD is exposure to 
cigarette smoke (GOLD 2015).
Airway inflammation is considered to play a central role in the development of COPD (Barnes 
et al. 2003) and it is associated with frequent exacerbations (GOLD 2015). Neutrophils 
are key inflammatory cells in COPD. Both neutrophils and its major chemotactic factor, 
interleukin 8 (IL-8), are increased in the airways of patients with COPD (Barnes et al. 2003). As 
a key inflammatory mediator, the role of IL-8 in cigarette smoke-induced lung inflammation 
has been well studied in several in vivo and in vitro models (D’hulst et al. 2005; Gosens et 
al. 2009; Oenema et al. 2010; Ko et al. 2015). Cigarette smoke induces the release of IL-8 
from several types of cells, including airway smooth muscle (ASM) cells (Gosens et al. 2009; 
Oenema et al. 2010; Oldenburger et al. 2012; Pera et al. 2012; Chen et al. 2014; Poppinga et 
al. 2015). The neutrophils that are recruited by IL-8 may further secrete IL-8 as well as other 
inflammatory mediators to trigger downstream events involved in the pathophysiology of 
COPD (Keatings et al. 1996; Tanino et al. 2002; Hoenderdos and Condliffe 2013). 
COPD is also featured by a persistent and progressive airflow limitation induced by the chronic 
inflammation (Barnes et al. 2003). Although often underestimated in clinical assessment, 
airway hyperresponsiveness (AHR) to ASM contractile stimuli is an important characteristic 
of COPD (van den Berge et al. 2012) and associates with accelerated lung function decline 
(Postma et al. 1986; Tashkin et al. 1996). In COPD patients, the ASM responsiveness of ASM is 
strongly associated with lung neutrophils (van den Berge et al. 2012) and a number of pro-
inflammatory cytokines, including IL-8 (Postma et al. 1988; Barnes et al. 2003). 
In order to reduce airflow limitation and airway inflammation, (combinations of ) 
bronchodilators, such as β
2
-adrenoceptor  agonists (β
2
-agonists) and anticholinergics and 
anti-inflammatory glucocorticosteroids are widely prescribed in the first-line pharmacological 
treatment of COPD (Osthoff et al. 2013; GOLD 2015). However, bronchodilators are not always 
effective and the majority of patients show resistance to these medications, particularly 
glucocorticosteroids (Barnes et al. 2003; Broadley 2006; Barnes 2008; Matera et al. 2014). 
Therefore, studies for novel medications for COPD are highly necessary. 
Several novel compounds (Sul-90, Sul-121, Sul-127 and Sul-136), which exhibited 
promising anti-oxidative cell protective effects (Van der Graaf et al. 2014), have recently 
been developed. Based on these effects the Sul compounds were considered as potential 
candidate drugs for COPD, which is characterized by a high oxidative stress. In the present 
study, we investigated the pharmacological potential of the Sul compounds to treat COPD 
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symptoms by studying their anti-inflammatory and relaxing properties in ASM. Out of these 
4 compounds, we report that Sul-121 prevented cigarette smoke extract (CSE) induced 
IL-8 release from ASM cells and reduced methacholine-induced ASM contraction, and may 
therefore represent a potential novel treatment of COPD deserving further studies. 
Materials and Methods
Sul compounds
Sul-90, Sul-121, Sul-127 and Sul-136 were developed and produced by Sulfateq (Van der 
Graaf et al. 2014). We screened these 4 compounds on their effects on cell viability, CSE-
induced IL-8 release and methacholine-induced ASM tone. 
CSE preparation
CSE was freshly prepared using 3R4F research cigarettes (Reference Cigarette Program, 
University of Kentucky) as described previously (Oldenburger et al. 2012; Oldenburger et al. 
2014; Poppinga et al. 2015). Briefly, the smoke from two combusted cigarettes was pumped 
(Watson Marlow 323 E/D) through 25 ml of serum-free Dulbecco’s modified Eagle’s medium 
(DMEM, 11965-092, Life technologies), which was designated as 100% CSE and was further 
diluted to a 15% working concentration. 
Cell culture
Human telomerase reverse transcriptase immortalized ASM cells were used in the study 
(Oldenburger et al. 2012; Poppinga et al. 2015). For all experiments, ASM cells below passage 
30 were used. The cells were maintained in DMEM containing 10% heat-inactivated fetal 
calf serum supplemented with HEPES (25 mM), L-glutamine (2 mM), amphotericin B (1.5 µg/
mL) and penicillin (100 U/ml)/streptomycin (100 µg/ml) in a humidified atmosphere at 37 
oC in air/CO
2
 (95:5 % vol/vol). 
CSE-induced IL-8 release 
IL-8 release from ASM cells was used as marker of CSE-induced inflammatory responses. 
ASM cells were plated on 24-well plates at 20,000 cells/well. After grown to confluence, 
cells were treated with indicated concentrations of the Sul compounds or 1 µM fenoterol 
(positive control) for 30 min prior to the addition of 15 % CSE for 24 hours. IL-8 concentration 
in cell culture medium was measured by using a commercial ELISA kit (PeliKine Compact 
ELISA kit, Sanquin, The Netherlands). 
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Cell viability
The effect of the Sul compounds on cell viability was tested using trypan blue and Alamar 
Blue. Trypan blue is a dye that is not absorbed by viable cells, but traverses the membrane 
of dead cells thereby staining these cells (Strober 2001). Trypan blue cell counting was 
performed as previously described (Oldenburger et al. 2012). Briefly, ASM cells were 
plated on 24-well plates. After grown to confluence, cells were treated with the indicated 
concentrations of the Sul compounds for 24 hours. At the end of treatment, cells were 
trypsinized and mixed with a trypan blue solution (0.4 % (w/v) in saline) at a ratio of 1:1 
(v/v). Living and dead cells were then determined and counted using a hemocytometer. 
The effect of the Sul compounds on cell viability was confirmed by an AlamarBlue® assay as 
described before (Roscioni et al. 2009). Briefly, after the treatment mentioned above, cells 
were washed twice with PBS and incubated with 5% vol/vol AlamarBlue® (DAL1100, Thermo 
Fisher) in Hank’s Balanced Salt Solution for about 45 min. AlamarBlue® is converted into its 
fluorescent form by mitochondrial cytochromes in living cells. Therefore, the amount of 
fluorescence, measured using a Wallac 1420 Victor 2TM (excitation: 570 nm, emission: 590 
nm), is proportional to the number of living cells. 
Preparation of bovine tracheal smooth muscle (BTSM) strips
Bovine tracheal smooth muscle (BTSM) was prepared as described previously (Gosens et al. 
2002). Briefly, bovine tracheal were purchased from local slaughter house and immediately 
transported to the laboratory in Krebs-Henseleit buffer (composition in mM: 117.5 NaCl, 5.60 
KCl, 1.18 MgSO4, 2.50 CaCl2, 1.28 NaH2PO4, 25.00 NaHCO3, and 5.50 glucose), pre-gassed 
with 5 % CO2 and 95 % O2, pH 7.4. After dissection of the smooth muscle layer and careful 
removal of connective tissues, BTSM strips of approximately 1 cm length and 2 mm width 
were prepared. Tissue strips were maintained in DMEM supplemented with nonessential 
amino acid mixture (1 mM for all. glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic 
acid, L-proline, L-serine), sodium pyruvate (1 mM), gentamicin (45 µg/ml), penicillin (100 U/
ml), streptomycin (100 µg/ml), amphotericin B (1.5 µg/ml) apo-transferrin (5 µg/ml) and 
ascorbic acid (100 µM), in an Innova 4000 incubator shaker 37 oC, 55 rpm). The BTSM strips 
that maintained in above medium for no more than 3 days were used in present study.
Isometric contraction and relaxation measurements
Strips were mounted for isometric recording (Grass force-displacement transducer FT03) 
in 20 ml water-jacked organ baths containing KH buffer at 37°C, continuously gassed with 
5 % CO2 and 95 % O2, pH 7.4. Before isometric tension measurement, BTSM strips were 
calibrated as described previously (Dekkers et al. 2007). Briefly, each strip was gradually 
adjusted to a resting tension of 3 gram. Then, the strips were equilibrated for 60 minutes 
132
Chapter 5
with washouts every 20 min. Subsequently, muscle strips were pre-contracted with 0.1, 
1 and 10 μM methacholine. Following two washouts, maximal relaxation was established 
by the addition of 0.1 μM (-)-isoproterenol. Subsequently, tension was readjusted to 3 
gram, followed by two changes of fresh KH buffer. After another equilibration period of 30 
min, muscle strips preparation were ready for following test. In the end of each following 
protocols, through washout were performed and isoprenaline was added to set the basal 
line. 
To analyze acute effects of the Sul compounds on the airway smooth muscle isometric 
tension, the strips were first pre-contracted by 0.3 µM methacholine, followed by 
accumulative doses of the Sul compounds (1 - 600 µM). 
To analyze the potential role of the β
2
-AR in the effects induced by the Sul compounds, after 
pre-contracted with 0.3 µM methacholine, the strips were incubated with 1 μM nonselective 
β-AR antagonist propranolol for 30 minutes prior addition of accumulative doses of the Sul 
compounds. Doses responsive curve of classic β
2
-agonist isoprenaline (1 x 10-10 – 3 x 10-4 M) 
was served as the positive control. 
Statistics
Data are expressed as means ± SEM from n individual experiments. Statistical significance 
of differences was evaluated by a one-way or two way ANOVA with Bonferroni post-hoc 
tests as appropriate, using Prism 5 software. Differences were considered to be statistically 
significant when P<0.05. 
Results
Effect of the Sul Compounds on IL-8 release 
Treatment with 15% CSE increased the release of IL-8 from ASM cells on average by 6.6-fold 
(P<0.001, Figure 1A-D). The Sul compounds exerted differential effects on the cellular release 
of IL-8 induced by CSE. Treatment of cells with Sul-121 or Sul-90 dose-dependently reduced 
CSE-induced IL-8 release up to 90%, which were comparable to that of fenoterol (1 µM) as 
a positive control (Figure 1A, B). Sul-90 started to significantly reduce CSE-induced IL-8 at 
100 µM, and almost fully abrogating IL-8 release at 300 µM (Figure 1A). Sul-121 significantly 
reduced CSE-induced IL-8 release at 300 µM (Figure 1B). On the contrary, while 300 µM Sul-
127 caused a small, non-significant reduction of the CSE-induced IL-8 release (Figure 1C). 
Sul-136 even increased the CSE-induced IL-8 release from the cells by 1.4-fold (Figure 1D). 
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Figure 1. Sul-90 and Sul-121, but not Sul-127 and Sul-136, inhibit CSE-induced IL-8 release 
from ASM cells. Human ASM cells were incubated for 24 hours with indicated concentrations of 
Sul-90 (A), Sul-121 (B), Sul-127 (C) or Sul-136 (D) in the absence of presence of 15 % CSE. The β2-
agonist fenoterol (1 µM) served as positive control. Data are expressed as means ± SEM of n=7-8 
experiments., *P<0.05 and ***P<0.001, compared to CSE vehicle, two way ANOVA with Bonferroni 
post-tests. ##p<0.01 and ###p<0.001, compared to corresponding basal IL-8 release, two way ANOVA 
with Bonferroni post-tests. 
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Effect of the Sul Compounds on cell viability
Although the cell viability was not affected at the lower concentrations, 300 µM Sul-90 
significantly decreased viability of ASM cells by 65% (P<0.05, Figure 2A). The viability of ASM 
cells was not affected by any of the tested concentrations (10, 30, 100 and 300 µM) of Sul-
121, Sul-127 or Sul-136 (Figure 2B-D). Similar effects were obtained using the AlamarBlue® 
assay (data not shown). 
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Figure 2. Effect of Sul-90, Sul-121, Sul-127 and Sul-136 on cell viability. Human ASM cells were 
incubated for 24 hours with the indicated concentrations of Sul-90 (A), Sul-121 (B), Sul-127 (C) or Sul-
136 (D). Cells were trypsinized for trypan blue staining and cell counting to determine cell viability. 
Data are expressed as means ± SEM of n=4-5 experiments. *P<0.05 compared to untreated (0 µM), 
one way ANOVA with Bonferroni post-test. 
Effects of Sul compounds on BTSM contractility
Sul-90 and Sul-121 significantly decreased methacholine-induced contraction in BTSM 
strips (Figure 3A and 3B). This effect was statistically significant at the higher concentrations: 
600 µM for Sul-90, and 300 and 600 µM for Sul-121. The maximal relaxation (E
max
) induced 
by Sul-121 as - compared to the effect of DMSO as a vehicle control  was significantly 
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larger than for Sul-90 (~67% and ~25%, respectively, P<0.05). Sul-127 and Sul-136 did not 
significantly affect methacholine-induced contraction at any concentration (Figure 3C 
and 3D). The vehicle control DMSO by itself caused a small, but non-significant increase in 




















































































































































Figure 3. Sul-90 and Sul-121, but not Sul-127 and Sul-136, induced relaxation of methacholine-
pre-contracted BTSM strips. BTSM strips were pre-contracted with 0.3 µM methacholine and 
cumulative concentration-response curves were constructed for Sul-90 (A), Sul-121 (B), Sul-127 
(C) and Sul-136 (D). Cumulative addition of DMSO (up to 0.5%) served as vehicle control. Data are 
expressed as means ± SEM of n=5-6 experiments. **P<0.01 and ***P<0.001 compared to DMSO, two 
way ANOVA with Bonferroni post-tests. 
The β
2
-agonist isoprenaline induced a potent and full relaxation of methacholine-induced 
BTSM contraction (Figure 4A), which was shifted to the right by the 1 μM β-adrenoceptor 
antagonist propranolol (pD
2
-values 7.7±0.2 vs 5.4±0.1, P<0.001). Treatment with propranolol 





















































































Figure 4. The relaxation of BTSM strips induced by Sul-90 and Sul-121 is not mediated by 
the β2-adrenoceptor. BTSM strips were pre-contracted with 0.3 µM methacholine and cumulative 
concentration-response curves were constructed for isoprenaline (A) and Sul-90 and Sul-121 (B) in the 
absence and presence of 1 µM propranolol. Cumulative addition of DMSO (up to 0.5 %) in the absence 
and presence of propranolol served as a vehicle control. Data are expressed as mean ±SEM of n=3 
experiments. *P<0.05 and *** P<0.001, compared to the isoprenaline control group, two way ANOVA 
with Bonferroni post-test.
Discussion
The role of ASM in the pathophysiology of COPD is well recognized as it contributes to aspects 
of airway constriction, airway remodeling, and, through the production of inflammatory 
chemokines, cytokines, proteases, and growth factors, airway inflammation (Chung 2005). 
Cigarette smoke is the most important risk factor for COPD and treatment of ASM cells with 
CSE leads to the production of various inflammatory mediators, including IL-8 (Oldenburger 
et al. 2012; Pera et al. 2012; Chen et al. 2014; Poppinga et al. 2015). Neutrophilic infiltration 
within the ASM was found to be higher in smokers with COPD compared to non-smokers 
without COPD (Baraldo et al. 2004). In the present study, we found that 15% CSE induced 
a 6.6-fold increase in IL-8 release from ASM cells, which is in line with previous studies from 
our group (Oldenburger et al. 2012; Pera et al. 2012; Poppinga et al. 2015). Treatment with 
100 µM Sul-90 or 100 µM Sul-121 (a concentration that did not alter cell viability) almost 
completely prevented this CSE-induced IL-8 release, demonstrating that Sul-90 and Sul-121 
possess anti-inflammatory properties. Sul-90 and Sul-121 did not affect basal IL-8 release, 
suggesting that these compounds specifically inhibit CSE-induced pro-inflammatory 
pathways. Sul-127 did not significantly alter CSE-induced IL-8 release, indicating that Sul-127 
does not have anti-inflammatory properties at the tested concentration, whereas 300 µM 
Sul-136, on the other hand, even further increased CSE-induced IL-8 release. Based on these 
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results, Sul-90 and Sul-121, but not Sul-127 and Sul-137, may have therapeutic potential for 
the treatment of inflammation in COPD.
Another feature of COPD is chronic airflow limitation which is treated with inhaled 
bronchodilators such as β
2
-agonists (GOLD 2015). To circumvent the limited access to human 
ASM strips, we used BTSM strips as an established model to test bronchodilatory responses 
(Boterman et al. 2005). Importantly, Sul-90 and especially Sul-121 were able to relax BTSM 
precontracted with methacholine, demonstrating that they have bronchodilating properties 
in addition to their anti-inflammatory properties. For Sul-90, the concentration needed to 
significantly relax the precontracted BTSM strips (600 µM) was higher than the dose that had 
strong anti-inflammatory effects (100 and 300 µM). Sul-121 induced a significantly larger 
relaxation than Sul-90 and the effect was already present at the same concentration that 
inhibited CSE-induced IL-8 release (300 µM). The effects of Sul-90 and Sul-121 cannot be 
explained by a vehicle effect, because cumulative addition of the vehicle (DMSO, maximum 
concentration: 0.5%) even slightly increased the metacholine-induced contraction. Sul-127 
and Sul-136 did not alter BTSM contraction at any tested concentrations. 
Inhaled β
2
-agonists are potent bronchodilators, mainly due to their effective relaxation of 
ASM (GOLD 2015). β
2
-agonists bind and activate β
2
-adrenoceptors on ASM cells, thereby 
triggering a signaling cascade involving cAMP which induces ASM relaxation (Cazzola et 
al. 2013). To test whether the effects of Sul-90 and Sul-121 on ASM tone are mediated by 
activation of the β
2
-adrenoceptor, the effect of the nonselective β-antagonist propranolol 
on Sul-90 and Sul-121 induced relaxation was tested. Whereas propranolol strongly 
counteracted the relaxation induced by the non-selective β-agonist isoprenaline, it left the 
relaxation induced by Sul-90 and Sul-121 unaffected, demonstrating that Sul-90 and Sul-
121 induce relaxation of ASM independent of the β
2
-adrenoceptor. There results suggested 
that Sul-90 and Sul-121, next to anticholinergics, could possess several advantages over β
2
-
agonists for the treatment of COPD. β
2
-Agonists, although a potent bronchodilators, should 
be used with caution in patients with diabetes, hypokalemia, hyperthyroidism and certain 
cardiovascular diseases due to the activation of β
2
-adrenoceptors in peripulmonary organs 
(Broadley 2006; Cazzola et al. 2013). Moreover, repeated and prolonged treatment of β
2
-
agonists can cause desensitization of the β
2
-adrenoceptor, which is believed to be one of 
the main mechanisms of β
2
-agonists tolerance (Broadley 2006). Currently, the mechanisms 
of actions for Sul-90 and Sul-121 in inducing ASM relaxation is still unknown, and it would 
be interesting to test it on other novel bronchodilating pathways, including the bitter 
taste receptor. As COPD is featured with both chronic inflammation and progressive 
airflow limitation in the lungs (Soriano and Rodríguez-Roisin 2011; GOLD 2015), the most 
effective pharmacological therapy for COPD would be with a drug that possesses both 
anti-inflammatory and bronchodilating properties. Here, we reported that both Sul-90 and 
particularly Sul-121 show promising anti-inflammatory and some ASM-relaxing properties. 
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However, to screen the potential candidates for novel therapies, it is necessary to take into 
account not only the beneficial effects but also the adverse effects. We also found Sul-90 
decreased cell viability at concentrations needed to induce ASM relaxation, making Sul-90 
a less favorable candidate for further studies. Importantly, this adverse effect on cell viability 
was not observed for Sul-121, which has similar anti-inflammatory actions as Sul-90 and is 
the stronger bronchodilator of the two.
In conclusion, we identify Sul-121 as the most promising candidate of a series of Sul 
compounds for further screening for therapeutic potential in COPD using cell models in 
vitro and animal models of COPD in vivo, as it possesses an attractive combination of anti-
inflammatory and bronchodilating properties. 
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COPD is characterized by persistent airflow limitation, neutrophilia and oxidative stress from 
endogenous and exogenous insults. Current COPD therapy involving anticholinergics, β
2
-
adrenoceptor agonists and/or corticosteroids, do not specifically target oxidative stress, nor 
do they reduce chronic pulmonary inflammation and disease progression in all patients. 
Here, we explore the effects of Sul-121, a novel compound with anti-oxidative capacity, on 
hyperresponsiveness (AHR) and inflammation in experimental models of COPD. 
Using a guinea pig model of lipopolysaccharide (LPS)-induced neutrophilia, we 
demonstrated that Sul-121 inhalation dose-dependently prevented LPS-induced airway 
neutrophilia (up to ~60%) and AHR (up to ~90%). Non-cartilaginous airways neutrophilia was 
inversely correlated with blood H
2
S, and LPS-induced attenuation of blood H
2
S (~60%) was 
prevented by Sul-121. Concomitantly, Sul-121 prevented LPS-induced production of the 
oxidative stress marker, malondialdehyde by ~80%. In immortalized human airway smooth 
muscle (ASM) cells, Sul-121 dose-dependently prevented cigarette smoke extract-induced 
IL-8 release parallel with inhibition of nuclear translocation of the NF-κB subunit, p65 (each 
~90%). Sul-121 also diminished cellular reactive oxygen species production in ASM cells, 
and inhibited nuclear translocation of the anti-oxidative response regulator, Nrf2. Our data 
show that Sul-121 effectively inhibits airway inflammation and AHR in experimental COPD 
models, prospectively through inhibition of oxidative stress. 
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Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death 
worldwide, which results a significant economic and social burden (GOLD 2015). It is 
characterized by persistent and progressive airflow limitation and prominent neutrophilic 
airway inflammation (Hoenderdos and Condliffe 2013; GOLD 2015). Currently, reduction 
of COPD symptoms is achieved mainly with (a combination of) anticholinergics, β
2
-
adrenoceptor agonists and glucocorticosteroids (GOLD 2015). However, the current 
medications fail to reduce the progression of COPD and have even been associated with 
fatal side effects (Barnes et al. 2003; Broadley 2006; Barnes 2008; Matera et al. 2014). 
Oxidative stress, caused by an anti-oxidant/oxidant imbalance that leads to increased 
generation of reactive oxygen species (ROS), is believed to play an important role in 
the pathogenesis of COPD (Kirkham and Barnes 2013). ROS derived from exogenous 
(environmental pollution, cigarette smoke) or endogenous (inflammatory cells, such as 
neutrophils) insult, promote the activation of the pro-inflammatory transcription factor 
nuclear factor (NF)-κB in structural lung cells including airway smooth muscle cells (Luo et 
al. 2009). Activation of NF-κB results in increased secretion of inflammatory cytokines such 
as interleukin (IL)-8 (Oenema et al. 2010; Oldenburger et al. 2012; Pera et al. 2012), which 
recruit inflammatory cells, including neutrophils (Barnes 2008). Moreover, ROS trigger the 
peroxidative breakdown of lipids, a process implicated in lung injuries due to increased 
airway epithelial permeability (Shintani et al. 2015). ROS have also been implicated as an 
important cause of steroid resistance in COPD (Barnes 2013). Targeting oxidative stress 
might be a beneficial approach for the management of COPD. Although evidence for clear 
clinical benefit is currently lacking, many anti-oxidative strategies using anti-oxidants or 
pharmacological agents have shown promising effects in COPD (Rahman 2006; Kirkham 
and Barnes 2013). 
Due to its anti-oxidative capacities, the gasotransmitter hydrogen sulfate (H
2
S), synthesized 
by enzymes such as cystathionine β synthetase (CBS) (Chen and Wang 2012), has been 
proposed as a potential COPD treatment (Faller et al. 2012). By contrast, some studies 
indicated that its redox potential may provoke pro-inflammatory responses, for instance, 
oxidative stress originated from activated neutrophils can convert H
2
S to sulfite (Mitsuhashi 
et al. 2005), which is considered an inflammatory mediator in airway diseases (Mitsuhashi et 
al. 2004). Therefore, the usage of H
2
S or its donors to treat COPD is still under debate.
One mechanism that could underpin an anti-oxidant response to H
2
S is the activation of 
nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that increases the 
expression of anti-oxidant proteins in structural airway cells, including smooth muscle cells 
(Michaeloudes et al. 2011; Shintani et al. 2015). Indeed, H
2
S is able to activate Nrf2 both in 
vivo in mouse models of lung injury and in vitro in embryonic fibroblasts (Han et al. 2011; 
Francis et al. 2011; Hourihan et al. 2013). 
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Recently, we developed a novel class of pharmacological compounds of which Sul-121 
(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl (piperazin-1-yl) methanone, Figure 1A) is one 
of its leads with promising cell protective effects due to anti-oxidant capacities (Van der 
Graaf et al. 2014). In the present study, we explored the pharmacological potential of Sul-
121 in in vitro and in vivo experimental models of COPD. We report that Sul-121 prevents 
lipopolysaccharide (LPS)-induced neutrophilia, hyperresponsiveness (AHR) and oxidative 
stress in guinea pigs. In addition, Sul-121 reduces the cigarette smoke-induced release 
of IL-8 in cultured human airway smooth muscle (ASM) cells, which is accompanied by a 
reduction in cellular ROS production and nuclear translocation of Nrf2. 
Methods
Animals
Outbred male, specified pathogen-free Dunkin Hartley guinea pigs (Harlan, Heathfield, 
UK) weighing 350–450 g were used. Guinea pigs were randomly divided into indicated 
experimental groups with 4-6 guinea pigs per group. All in vivo protocols described in 
this study were approved by the University of Groningen (Groningen, The Netherlands) 
Committee for Animal Experimentation. All the methods were carried out in accordance 
with the approved guidelines. 
Animal Model of COPD
Guinea pigs were intranasally instilled with LPS (Sigma, L-2880) to induce neutrophilic 
airway inflammation and AHR (Toward and Broadley 2000; Pera et al. 2011; Smit et al. 2013). 
Guinea pigs were held in upright position while 300 μl LPS (5 mg/ml in sterile saline) was 
slowly instilled intranasally and kept in the upright position for an additional 2 min to allow 
sufficient spreading of the fluid throughout the airways. Control animals were instilled with 
300 μl sterile saline. 
Experimental In Vivo Protocols
As shown in Figure 1A, 30 min before LPS or saline instillation animals were treated by 
inhalation of aerosolized vehicle (2% dimethyl sulfoxide and 0.2% Tween80 in saline) or Sul-
121 solutions (3 or 30 mM, nebulizer concentrations) for 3 min in a 9-liter Perspex cage (Meurs 
et al. 2006). A DeVilbiss nebulizer (type 646) driven by an airflow of 8 l/min provided the 
aerosol with an output of 0.33 ml/min. Airway responsiveness to histamine was measured 
24 hours before (basal) and 1, 2, 3, 6 and 24 hours after LPS/saline instillation by lung function 
measurements as described below. At 25 hours after LPS challenge, bronchoalveolar 
lavage (BAL) was performed to assess inflammatory cell infiltration in the airways. 
In a separate protocol, guinea pigs inhaled Sul-121 (30 mM, 3 min) or vehicle 30 min before 
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LPS or saline challenge, followed by blood and lung tissue collection at 25 hours later. Blood 
was collected by heart puncture and stored in EDTA coated tubes. Neutrophil numbers were 
determined in blood. Serum was obtained by centrifuging (2000 rcf, 10 min) to quantify 
levels of Sul-121 and H
2
S. Lung tissue was snap frozen and used for histology (neutrophils) 
and immunohistochemistry (CBS, Nrf2) using transverse frozen cross-sections (5 μm) of the 
upper right lung lobe, and for Western blotting (CBS, Nrf2) and malondialdehyde (MDA) 
measurements using homogenates of the other parts of the lungs.
Measurement of Airway Responsiveness to Histamine
Lung function was assessed by online measurement of pleural pressure (P
pl
) under conscious 
and unrestrained conditions (Meurs et al. 2006). In short, a small fluid-filled latex balloon 
catheter was surgically implanted inside the thoracic cavity and connected to a pressure 
transducer (TXX-R; Viggo-Spectramed, Bilthoven, The Netherlands) via an external saline-
filled cannula. P
pl
 was continuously measured using an online computer system. Changes 
in P
pl
 are linearly related to changes in airway resistance and serves as a sensitive index for 
stimulus-induced bronchoconstriction (Meurs et al. 2006). 
Histamine provocations were performed by inhalation of stepwise increasing concentrations 
of histamine (Sigma, H-7250) in saline (0, 25, 50, 75, 100, 125 and 150 µg/ml). Solution were 
nebulized for maximally 3 minutes with intervals of 7 minutes, until the P
pl
 was increased 
by more than 100% above baseline for at least 3 consecutive minutes. The provocation 
concentration of histamine causing a 100% increase in P
pl
 (PC100) was derived by linear 
interpolation of the concentration-P
pl
 curve and used as an index for airway responsiveness. 
Animals were habituated to the experimental conditions as previously described (Meurs et 
al. 2006).
Neutrophil Counting in BAL Fluid and Lung Tissue
BAL was performed as previously described (Smit et al. 2014). After anesthesia with 
pentobarbital (Euthasol 20% i.p.), the trachea was exposed and cannulated, and the lungs 
were gently lavaged using 5 ml of sterile saline (37°C), followed by three subsequent aliquots 
of 8 ml of saline. The recovered BAL fluids (BALFs) were kept on ice and centrifuged at 200 
rcf for 10 min at 4°C. Pellets were re-suspended into a final volume of 1 ml phosphate-
buffered saline (PBS), and a CASY cell counter (Model TT; Innovatis, Reutlingen, Germany) 
was used to count total cell numbers. For neutrophil determination, cytospin preparations 
were stained with May-Grünwald and Giemsa stain (Smit et al. 2014). Cell differentiation was 
performed by counting at least 400 cells in duplicate. 
Tissue nonspecific alkaline phosphatase (TNAP) staining was used to identify neutrophils 
on frozen lung sections (Erjefält et al. 1996; Pera et al. 2011). Sections were rinsed in a 
TRIS-base buffer (pH 7.6) for 2 min, and then incubated for 5 min in a TRIS-base buffer 
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(pH 9.0) containing 1 mg/ml naphthol AS-BI phosphate (Sigma, N2125) and 1 mg/ml Fast 
Red TR Salt hemi (zinc chloride) salt (Sigma, F8764). Sections were rinsed in a TRIS-base 
buffer (pH 7.6) for 2 min, counterstained with haematoxylin (Sigma, GHS3) for 1 min, and 
mounted in Kaiser’s glycerol gelatin. Airway neutrophils were counted in the adventitia and 
sub-mucosa, and expressed as the number of positively stained cells per mm basement 
membrane length. 
CBS and Nrf2 Immunohistochemistry





) for 30 min, followed by 1 hour blocking in 10% serum (normal rabbit serum (Dako, 
X0902) for CBS, normal goat serum (Dako, X0907) for Nrf2). Sections were then incubated with 
primary antibodies (Santa-Cruz, sc-271886, 1:50 for CBS; Abcam, ab31163, 1:100 for Nrf2) for 1 
hour at room temperature. Primary antibodies were visualized using horseradish peroxidase-
labelled secondary antibodies (1:100) and diaminobenzidine. Sections were counterstained 
with haematoxylin (Sigma, GHS3) for 1 min and mounted in Kaiser’s glycerol gelatin. 
CBS and Nrf2 Western Blotting 
Guinea pig lung homogenates were prepared by pulverizing lung tissue in liquid nitrogen, 
followed by ultra-sonication in RIPA buffer (composition: 50 mM Tris, 150 mM NaCl, 0.1% 
sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% nonyl phenoxypolyethoxylethanol), 




, 1 mM NaF, 1.06 mg/ml β-glycerolphosphate, 10 μg/
ml apoprotein, 10 μg/ml leupeptin, and 7 μg/ml pepstatin A. Lysates were centrifuged at 
12000 rcf for 20 min at 4°C, and supernatants were collected. 
Protein content was determined using the Pierce BCA protein assay (ThermoFisher, 23225). 
Equal amounts of protein were separated on a 10% polyacrylamide gel, transferred onto 
nitrocellulose membranes, blocked with 1x Roti block reagent, and incubated overnight 
with primary antibodies (Santa-Cruz, sc-271886, CBS: 1:100; Abcam, ab31163, Nrf2: 1:1000; 
Santa-Cruz, sc-47724, GAPDH: 1:400) at 4oC. After washing, membranes were incubated 
with horseradish peroxidase-labelled secondary antibodies. Protein bands were visualized 
using Western lightning plus ECL (PerkinElmer, NEL105001EA) and quantified using Image 
J 1.48v. CBS and Nrf2 were normalized to GAPDH. 
MDA Measurement
MDA concentrations in guinea pig lung homogenates was measured by the thiobarbituric 
acid reactive substances assay (Draper and Hadley 1990). Lung lysates were mixed with 
10% trichloroacetic acid (Sigma, T9159; 1:1, v/v) and centrifuged at 2,200 x g for 15 min 
for protein removal. Samples were mixed with 6.7 g/l thiobarbituric acid (Sigma, T5500; 
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1:1, v/v) and heated at 95°C. MDA levels were determined by measuring absorption 
at 550 nm. The standard curve was made by measuring a series of gradually diluted 
1,1,3,3,-tetramethoxypropane (Sigma, 108383) solutions. MDA levels in lung homogenates 




S levels were determined by measuring sulfide levels in alkaline liquid solutions. Equal 
amounts of serum or cell culture supernatant and SOAB buffer (390 mM sodium salicylate, 
9.2 mM ascorbic acid, 531 mM NaOH in H
2
O) were mixed. The resulting sulfide levels were 
measured using an ISM-146S electrode (Lazar, Los Angeles, USA) in combination with a 
6230N mV meter (Jenco, San Diego, USA). 
ASM Cell Culture
Three human airway smooth cell lines, immortalized by human telomerase reverse 
transcriptase (hTERT) (Gosens et al. 2006) were used for all the experiments. The primary 
cultured human airway smooth cells used to generate each hTERT immortalized cell line 
were prepared as described previously (Gosens et al. 2006). Informed consent was obtained 
from all subjects. All procedures were in accordance with the relevant guidelines and 
approved by the Human Research Ethics Board of the University of Manitoba. The cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies, 11965-
092) containing heat-inactivated fetal bovine serum (10% vol/vol), streptomycin (50 U/ml), 
penicillin (50 mg/ml) in a humidified atmosphere at 37°C in air/CO
2
 (95%:5% vol/vol). 
Cigarette Smoke Extract Preparation
Cigarette smoke extract (CSE) was freshly prepared by pumping the smoke from two 
combusted 3R4F research cigarettes (Reference Cigarette Program, University of Kentucky) 
through 25 ml of serum-free DMEM (Oldenburger et al. 2012; Poppinga et al. 2015). This was 
designated as 100% CSE. 
IL-8 Measurement
hTERT-ASM cells were plated on 24-well plates. After grown to confluence, cells were treated 
with the indicated concentrations of the Sul-121 in the absence and presence of 15% CSE for 
24 hours in serum-free DMEM. Culture medium was collected to measure IL-8 concentrations 
using an IL-8 enzyme-linked immunosorbent assay (ELISA) kit (Pelikine, M1918) according 
to the manufacturer’s instructions. Fenoterol (Boehringer Ingelheim, 217-742-8, 1 μM) 
treatment was used as a positive control. Cells were trypsinized for trypan blue cell counting 
to determine cell viability (Oldenburger et al. 2012). Data represent from 7-24 experiments. 
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Nrf2 and p65 Immunofluorescence 
ASM cells were plated on cover slips in 12-well plate. After grown to confluence, cells were 
treated with 300 µM Sul-121, with or without 15% CSE or 10 µg/ml LPS (Sigma, L-2880), for 2 
hours. Cells were then fixed with a solution containing 4% paraformaldehyde and 4% sucrose 
for 15 min at room temperature, followed by treatment with 0.3% Triton X-100 for 5 min at 
room temperature. Cells were blocked for 1 hour at room temperature with PBS containing 
5% bovine serum albumin and 2% donkey serum. Cells were then incubated overnight at 
4°C with primary antibodies against Nrf2 (Abcam, ab31163, 1:100) and p65 (Cell Signaling, 
#3033S, 1:20). The next day, cells were washed with PBS and incubated with secondary 
antibodies (1:500) for 1 hour at room temperature. After wash with PBS, nuclei were stained 
with Hoechst (Invitrogen, H3570, 1:10000) for 5-10 sec, immediately followed by two 
quick and four 10 min washing steps with ultra-pure water. After staining, coverslips were 
mounted using ProLong® Gold Antifade Mountant reagent (Life Technologies, P36930) and 
imaged using an Olympus AX70 microscope equipped with digital image capture system 
(ColorView Soft System with Olympus U CMAD2 lens, Olympus Corporation, Tokyo, Japan). 
The background corrected fluorescence measurements were performed with Image J 1.48v 
(Burgess et al. 2010). Data represent from 4-5 experiments.
ROS Measurement
The 7’-dichlorofluorescein-diacetate (DCF-DA) fluorescence method was used for 
the determination of ROS level. 6-carboxy-2’,7’-dichloro-dihydrofluorescein diacetate, 
di(acetoxymethyl ester) (Carboxy-H2DCF-DA, Life technologies, C-2938, 0.1 µM) was 





KGaA, 1.07209.0250, 2 mM) or CSE (15%). The ROS level was measured by the intensity of 
DCF emission at 525 nm (excitation 503 nm). Alternatively, dihydroethidium (DHE, Life 
technologies #D11347, Carlsbad, CA, 5 µM) was dissolved in DMEM and supplemented 




, MerckMillipore #107209, Darmstadt, 
Germany, 5 µM) was added as reactive oxygen donor and samples were incubated at room 
temperature for 1 hour. Fluorescence was recorded on a Varioskan spectrofluorometer 
(ThermoScientific, Waltham, MA) at Ex/Em 488/525 nm and 518/605 nm for DCF and DHE, 
respectively. Data represent 3-12 experiments.
To examine the production of ROS, ASM cells were plated on 96-well plates. After grown to 
confluence, cells were treated with 300 µM Sul-121 in the absence and presence of 0.1 µM 
PMA (Sigma, P-8139) as control (Swindle et al. 2002) for 2 hours. 10 mM NAC (Sigma, A9165) 
served as positive control. After removal of the supernatant, cells were incubated with 0.1 
µM carboxy-H2DCFDA for 1 hour and ROS production was measured as described above. 
Data represent 4 experiments. 
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Statistics
Data represent means±SEM, from n experiments. Statistical significance of differences was 
evaluated by one-way or two way ANOVA with Bonferroni post-hoc tests, or by two tailed 
Student’s t-test using Prism 5 software. Pearson’s correlation tests were also performed by 
using Prism5. Differences were considered to be statistically significant when p<0.05. 
Results 
Effects of Sul-121 on LPS-induced AHR
In line with earlier reports (Toward and Broadley 2000; Smit et al. 2013), we observed 
increased airway responsiveness to histamine 2 and 3 hours after LPS instillation, with PC100 
values (the provocation concentration of histamine causing a 100% increase in P
pl
) at these 
time points significantly lower than that for LPS-naive animals that received only saline 
instillation (Figure 1B). Although inhaled Sul-121 did not affect airway responsiveness in 
LPS-naive control animals (Figure 1B), it did prevent LPS-induced AHR in a dose-dependent 
manner up to 90 % (Figure 1C). At 30 mM (nebulizer concentration), Sul-121 almost fully 
prevented LPS-induced AHR (0.89±0.09, p<0.01; Figure 1C). In line with our observation that 
Sul-121 did not affect airway responsiveness in LPS-naive, saline-challenged animals, it also 
did not affect methacholine-induced contraction of bovine tracheal smooth muscle strips 
(Supplementary Figure). This finding strongly suggests that Sul-121 does not have a direct 
effect on airway smooth muscle tone.
Effects of Sul-121 on LPS-induced Neutrophilia in BALF and Airway Tissue
As expected (Toward and Broadley 2000; Pera et al. 2011; Smit et al. 2013), LPS challenge 
significantly increased the number of lung neutrophils in both cartilaginous (from 3.0±0.8 
to 19.8±4.2 cells/mm basement membrane) and non-cartilaginous airways (from 4.7±0.5 
to 8.008±1.099 cells/mm basement membrane), which was largely prevented by 30 mM 
Sul-121 in both airway categories (cartilaginous airways: 7.340±2.402 cells/mm basement 
membrane; non-cartilaginous airways: 3.834±0.824 cells/mm basement membrane; p<0.01 
both; Figures 2A, B & C). Similar to the neutrophil changes in the airways, LPS induced a 
significant increase of neutrophils in BALFs (from 0.07±0.02 to 2.28±0.66 x 107 cell number 
retrieved from the BAL, Figure 2D). Inhalation of Sul-121 dose-dependently prevented LPS-
induced neutrophilia by up to 60% using 30 mM Sul-121 (to 0.91±0.30 x 107 cell number 
retrieved from the BAL; p<0.001; Figure 2D). Sul-121 was without effect on basal neutrophil 
numbers in the lungs of saline challenged, LPS-naive animals (Figure 2D). 
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Figure 1. Effects of Sul-121 on LPS-induced airway responsiveness in guinea pigs. Guinea pigs 
were intranasally instilled with LPS (5 mg/ml in saline, 300 µl; t=0 h) to induce AHR, or with saline 
(control) as outlined in the Material and Methods. At 30 min before LPS or saline instillation, animals 
were treated by inhalation of aerosolized vehicle or Sul-121 (3 or 30 mM nebulizer concentration). 
Inset, structure of Sul-121 (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl (piperazin-1-yl) methanone. At 
25 h after LPS challenge, animals were terminated (A). Airway responsiveness to histamine in the 
different treatment groups was assessed by determining the provocation concentration of histamine 
causing a 100% increase in P
pl
 (PC100). Data are expressed as ratio between the PC100-value at 
the different time points over the PC100-value at baseline (t=-24 h), with a value of 1 representing 
normoresponsiveness (B, C). N=4-6 animals per group. C: #p<0.05, ##p<0.01, compared with baseline 
(t=-24 h); one way ANOVA repeated measurement with bonferroni’s multiple comparison tests. B, C: 
*p<0.05, **p<0.01, ***p<0.001 compared with the LPS control group at the same time point; two way 
ANOVA with bonferroni post-tests. 
151
































































































Figure 2. Effects of Sul-121 on LPS-induced neutrophilia in BALF, blood and airway tissue. 
Guinea pigs were treated for 3 min by inhalation of vehicle or Sul-121 (3 or 30 mM nebulizer 
concentration) 30 min before intranasal instillation of 300 µl saline or LPS (5 mg/ml) at 0 h. After animal 
termination at 25 h, BAL were performed, and blood and lungs were collected for further analysis. 
Neutrophils were stained with TNAP (red staining, arrows) in transverse frozen cross-sections of the 
lung. Representative images are shown (A, magnification: 10X, inset, 20X). Neutrophils in cartilaginous 
(B) and non-cartilaginous airways (C) on sections were quantified in the adventitia and sub-mucosa, 
and expressed as the number of positively stained cells per mm basement membrane length. 
Neutrophil numbers were determined in BALF (D) and blood (E). N=4-6. B, C, D: **p<0.01, ***p<0.001; 
two way ANOVA with bonferroni post-tests. 
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Blood H2S level and Lung CBS expression 
H
2
S may have a protective role in inflammatory airway diseases (Faller et al. 2012). LPS 
challenge tended to decrease levels of serum H
2
S (from 342±99 to 134±56 x 10-7 M), an 
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Figure 3. Effects of Sul-121 on blood H2S level and lung CBS expression. Guinea pigs were 
treated for 3 min by inhalation of vehicle or 30 mM Sul-121 at 30 min before intranasal instillation of 
300 µl saline or LPS (5 mg/ml) at 0 h. After animal termination at 25 h, blood/serum was collected and 
H
2
S levels were measured (A). Correlations between serum H
2
S levels and neutrophil numbers in non-
cartilaginous (B) were determined. Western analysis of CBS protein expression was performed in lung 
homogenates. Cropped images are shown. Gels have been run under the same experimental condition 
(C). CBS expression (yellow brown staining, arrows) was determined using immunohistochemistry in 
transverse frozen cross-sections of the lung. Representative images are shown (D). N=4-6. A: n.s: not 
significant versus saline vehicle. 
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As shown in Figures 3B, in both LPS-naive, saline challenged and LPS challenged animals 
we found an inverse correlation between serum H
2
S levels and the number of neutrophils 
in non-cartilaginous airways (p=0.041, r=0.45). Neither immunohistochemistry nor western 
blotting revealed any difference in the abundance of the H
2
S producing enzyme, CBS (Chen 
and Wang 2012), in the lungs of animals in any of our study groups (Figures 3C, D). Overall, 
our data suggest that Sul-121 protects concomitant loss of serum H
2
S and against the 
accumulation of lung neutrophils that are otherwise induced by LPS challenge.
Lung Nrf2 expression and MDA Levels
Neither LPS nor Sul-121, alone or in combination altered the expression of the anti-oxidant 
transcription factor Nrf2 expression in lung homogenates (Figure 4A) or lung sections 
(Figure 4B). Polyunsaturated lipids can be degraded under oxidative stress leading to 
the formation of MDA (Ayala et al. 2014). We therefore analyzed oxidative stress in lung 
tissue by measuring total MDA levels. LPS induced a 2-fold increase in MDA abundance 
(from 0.06±0.01 to 0.12±0.01 µmol/g protein; p<0.01), confirming that oxidative stress had 
developed, and 30 mM Sul-121 fully prevented the LPS-induced MDA in lungs (0.07±0.01 
µmol/g protein; p<0.05; Figure 4C). Moreover, we found a positive correlation between lung 
MDA level and airway neutrophil number (p=0.0324, r=0.457; Figure 4D). Taken together, 
these findings indicate that Sul-121 may - at least partially, exert its protective effects in the 
lung by normalization of LPS-induced oxidative stress. 
IL-8 Release and p65 Nuclear Translocation in hTERT Cells
The mechanisms by which Sul-121 may decrease airway neutrophilia were further studied 
in vitro using human ASM cells, which we have previously shown, and confirm here, to 
be capable of expressing and releasing abundant IL-8 in response to challenge with CSE 
by about 5-fold above basal (34±13 pg/ml) (Oenema et al. 2010; Oldenburger et al. 2012) 
(Figure 5A). Treatment of cells with Sul-121 dose-dependently reduced 15% CSE-induced 
IL-8 release up to 90%, with 300 µM Sul-121 almost fully abrogating IL-8 release (p<0.001); 
an effect on par with that elicited by 1 μM fenoterol, a first line COPD therapeutic (Poppinga 
et al. 2015) (Figure 5A). Cell viability was not compromised by any concentrations of Sul-121 
(Figure 5B). CSE exposure significantly increased nuclear translocation of the NF-κB subunit, 
p65, an effect that was fully prevented by Sul-121 (from 255±46 to 126±12 fluorescence % 
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Figure 4. Effects of Sul-121 on lung Nrf2 expression and MDA level in lung homogenates. 
Guinea pigs were treated for 3 min by inhalation of vehicle or 30 mM Sul-121 at 30 min before 
intranasal instillation of 300 µl saline or LPS (5 mg/ml) at 0 h followed by animal termination on 25 
hours. Western analysis of Nrf2 protein expression was performed in lung homogenates. Cropped 
images are shown. Gels have been run under the same experimental condition (A). Nrf2 expression 
(yellow brown staining, arrows) was determined using immunohistochemistry in transverse frozen 
cross-sections of the lung. Representative images are shown (B). MDA levels were measured in lung 
homogenates (C). Correlation between lung MDA concentration and total airway neutrophil numbers 
was performed (D). N=4-6. C: *p<0.05, **p<0.01; two way ANOVA with bonferroni post-tests. 
ROS production and Nrf2 nuclear translocation in ASM cells




 (from 177±17 to 123±4.9 fluorescence 
% of vehicle; p<0.001) or 15% CSE (from 183±12 to 136±6.9 fluorescence % of vehicle; 
p<0.001) solutions under cell-free condition (Figure 6A). In addition, Sul-121 completely 




(Figure 6B), indicating that 
Sul-121 normalizes exogenous ROS in all experimental conditions. 
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Figure 5. Effects of Sul-121 on IL-8 release and p65 nuclear translocation in ASM cells. 
Immortalized human ASM cells were incubated with Sul-121 (10-300 μM) in the absence of presence 
of 15% CSE for 24 h. Fenoterol (1 µM) served as positive control. IL-8 concentrations in supernatants 
were measured by ELISA (A). Cells were trypsinized for trypan blue cell counting to determine cell 
viability (B). For immunofluorescence of p65 (C), hTERT cells were incubated with 300 µM Sul-121 in 
the absence and or presence of 15% CSE for 2 hours. Representative images are shown. Images were 
quantified by Image J 1.48v (D). A, B: N=7-24; ***p<0.001 compared to CSE vehicle; two way ANOVA 
with Bonferroni post-tests; ##p<0.01, ###p<0.00, compared to corresponding basal IL-8 release, two way 




Thus the effects of Sul-121 on cell responses are likely due to direct effects on cellular 
oxidative stress and associated cell responses. Indeed, Sul-121 reduced endogenous 
ROS production by human ASM cells to the same degree as the broadly effective ROS 
inhibitor, 10 mM N-acetyl-L-cysteine (NAC; to 62±6.4 and 69±5.7 fluorescence % of 
vehicle, respectively; Figure 6C). However, Sul-121, but not NAC, significantly reduced 0.1 
µM phorbol 12-myristate 13-acetate (PMA)-induced ROS production by ASM cells (from 
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Figure 6. Effects of Sul-121 on ROS production. Under cell-free condition, carboxy-H2DCF-DA (0.1 




(2 mM) or 
CSE (15%). ROS was measured by the intensity of DCF emission (A). Alternatively, DHE (5 µM) was 




 (5 μM). ROS was 
measured by the intensity of DHE emission (B). Immortalized human ASM cells were incubated with 
300 µM Sul-121 in the absence and presence of PMA (0.1 µM) for 2 hours. 10 mM NAC served as 
positive control. After removal of the supernatant, cells were incubated with carboxy-H2DCFDA (0.1 
µM) for 1 h. ROS was measured by the intensity of DCF emission (C). A: N=12; **p<0.01, ***p<0.001; 
two way ANOVA with Bonferroni post-tests. B: N=3, ***: p<0.001, compared to Basal; one way ANOVA 




 treatment; one way ANOVA 
with Bonferroni post-tests. C: N=4; *p<0.05, **p<0.01, ***p<0.001; two way ANOVA with Bonferroni 
post-tests. 
157
The Novel Compound Sul-121 Inhibits Airway Inflammation and Hyperresponsiveness 
6
We found that 15% CSE and 10 µg/ml LPS exposure significantly increased the nuclear 
translocation of the anti-oxidant transcription factor Nrf2 (CSE: 368±52 fluorescence % of 
vehicle, p<0.001; LPS: 338±88 fluorescence % of vehicle, p<0.001; Figure 7A, B) as measured 
by immunofluorescence. Notably, 300 µM Sul-121 completely prevented Nrf2 translocation 
to the nucleus induced by both CSE (127±16 fluorescence % of vehicle; p<0.001; Figure 7A, 
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Figure 7. Effects of Sul-121 on Nrf2 nuclear translocation in ASM cells. For immunofluorescence 
of Nrf2, immortalized human ASM cells were incubated with 300 µM Sul-121 in the absence and or 
presence of 15% CSE or 10 µg/ml LPS for 2 h. Representative images are shown (A). Images were 





COPD is characterized by persistent and progressive airflow limitation associated with 
chronic pulmonary inflammation (GOLD 2015). Although often underestimated in clinical 
assessment, AHR is an important characteristic of COPD (van den Berge et al. 2012) that 
associates with accelerated lung function decline (Postma et al. 1986; Tashkin et al. 1996). 
There is a strong association between AHR and accumulation of lung neutrophils (van den 
Berge et al. 2012), which are associated with production of ROS and a number of potent pro-
inflammatory cytokines (Postma et al. 1988; Barnes et al. 2003). In our present study, using 
a guinea pig model of LPS-induced neutrophilia that mimics that in COPD and promotes 
the development of AHR, we show that Sul-121 dose-dependently prevents AHR induced 
by intranasal instillation of LPS in vivo. The acute LPS-challenge model we employ induces 
marked accumulation of lung neutrophils, a feature that correlates strongly with clinical 
outcomes (Stockley 2006; Gernez et al. 2010; Hoenderdos and Condliffe 2013). Here we 
report from in vitro and in vivo studies that though Sul-121 has no direct bronchodilatory 
effects, it does strongly inhibit the development of AHR, primarily by inhibiting LPS-induced 
lung inflammation. Indeed, inhaled Sul-121 prevents LPS-induced lung neutrophilia, 
confirmed in BALF and in both cartilaginous and non-cartilaginous airways, as well as the 
induction of markers of oxidative stress in the lungs, demonstrating that Sul-121 possesses 
significant anti-oxidant and anti-inflammatory properties.
As a potent neutrophil chemoattractant and activator (Hoenderdos and Condliffe 2013), 
levels of IL-8 in the lungs are strongly correlated with neutrophil number in COPD patients 
(Keatings et al. 1996; Tanino et al. 2002). We report that Sul-121 dose-dependently reduces 
CSE-induced IL-8 release from human ASM cells in vitro, potentially explaining the capacity 
for inhaled Sul-121 to block LPS-induced lung neutrophilia in vivo. NF-κB is involved in the 
transcription of a variety of pro-inflammatory genes, including IL-8, and is activated by CSE 
(Oenema et al. 2010; Oldenburger et al. 2012). The activation of NF-κB is associated with 
the translocation of its p65 subunit to the nucleus, subsequently triggering transcription of 
inflammatory cytokines and chemokines (Chandel et al. 2000). We show that Sul-121 pre-
treatment effectively prevents CSE-induced p65 nuclear translocation in human ASM cells, 
an effect that parallels suppression of CSE-induced IL-8 release. Taken together, our current 
findings indicate that Sul-121 may prevent airway neutrophilic inflammation by decreasing 
IL-8 release upon inhibition of NF-κB activation and subsequent nuclear translocation. 
Oxidative stress plays a central role in inflammatory responses in COPD (Kirkham and Barnes 
2013). NF-κB can be activated by oxidative stress, leading to downstream inflammatory 
responses (Sen and Packer 1996). Therefore, the anti-inflammatory effect of Sul-121 could 
be explained by an anti-oxidant effect. Nrf2 is a nuclear factor that controls cellular anti-
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oxidative responses (Itoh et al. 1999). Under favorable physiological conditions, the Nrf2 
activity is suppressed by Keap1, a cytosolic protein binding partner that prevents Nrf2 
nuclear translocation. Under conditions of oxidative stress, Keap1 dissociates from, and 
permits nuclear translocation of Nrf2 (Kobayashi et al. 2004). Subsequently, Nrf2-induced 
transcription of anti-oxidant genes initiates adaptive responses that can counteract 
oxidative stress (Itoh et al. 1999). We now report that CSE, as well as LPS, exposure of human 
ASM cells induces Nrf2 nucleus translocation, and that Sul-121 significantly decreases Nrf2 
nucleus translocation induced by both CSE and LPS. Although these findings at first seem 
contradictory, they actually do support an anti-oxidant role for Sul-121 as they diminish 
the requirement for endogenous pathways to increase the transcription of anti-oxidative 
stress genes. In support of an anti-oxidant property for Sul-121, we report that it significantly 




), as well as 
endogenous ROS produced by ASM cells in response to PMA. Taken together, our findings 
support a hypothesis that Sul-121 exerts anti-inflammatory effects through normalization 
of oxidative stress.
Accordingly, LPS-induced elevation of MDA, a product of peroxidative breakdown of 
polyunsaturated fatty acids (Ayala et al. 2014), is effectively reduced in guinea pigs pretreated 
with Sul-121. Importantly, lung MDA levels correlate with lung neutrophil infiltration induced 
by LPS in vivo. The anti-oxidant properties of Sul-121 may explain, at least in part, its capacity 
in the present study to suppress LPS-induced AHR, as oxidative stress has been directly 
implicated to underpin pathogenesis leading to decreased lung function (Schünemann et 
al. 1997; Stanojkovic et al. 2011). In addition, peroxidative breakdown of polyunsaturated 
fatty acids contributes to impairment of the epithelial integrity (Rahman and Adcock 
2006; Rajendrasozhan et al. 2008), which can contribute to increased transmigration of 
neutrophils to the airway lumen (Chignard and Balloy 2000). Since CSE has been shown 
to impair airway epithelial integrity in vitro (Heijink et al. 2012; Oldenburger et al. 2014), it 
is tempting to speculate that the prevention of LPS-induced airway neutrophilia by Sul-
121 may be associated with maintenance of epithelial integrity due to its anti-oxidative 
properties. Our work supports future studies to fully investigate this possibility.
Notably, H
2
S reportedly protects against LPS-induced lung injury (Faller et al. 2012). Several 
studies have focused on the effects of exogenous H
2
S donors on inflammation (Li et al. 
2008; Chen et al. 2011; Han et al. 2011). Nonetheless, little is known about the relationship 
between airway inflammation and endogenous H
2
S production. Serum H
2
S levels may be 
decreased in COPD patients during acute exacerbation (Chen et al. 2005), and patients 
requiring antibiotics due to lower respiratory tract infections exhibit significantly reduced 
serum H
2
S levels compared subjects not requiring antibiotics (Chen et al. 2009). In line with 
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S levels negatively correlate with neutrophil number in non-cartilaginous 
(p=0.0406). The oxidation of blood H
2
S to its pro-inflammatory sulfite form occurs during 
oxidative stress generated upon exposure of neutrophils to LPS (Mitsuhashi et al. 2005). 
Therefore, we speculate that LPS-induced oxidative stress leads to loss of serum H
2
S in the 
guinea pig model we have employed. Interestingly, resistance to corticosteroid therapies in 
COPD patients has been attributed to the imbalance of acetylation-deacetylation states of 
histones due to the impact of oxidative stress on histone deacetylase (Marwick et al. 2007; 
Barnes 2013). Thus, it would be interesting to study whether Sul-121 prevents or reverses 
corticosteroid resistance in experimental models of COPD.
In conclusion, we show that Sul-121 reduces neutrophilic inflammation and AHR in an LPS-
induced experimental model of COPD in vivo, which corresponding to the reduction of Nrf2 
activation, probably due to the reduction of oxidative stress as well as inhibition of NF-κB. 
These findings support future work to determine the potential for Sul-121 as a candidate 
for treatment of COPD. 
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Supplementary Figure. Bovine tracheal smooth muscle (BTSM) strips were prepared and mounted 
for isometric recording as previously described (Dekkers et al. 2007; Roscioni et al. 2011). To study 
effects of Sul-121 on muscarinic receptor agonist-induced contraction, BTSM strips were incubated 
with 30 µM Sul-121 or vehicle for 30 min, followed by cumulative dosing of the indicated methacholine 
concentrations (A). To analyze Sul-121 effects on contractile muscle function tone, BTSM strips were 
first contracted by 0.3 µM methacholine, followed by washout, incubation of 600 µM Sul-121 for 2 
hours, and a subsequent washout. BTSM strips were contracted again with 0.3 μM methacholine. 
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According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), chronic 
obstructive lung disease (COPD) is characterized by “persistent airflow limitation that is 
usually progressive and associated with an enhanced chronic inflammatory response in 
the airways and the lung to noxious particles or gases” (GOLD 2015). The formation of 
oxidative stress is believed to play a central role in the pathophysiology of COPD (Barnes 
2004; Kirkham and Barnes 2013).
Signaling by cAMP plays an important role in regulation airway smooth muscle (ASM) 
contraction and proliferation that are also involved in the pathophysiology of COPD 
(Billington et al. 2013). A-kinase anchoring proteins (AKAPs) enable compartmentalized 
cAMP signaling by forming a complex with receptors (including β
2
-adrenoreceptors), cAMP 
effectors, phosphodiesterases (PDEs) and other downstream targets (Logue and Scott 2010; 
Dekkers et al. 2013). In this thesis, we studied the role of AKAPs in regulating ASM plasticity 
by analyzing the effects of the AKAP-PKA complex disrupting peptide st-Ht31 on markers of 
the proliferative and contractile ASM phenotypes.
Given the important role of oxidative stress in the pathophysiology of COPD, compounds 
with anti-oxidant properties could be candidate drugs for the treatment of COPD. A series of 
Sul compounds (Sul-90, Sul-121, Sul-127 and Sul-136) were developed as such candidates 
for the pharmacotherapy of COPD. These compounds were previously shown to exert 
promising cell protection against damage induced by hypothermia and rewarming due to 
their anti-oxidative properties (Van der Graaf et al. 2014). In this thesis, we screened these 
Sul compounds for anti-inflammatory and bronchodilatory properties to test which of these 
compounds have therapeutic potential for the treatment for COPD. The best candidate of 
these Sul compounds, Sul-121, was used for further study in a lipopolysaccharide (LPS)-
induced guinea pig model of neutrophilia and airway hyperresponsiveness (AHR) that 
mimics symptoms of COPD. In addition, the molecular mechanism of action of Sul-121 was 
studied in detail. 
AKAPs: Impact on ASM Proliferation and Contractility
Although many cellular elements play a role in the pathophysiology of COPD, many of 
the current COPD medications target either the G protein-coupled receptors (GPCRs: 
e.g. β
2
-agonists and anticholinergics) or their downstream signals (e.g. PDE4 inhibitors) 
(Caramori and Adcock 2003; Salon et al. 2011; GOLD 2015). As one of the best studied signal 
transduction pathways involving GPCRs, the cAMP signaling pathway mediates a range of 
diverse cellular events in relation to airway function (Grandoch et al. 2010). Activation of β
2
-
adrenoceptors stimulates adenylyl cyclase (AC), thereby enhancing the biosynthesis of the 
second messenger cAMP from ATP. Subsequently, cAMP regulates diverse cellular functions 
by activating its downstream effector proteins, such as protein kinase A (PKA) and exchange 
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protein directly activated by cAMP (Epac) (Grandoch et al. 2010; Schmidt et al. 2013). On the 
other hand, cAMP signaling is terminated by the action of PDEs, which degrade cAMP into 
5’AMP (Taskén and Aandahl 2004). Several physiological responses are regulated due to 
the phosphorylation by cAMP-dependent PKA, including the relaxation of ASM (Billington 
et al. 2013) and antagonism at the level of pro-inflammatory transcription factors (such as 
nuclear factor (NF)-κB) (Oldenburger et al. 2012). 
It is has become evident that spatio-temporal regulation of cAMP signaling within 
individual cells is important for proper physiological responses to cAMP elevation. PDEs 
represent one mechanism by which this spatio-temporal regulation is achieved. In addition, 
several studies indicate that the communication between receptors, cAMP effectors, PDEs 
and other downstream targets are regulated by AKAPs, thereby representing another 
mechanisms of spatio-temporal regulation (Wong and Scott 2004; Dekkers et al. 2013). 
AKAPs are a group of scaffolding proteins with the ability to associate with PKA via a short 
α-helical structure. AKAPs act as targeting devices that assemble a large variety of structural 
and signaling molecules and thereby help those signaling elements to target to different 
microdomains in cells (Wong and Scott 2004). As indicated by their name, all AKAPs bind 
to the regulatory subunits of PKA through a conserved short α helical structure, allowing 
guidance to different sub-cellular domains (Pawson and Scott 1997). Based on this feature, 
a cell permeable inhibitor peptide, stearated (st)-Ht31, was developed to mimic this short α 
helical structure, thereby blocking the interaction between all members of the AKAP family 
and PKA (Vijayaraghavan et al. 1997). 
ASM cells are considered to have phenotypic plasticity, allowing it to possess proliferative 
and/or contractile phenotypes depending on the presence of exogenous stimuli (Halayko 
et al. 2008). This phenotypic plasticity of ASM plays an important role in the pathophysiology 
of obstructive pulmonary diseases, such as COPD and asthma, by enabling increased ASM 
contractility and mass (Halayko et al. 2008). Both processes contribute to airway narrowing 
and airflow limitation (Amrani and Panettieri 2003; Chung 2005). The hypercontractile 
phenotype is characterized by an increased expression of contractile proteins, such as 
α-smooth muscle actin (SMA) and calponin (Halayko et al. 2008). We now demonstrate 
that long-term treatment with the AKAP-PKA interaction disruptor st-Ht31 increased the 
contractility of ASM strips. Moreover, st-Ht31 was able to increase expression of typical 
contractile proteins, such as α-SMA, both in intact ASM strips and cultured ASM cells 
(Chapter 3). Notably, it seems that the effect of st-Ht31 on contractile protein expression 
occurs on a post-translation level, as st-Ht31 does not increase mRNA transcription of 
α-SMA and calponin. In support, blocking RNA synthesis using actinomycin D or inhibiting 
protein synthesis using cycloheximide did not prevent the increased α-SMA and calponin 
protein expression induced by st-Ht31 (Chapter 3). Indeed, AKAPs were recently reviewed 




et al. 2015). In this system, proteins are first marked with ubiquitin molecules, then later 
are degraded through the proteasome (Ciechanover 2005). In Chapter 3, we report that 
calponin stability seems to be affected by proteasomal degradation, as basal calponin 
expression was induced in the presence of proteasomal degradation inhibitor MG-132. 
Moreover, MG-132 did not further increase the st-Ht31-induced expression of calponin, 
suggesting that st-Ht31, like MG-132, can inhibit proteasomal degradation (Chapter 3). 
In addition, by inhibiting proteasomal activity, MG-132 has been shown to increase the 
accumulation of ubiquitin-tagged proteins (Ding et al. 2007). Similarly, using Co-IP, we have 
shown that treatment with st-Ht31 increases ubiquitin-tagged α-SMA protein (Chapter 3). 
However, treatment of ASM cells with MG-132 alone did not significantly increase basal 
α-SMA protein, suggesting that the stability of α-SMA protein is not mainly dependent on 
proteasomal degradation. Thus, st-Ht31-induced increase in α-SMA protein expression may 
not be primarily dependent on the inhibitory effects of st-Ht31 on proteasomal activity, 
although it did induce the accumulation of ubiquitinated α-SMA protein. 
Exposing ASM cells to growth factors leads to the phosphorylation (and activation) of 
p70S6 kinase (p70S6K) (Scott et al. 1996; Karpova et al. 1997; Grewe et al. 1999; Roscioni 
et al. 2011), which upregulates the expression of cyclins such as cyclin D1 (Takuwa et al. 
1999; Ravenhall et al. 2000; Chambard et al. 2007). Subsequently, cyclin D1 combines with 
pre-existing cyclin-dependent kinases (CDKs) to phosphorylate target proteins, such as 
retinoblastoma protein (Rb), thereby allowing progression of cell proliferation (Lundberg 
and Weinberg 1998). As mentioned above for ASM phenotypic plasticity, ASM cells exhibit 
(depending on the presence of exogenous stimuli) distinct proliferative and/or contractile 
phenotypes (Halayko et al. 2008). Indeed, we showed that st-Ht31, beside increased 
contractile markers, could increase several typical proliferative markers including DNA 
synthesis, p70s6K phosphorylation, cyclin D1 expression and Rb phosphorylation (Chapter 
3). While exhibiting increased contractility, those st-Ht31 treated ASM strips also showed 
increased protein expression of proliferating cell nuclear antigen (Chapter 3), a protein that 
is expressed during the S phase of the cell cycle (Leonardi et al. 1992). Interestingly, despite 
the increased S phase activity, we reported that st-Ht31 treatment did not induce an increase 
in cell number (Chapter 3), suggesting that st-Ht31 induces simultaneously a cell cycle 
arrest after the S phase. Notably, we found that the treatment of st-Ht31 is correlated with a 
significant downregulation of AKAP8 (Chapter 3). AKAP8, identified to reside in the nucleus, 
regulates DNA replication and the expression of several proteins known to be involved in 
the cell cycle regulation (Coghlan et al. 1994; Eide et al. 1998; Han et al. 2015). Although 
we did not study how st-Ht31 leads to the downregulation of AKAP8, we hypothesize that 
this process may be responsible for the increased S phase activity and cell cycle arrest in 
ASM cells. On one hand, AKAP8 was found overlaid with the CDK4 binding site on cyclin D, 
suggesting that AKAP8 may compete cyclin D1 binding to CDK4 (Arsenijevic et al. 2006). 
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Therefore, downregulation of AKAP8 could facilitate the interaction of cyclin D1 and CDK4, 
thereby increasing Rb phosphorylation and S phase activities. On the other hand, AKAP8 
has been found to regulate M phase events, such as chromatin condensation, by interacting 
with the DNA and other proteins, such as a condensin complex component, Eg7 (Collas et 
al. 1999; Steen et al. 2000), and histone deacetylase 3 (HDAC3) (Li et al. 2006). Therefore, 
downregulation of AKAP8 could lead to the dysregulation of the M phase, resulting in a cell 
cycle arrest in the S phase. 
In conclusion, st-Ht31 leads to a simultaneous increase in hypercontractile and 
hyperproliferative markers in both ASM cells and intact ASM strips. The overall functional effect 
is increased ASM contractility, without alterations in ASM cell number. We believe that our 
results could have major implications in obstructive respiratory disease, such as COPD, since 
such patients very often experience both ASM hyperproliferation and hypercontractility at 
the same time (Lambert et al. 1993; Chung 2005; Bentley and Hershenson 2008; Chung 2008). 
Sul Compounds as Potential Novel Treatment for COPD
Two of the most important features of chronic obstructive pulmonary disease (COPD) 
are chronic inflammation and airflow limitation. Next to smoking cessation, the most 





-agonists), and anti-inflammatory medications, such as glucocorticoids 
(GOLD 2015). Since these drugs are not always effective and particularly resistance to 
glucorticosteroids in COPD patients is a major clinical problem, we screened the novel anti-
oxidative Sul compounds for their anti-inflammatory as well as bronchodilatory actions in 
vitro, to investigate their potential usefulness for the treatment of COPD. In Chapters 5 it was 
found that out of the four Sul compounds tested, Sul-90 and Sul-121 effectively reduced 
CSE-induced IL-8 production by human ASM cells by approximately 90%, indicating an 
potent anti-inflammatory effect of these drugs. As a positive control (Wang et al. 2009; 
Poppinga et al. 2015; Wang et al. 2015), a similar effect was found by the β
2
-agonist fenoterol, 
whereas the other two Sul compounds were either inactive (Sul-127) or even enhanced the 
CSE-induced IL-8 release (Sul-136). In Chapter 5, we also reported that Sul-90 decreased cell 
viability at higher concentrations, whereas Sul-121 as well as the two other Sul compounds 
did not have an effect on cell viability at any of the tested concentrations.
To determine potential ASM relaxing properties of the Sul compounds, we tested the 
effect of these compounds on ASM strip preparations precontracted with methacholine, 
and compared these effects with the classical β-agonist isoprenaline (Chapter 5). We 
demonstrated that out of the four tested Sul compounds, Sul-90 and Sul-121 induced ASM 
relaxation. The maximum relaxation at the highest concentration tested induced by Sul-





To study whether the relaxing properties of the Sul compounds are mediated through 
activation of β
2
-adrenoceptors, we applied the subtype-nonselective β-adrenoceptor 
antagonist, propranolol (Chapter 5). As expected, propranolol significantly shifted the 
isoprenaline-induced relaxation to the right. The relaxation induced by Sul-90 or Sul-121, 
however, was unaffected, demonstrating that Sul-90 and Sul-121 induce relaxation of ASM 
independent of the β
2
-adrenoceptors. 
Taken together, these findings indicate that Sul-90 and Sul-121 are unique new anti-
inflammatory compounds with bronchorelaxing properties that could be useful for novel 
treatment of COPD. This is particularly important as currently there is no effective anti-
inflammatory therapy for this disease (Barnes 2013). In addition, the potential bronchodilator 
effect of these drugs may add to their anti-inflammatory action. Of the two compounds, Sul-
121 seems to be the most promising candidate. Although it has similar anti-inflammatory 
effects as Sul-90, it has better bronchodilatory properties and – in contrast to Sul-90 – does 
not affect cell viability. Thus, our data in Chapter 5 indicate that Sul-121, out of the four Sul 
compounds being analyzed, is the most promising candidate for a novel treatment of COPD. 
Sul-121: Potential Mode of Action
Having identified Sul-121 [6-hydroxy-2,5,7,8-tetramethylchroman-2-yl(piperazin-1-yl) 
methanone hydrochloric acid] as a potential candidate for the treatment of COPD, we studied 
Sul-121 in a guinea pig model of LPS-induced AHR and neutrophilia in vivo. Data in Chapter 
6 show that intranasal LPS instillation induced AHR against histamine and increased the 
number of neutrophils in the BALF as well as in cartilaginous and non-cartilaginous airways, 
strongly supporting the validity of our model. We showed that pretreatment with inhaled 
Sul-121 was able to dose-dependently prevent the LPS-induced AHR towards histamine 
in vivo, which was associated with inhibition of the LPS-induced neutrophilia. Since we 
showed in Chapter 5 that Sul-121 reduced methacholine-induced ASM contraction as well 
as IL-8 release, it is tempting to explain the protective effect of Sul-121 on AHR by both 
a bronchodilatory and anti-inflammatory effect. However, the drug appeared to have no 
effect on basal airway reactivity in this model. Moreover, the actual concentration of Sul-
121 in the airways of the treated animals in vivo was most likely lower than that causing the 
relaxation of ASM in vitro. Therefore, we assume that the protective effect of Sul-121 on LPS-
induced AHR was primarily caused by its anti-inflammatory effect on neutrophilia. Indeed, 
it has been established that neutrophil infiltration is associated with AHR in COPD patients 
(van den Berge et al. 2012). 
As a potent neutrophil chemoattractant and activator (Hoenderdos and Condliffe 2013), 
IL-8 levels are positively correlated with neutrophil numbers in COPD patients and in animal 
models (Keatings et al. 1996; Mio et al. 1997; Yamamoto et al. 1997; Tanino et al. 2002; Zhang 
et al. 2011; Smit et al. 2013). Under cigarette smoke exposure, increased IL-8 release has 
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been described for inflammatory cells (Yang et al. 2006; Mortaz et al. 2008) and pulmonary 
resident cells (Mio et al. 1997; Numanami et al. 2003), including ASM cells (Oltmanns et al. 
2005; Oenema et al. 2010). In accordance, the in vitro studies in Chapters 5 and 6 showed 
that Sul-121 dose-dependently reduced CSE-induced IL-8 release from ASM cells, which 
could explain the inhibitory effect of Sul-121 on LPS-induced neutrophilia (Chapter 6). 
We studied NF-κB as a potential target for Sul-121, since NF-κB is involved in the transcription 
of a variety of cellular genes that regulate the inflammatory response upon producing 
cytokines, chemokines and cell adhesion molecules (Tak and Firestein 2001; Lawrence 
2009). Activation of NF-κB is featured with translocation of its subunit p65 into the nucleus 
thereby triggering downstream gene transcription (Chandel et al. 2000). Several studies 
demonstrated that CSE-induced transcription of IL-8 is regulated by NF-κB (Yang et al. 2006; 
Oenema et al. 2010; Oldenburger et al. 2012). Interestingly, Sul-121 effectively prevented 
CSE-induced NF-κB activation in ASM cells, measured by the nuclear translocation of the 
NF-κB subunit p65 (Chapter 6). Our current findings therefore indicate that Sul-121 prevents 
airway neutrophilic inflammation most likely by decreasing IL-8 release upon inhibition of 
NF-κB activation in pulmonary resident cells such as ASM cells (Figure 1). 
Hydrogen sulfide (H
2
S) is a gaseous mediator that forms a promising target for new drug 
development due to the growing evidence of its important physiological role. Serum 
H
2
S levels positively correlate with the lung function as indicated by an improved peak 
expiratory flow rate and peak inspiratory flow rate, and negatively correlate with the levels of 
neutrophils in bronchoalveolar fluid (Chen et al. 2009). H
2
S has been shown to be protective 
against inflammation in airway diseases such asthma and COPD (Esechie et al. 2008; Li et 
al. 2008; Chen et al. 2011; Han et al. 2011; Faller et al. 2012; Zhang et al. 2013). Serum H
2
S 
levels can be lowered by cigarette smoke in both acute exacerbations of COPD and in 
healthy control subjects (Chen et al. 2008). In accordance, our data in Chapter 6 indicate 
that LPS induced a trend towards a decrease in serum H
2
S levels. Data in Chapter 6 also 
showed a negative correlation between blood serum H
2
S level and lung neutrophils. Others 
reported that blood H
2
S can be oxidized by the oxidative stress generated by LPS activated 
neutrophils (Mitsuhashi et al. 2005). Therefore, we speculate Sul-121 might affect serum H
2
S 
by lowering its peroxidative conversion via decreasing oxidative stress, presumably caused 
by neutrophils. We did not find significant effects of Sul-121 on blood serum H
2
S levels 
(Chapter 6). Thereby, we assume that the small changes of H
2
S after treatment with Sul-121 
are most likely only an indirect consequence (via reduction of neutrophilia), instead of the 


















Figure 1. In the resting state, the activity of Nrf2 is suppressed by Keap1 upon prevention of its 
nuclear translocation. Under oxidative stress, Keap1 dissociates from Nrf2 thereby allowing its nuclear 
translocation. Subsequently, Nrf2-induced antioxidative elements start to alleviate oxidative stress 
responses (Itoh et al. 1999). NF-κB is a nuclear factor that drives several inflammatory pathways (Chandel 
et al. 2000). ROS is well known to activate NF-κB (Morgan and Liu 2011), which is characterized by 
nucleus translocation of its subunit p65, thereby triggering downstream gene transcription of several 
inflammatory responses such as IL-8 release and neutrophilia. Sul-121 could be an anti-oxidant that 
directly neutralize ROS, thereby reducing the activation of both Nrf2 and NF-κB.
Oxidative stress has been proposed to play a central role during the development of 
the COPD. The data in Chapter 6 suggested that Sul-121 prevented LPS-induced airway 
inflammation and AHR by targeting oxidative stress. Indeed, Sul-121 reduced cellular 
reactive oxygen species (ROS) production provoked by phorbol 12-myristate 13-acetate 
(PMA; Chapter 6). More importantly, in accordance with the decreased airway inflammation 
and AHR, Sul-121 decreased LPS-induced levels of malondialdehyde (MDA; Chapter 6), a 
product of peroxidative breakdown of polyunsaturated fatty acids (Ayala et al. 2014). The 
antioxidant role of Sul-121 was also supported by in vitro studies. Nuclear factor erythroid 
2-related factor 2 (Nrf2) is a nuclear factor that controls cellular anti-oxidative responses 
(Itoh et al. 1997). During the resting state, the activity of Nrf2 is suppressed by binding to 
Keap1 thereby preventing its nuclear translocation. Under oxidative stress, Keap1 dissociates 
from Nrf2 thereby allowing its nuclear translocation (Kobayashi et al. 2004). Subsequently, 
Nrf2-induced anti-oxidative elements start to alleviate oxidative stress responses (Figure 
1) (Itoh et al. 1999). The in vitro data in Chapter 6 showed that CSE induced oxidative 
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stress, measured by increased Nrf2 nucleus translocation in ASM cells. Importantly, Sul-121 
significantly decreased CSE-induced Nrf2 nucleus translocation, showing that Sul-121 can 
indeed reduce CSE-induced cellular oxidative stress. 
Currently, there are two main categories of anti-oxidative strategies. The first are anti-oxidants 
which target and neutralize the oxidative stress directly. The second are pharmacological 
agents known to increase the endogenous antioxidant level for example by increasing 
Nrf2 activity (Rahman 2006; Kirkham and Barnes 2013). Based on the data in Chapter 6, we 
hypothesize that Sul-121 acts as anti-oxidant by directly neutralizing ROS. Indeed, Sul-121 
did not alter basal Nrf2 nuclear localization. In support, Sul-121 was able to reduce CSE- 
and hydrogen peroxide-induced ROS levels in a cell-free environment. Since ROS is playing 
an important role, antioxidants have been shown to be effective in a number of animal 
models of lung disease (Haddad et al. 2002; Smith et al. 2002). Similar to our study, a catalytic 
antioxidant [manganese (III) meso-tetrakis (N,N’-diethyl-1,3-imidazolium-2-yl) porphyrin, 
(AEOL 10150)] has been shown to reduce airway inflammation and neutrophilia in smoke 
exposed rats (Smith et al. 2002). In addition, by mimicking the endogenous antioxidant 
glutathione peroxidase, a selenium-based organic complex has been shown to reduce 
neutrophil-recruiting mediators, as well as lung neutrophil recruitment in an LPS-induced 
rat pulmonary inflammation model (Haddad et al. 2002). 
Oxidative stress has been implicated in a decrease of lung function (Schünemann et al. 
1997; Gramiccioni et al. 2010; Stanojkovic et al. 2011; Moussa et al. 2014). In addition, several 
studies have indicated that ROS production potentiated the contraction of both skeletal and 
airway smooth muscle (Samb et al. 2002; Zuo and Clanton 2005). Moreover, oxidative stress 
was reported to directly increase ASM contractility in airways of both human and animal 
sources (Katsumata et al. 1990; Hulsmann et al. 1994). Therefore, we hypothesize that the 
anti-oxidative effects of Sul-121 may also contribute to the inhibition of AHR in vivo (Chapter 
6). Interestingly, oxidative stress is one of important causes of steroid resistance in COPD 
(Barnes 2013). By reduction of histone acetylation, histone deacetylase (HDAC) 2 mediates 
the action of steroids to switch off pro-inflammatory genes (Adenuga and Rahman 2007; 
Marwick et al. 2007; Barnes 2013). ROS was reported to induce imbalance of acetylation-
deacetylation states of histones by reducing HDAC2 activity, via nitrating tyrosine residues 
on HDAC2 (Ito et al. 2004; Osoata et al. 2009), and phosphorylation of HDAC2 by ROS-
activated phosphoinositide 3-kinase (To et al. 2010). Thus, it would be interesting to study 
in the future if Sul-121 is able to overcome corticosteroid resistance in experimental models 
of COPD due to its anti-oxidative properties. 
By impairing airway epithelial integrity, LPS has been shown to enhance airway epithelial 
permeability, thereby contributing to an increased infiltration of neutrophils in the airway 
lumen in several in vivo models (Chignard and Balloy 2000; Evans et al. 2002; Eutamene et al. 




2012; Oldenburger et al. 2014). Epithelial impairment can be attributed to the peroxidative 
breakdown of polyunsaturated fatty acids (Rahman and Adcock 2006; Rajendrasozhan et 
al. 2008). Indeed, we found that the lung MDA levels positively correlated with neutrophils 
in the BALF induced by LPS in vivo (Chapter 6). Therefore, we hypothesize that the Sul-121 
prevents LPS-induced airway neutrophilia by preventing epithelial impairment induced by 
anti-oxidative stress. 
Future Perspectives and Scientific Relevance
COPD is ranked as the fourth leading cause of death in the world (GOLD 2015) and is 
characterized by persistent airflow limitation and chronic lung inflammation. Since COPD 
is featured with both chronic inflammation and progressive airflow limitation in the lungs 
(Soriano and Rodríguez-Roisin 2011; GOLD 2015), the most effective pharmacological 
therapy is suggested to be the combination of anti-inflammatory and bronchodilatory 
medications (GOLD 2015). So ideally, a drug possessing both broncho-relaxing and anti-
inflammatory properties would yield the most efficient treatment of COPD. In the present 
study, we pre-screened 4 candidates that could represent a novel treatment for COPD. 
Based on the pre-screening data, we identified Sul-121 as the most promising candidate 
possessing both broncho-relaxing and anti-inflammatory properties. 
Oxidative stress, either induced by inflammatory cells or by inhaled noxious compounds, 
is an important player in the pathophysiology of COPD (Domej et al. 2014). Besides COPD, 
oxidative stress is also believed to be involved in the pathogenesis of asthma (Nadeem et al. 
2008; Comhair and Erzurum 2010; Dozor 2010; Zuo et al. 2013). Inflammatory cells recruited 
to the asthmatic airways can initiate the overproduction of ROS, which in turn activate 
inflammatory transcription factors (such as NF-κB) (Morgan and Liu 2011). Subsequently, 
the induced (pro-)inflammatory cytokines and chemokines facilitate the up-regulation of 
adhesion molecules and the increased release of inflammatory mediators, such as IL-4, IL-6, 
IL-8, TNF-α in this disease (Zuo et al. 2013; Mittal et al. 2014). ROS was also reported to reduce 
epithelial cell-cell adhesion, thereby contributing to the infiltration of inflammatory cells, 
including eosinophils, in airway lumen (Usatyuk et al. 2003; Usatyuk et al. 2013; Muresan et al. 
2015). Several studies have indicated that ROS production could potentiate the contraction 
of in airway smooth muscle (Samb et al. 2002). Moreover, ROS induced oxidative stress has 
also been shown to facilitate the AHR (Katsumata et al. 1990; Sutcliffe et al. 2012; Berair 
et al. 2013). We have shown that Sul-121 exerts both anti-inflammatory and ASM relaxing 
properties in vitro, ex vivo and in vivo. Therefore, we speculate that Sul-121 could similarly act 
as potential treatment option for asthma by targeting oxidative stress. 




, are mainly produced within the 
mitochondria (Aon et al. 2003; Zorov et al. 2006; Murphy 2009), which are largely found in the 
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smooth muscle cells due to their essential role of energy generation in muscle contractility 
(Hoppeler and Fluck 2003). Dysfunction of mitochondria can indirectly increase cellular 
ROS production and lead to oxidative stress (Wang et al. 2013; Murphy 2013). Interestingly, 
AKAP1 (aka AKAP121) is a widely expressed mitochondrial AKAP (Carlucci et al. 2008b), 
which has been identified as an essential regulator of mitochondrial function by interacting 
with a multivalent signaling complex localizing PKA on the outer wall of the mitochondria 
(Papa et al. 2002; Livigni et al. 2006; Carlucci et al. 2008b). A study reported that dislocation 
of AKAP1 from mitochondria by the synthetic P
mit
 peptides, that encompass the 15–21 or 
10–30 regions of the AKAP121 mitochondrial targeting domain, increased mitochondrial 
ROS production and triggered the death program in cardiomyocytes (Perrino et al. 2010). 
Others reported that AKAP1 knockout was associated with remarkable mitochondrial 
structural abnormalities and increased ROS production in a myocardial infarct mouse model 
(Schiattarella et al. 2016). Although the precise molecular signaling pathways involved in 
the increased mitochondrial ROS production in cardiac AKAP1 deficient mice are currently 
not known, the authors proposed that it is likely attributable to the reduced targeting of 
PKA and associated complexes on the outer mitochondrial membrane (Schiattarella et al. 
2016). Since AKAP1 is widely expressed in different tissues and cell types, including ASM 
cells (Skroblin et al. 2010; Horvat et al. 2012), it is reasonable to speculate that restoration 
and/or stabilization of mitochondrial AKAP-PKA (e.g. AKAP1-PKA) interactions could be an 
effective strategy to prevent oxidative stress in the development of obstructive pulmonary 
diseases such as COPD and asthma. In this context, it is of interest to note that the stability of 
AKAP1 seems to be controlled by the ubiquitin-proteasome system (Czachor et al. 2016). In 
response to hypoxic (low oxygen) conditions in the brain, an E3-ubiquitin ligase was found 
to bind AKAP1 and to tag it for rapid degradation via the ubiquitin/proteasome pathway 
(Carlucci et al. 2008a). Several studies have demonstrated that mild to moderate oxidative 
stress increases the activities of the ubiquitin-proteasome system, thereby increasing 
protein degradation (Shang et al. 1997; Shang et al. 2001; Zhang et al. 2008; Pickering et 
al. 2010; Shang and Taylor 2011). Therefore, we speculate that oxidative stress may lead to 
degradation of AKAP1, thereby provoking a further increase in the cellular ROS production. 
Since Sul-121 bears the property to reduce cellular oxidative stress by directly neutralizing 
ROS, we hypothesize that Sul-121 could support the maintenance of normal mitochondrial 





Overall, the studies presented in this thesis show that:
• Functional AKAP-PKA interactions are important to prevent the induction of a 
hypercontractile ASM phenotype, by inhibiting the expression of contractile proteins, 
such as α-SMA and calponin (Chapter 3). 
• AKAP-PKA interactions regulate the expression level of α-SMA and calponin on a post-
translational level, in a complex that presumably also involves proteasomes (Chapter 3). 
• Interruption of AKAP-PKA interactions induces an increase of proliferative markers in 
ASM, presumably by lowering the expression of AKAP8 known to regulate the cell cycle 
(Chapters 3 and 4). 
• Markers of a hypercontractile phenotype, such as contractile protein expression, and 
markers of a hyperproliferative phenotype, such as DNA synthesis and cell cycle proteins, 
can simultaneously be induced in ASM cells and tissue by a single trigger (Chapter 3).
• Sul-90 and Sul-121 have an anti-inflammatory effect in vitro by inhibiting CSE-induced 
IL-8 release from ASM cells (Chapter 5). 
• Sul-90 and Sul-121 cause ASM relaxation independent of an effect on β
2
-adrenoceptors 
(Chapter 5 and 6). 
• Based on the in vitro effects, out of four Sul compounds, Sul-121 is the most promising 
novel candidate for the treatment of COPD (Chapters 2 and 5). 
• Sul-121 directly neutralizes ROS induced by LPS, a process being accompanied by 
decreased nuclear translocation of Nrf2 (Chapter 6). 
• By directly targeting oxidative stress, Sul-121 reduces activation of NF-κB, thereby 
preventing IL-8 release and subsequent airway neutrophilia in LPS-treated guinea pigs 
(Chapter 6). 
• Sul-121 prevents LPS-induced AHR in a guinea pig model of COPD, which is not due 
to its bronchorelaxing effect, but likely caused by inhibiting the LPS-induced lung 
inflammation (Chapter 6).
• Based on its anti-oxidative, anti-inflammatory and bronchorelaxing effects Sul-121 may 
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COPD (chronic obstructive pulmonary disease, ofwel chronische obstructieve longziekte) 
wordt gekenmerkt door een aanhoudende, vaak voortschrijdende, beperking van de 
luchtstroom die gepaard gaat met een toegenomen chronische ontstekingsreactie in de 
luchtwegen en de longen op schadelijke deeltjes en gassen. Een van de processen die 
een cruciale rol spelen in het ziekteproces van COPD is de vorming van oxidatieve stress 
in de luchtwegen en longen, vandaar dat verbindingen die een antioxidante werking 
hebben mogelijk als geneesmiddelen gebruikt kunnen worden in de behandeling van 
COPD. Recent zijn op basis hiervan verschillende Sul-verbindingen ontwikkeld (Sul-90, 
Sul-121, Sul-127 en Sul-136) als kandidaatgeneesmiddelen voor COPD. Deze verbindingen 
beschermen door hun antioxidante eigenschappen cellen tegen schade veroorzaakt door 
afkoeling en opwarming. In dit proefschrift hebben we deze Sul-verbindingen onderzocht 
op ontstekingsremmende en luchtwegverwijdende werkingen om te bestuderen of 
deze verbindingen een rol kunnen spelen in de behandelingen van COPD. Van deze vier 
kandidaten bleek Sul-121 het meest veelbelovend, vandaar dat Sul-121 verder bestudeerd 
is in een diermodel voor COPD. Tevens werd het werkingsmechanisme van Sul-121 in deze 
processen nader onderzocht.
Het signaalmolecuul cylisch AMP (cAMP) spelt een belangrijke rol in het reguleren van de 
samentrekking (contractie) en ontspannen (relaxatie) alsmede de proliferatie (vermeerdering 
van het aantal cellen door celdeling) van luchtweggladde spiercellen. Verstoring van 
deze processen in luchtweggladde spiercellen draagt bij aan het ziekteproces van COPD. 
A-kinase anchoring proteins (AKAPs) zijn lichaamseigen eiwitten die compartimentalisatie 
van de cAMP signaalroute binnen de cel mogelijk doordat ze een complex vormen met 
receptoren (zoals de β
2
-adrenoreceptors die belangrijk zijn voor de vorming van cAMP), 
cAMP effector eiwitten (zoals protein kinase A, PKA), phosphodiesterases (PDEs, die cAMP 
afbreken en daarmee het signaal uitdoven) en andere eiwitten. In dit proefschrift hebben we 
de rol van AKAPs in het reguleren van luchtweggladde spierplasticiteit bestudeerd. Hiertoe 
bestudeerden we het effect van st-Ht31, een peptide die de normale complexvorming 
van AKAPs en PKA verstoren, op markers van een proliferatief fenotype en een contractiel 
fenotype bestudeert in luchtweggladde spieren. 
AKAPs: impact op luchtweggladde spierproliferatie en -contractie
Alhoewel er vele cellulaire processen zijn die een rol spelen in de pathofysiologie van 
COPD is het target van veel van de huidige geneesmiddelen die gebruikt worden in 
deze ziekte  gekoppelde receptoren (GPCR, G protein-coupled receptors; β
2
-agonisten and 
anticholinergica) of onderdelen van de GPCR signaling (PDE4 remmers). De signaalroute 
van cAMP is wellicht de best bestudeerde GPCR signaal-transductie route en beïnvloedt 





adenylyl cyclase (AC) tot het produceren van de second messenger cAMP vanuit ATP. 
Vervolgens reguleert cAMP diverse cellulaire processen door activatie van downstream 
effector eiwitten, zoals PKA en Epac (exchange protein directly activated by cAMP). De werking 
van cAMP wordt beëindigt door PDEs, die cAMP afbreken in inactief 5’AMP. Het door cAMP 
geactiveerde PKA is in staat om diverse fysiologische response te gereguleerd middels 
fosforylatie van eiwitten. Dit leidt onder andere tot relaxatie van luchtweggladde spiercellen 
en luchtwegverwijding en het tegenwerking van ontstekingsfactoren, zoals nuclear factor 
(NF)-κB. 
Spatio-temporele regulatie van de cAMP signaalroute binnen individuele cellen is van 
belang voor een normale fysiologische respons op toegenomen cAMP levels. Een van de 
mechanismen die dit mogelijk maken wordt gevormd door PDEs. Daarnaast is aangetoond 
dat AKAPs de communicatie tussen receptoren, cAMP effectoren, PDEs en andere cellulaire 
targets reguleren en daardoor ook een mechanisme vormen om de spatio-temporele 
regulatie mogelijk te maken. AKAPs zijn een groep die als het ware een aanlegplaats vormen 
voor diverse eiwitten. Een van deze eiwitten is PKA, wiens regulerende subunit via een korte 
α-helix verankerd is met AKAPs, waaraan AKAPs hun naam te danken hebben. Daarnaast 
zijn AKAPs in staat om een scala van eiwitten te binden die een rol spelen in signaal-
transductie en de cellulaire organisatie, waardoor ze processen kunnen beïnvloeden in een 
specifiek klein onderdeel van de cel. Op basis van de structuur van de α-helix waarmee PKA 
verbonden is met AKAPs is een celpermeabele peptide gemaakt, st-Ht31, die de interactie 
tussen de diverse AKAPs en PKA voorkomen. 
Luchtweggladde spiercellen vertonen zogenaamde fenotypische plasticiteit, hetgeen 
inhoudt dat, afhankelijk van de gebruikte stimulus, de cellen kunnen een proliferatief of juist 
een contractiel fenotype kunnen vertonen. Deze fenotypische plasticiteit in luchtweggladde 
spiercellen speelt een belangrijke rol in de pathophysiologie van obstructieve longziekten, 
zoals COPD en astma, doordat het zowel een toename in de contractiekracht van de 
luchtweggladde spieren als een toename in de hoeveelheid spiermassa mogelijkt maakt. 
Beide processen dragen bij aan luchtwegvernauwing en beperking van de luchtstroom. 
Het hypercontractiele fenotype wordt gekarakteriseerd door een toegenomen hoeveelheid 
contractiele eiwitten, waaronder α-smooth muscle actin (SMA) en calponine.
 De studies beschreven in dit proefschrift tonen aan dat langdurige blootstelling aan st-
Ht31, het peptide dat de interactie tussen AKAPs en PKA verstoort, de contractiekracht 
van luchtweg gladdespierpreparaten verhoogt. St-Ht31 verhoogde ook de hoeveelheid 
contractiele eiwiteen, zoals α-SMA, in zowel intacte preparaten als in gekweekte cellen 
(Hoofdstuk 3). Het is belangrijk op te merken dat deze door st-Ht31 verhoogde expressive 
van contractiele eiwitten op een post-transcriptioneel niveau plaatsvindt, aangezien de 
hoeveelheid mRNA α-SMA of calponine niet veranderde door st-Ht31. Deze bevinding 




remming van de eiwitsynthese door cycloheximide niet in staat waren om de door st-Ht31 
veroorzaakte toename in α-SMA en calponine te voorkomen (Hoofdstuk 3).
 Recentelijk werd beschreven dat AKAPs inderdaad een rol spelen in de stabiliteit van eiwitten 
middels het ubiquitine-proteasoomsysteem. In dit system worden eiwitten eerst gelabeld 
met ubiquitine molecule waarna ze afgebroken worden door de proteasoom. Hoofdstuk 3 
toont aan dat de stabiliteit van calponine wordt beïvloedt door proteasomale afbraak, 
aangezien de basale hoeveelheid calponine werd verhoogd door MG-132, een remmer van 
de proteasomale afbraak. MG-132 veroorzaakte niet een verdere toename van de door st-
Ht31-geïnduceerde hoeveelheid calponine, wat suggereert dat st-Ht31 zelf de protasomale 
afbraak remt (Hoofdstuk 3). Doordat MG-132 de proteasomale afbraak van eiwitten remt, 
maar niet de ubiquitinilatie, is er een toename in geübiquitinileerde eiwitten in cellen 
behandeld met MG-132. In overeenstemming hiermee is middels co-immunoprecipitatie 
door ons aangetoond dat st-Ht31 een verhoging van geübiquitinileerd α-SMA eiwit 
veroorzaakt (Hoofdstuk 3). Echter, MG-132 veroorzaakte niet een significante toename 
in de basale hoeveelheid α-SMA eiwit, hetgeen suggereert dat de stabiliteit van α-SMA 
eiwitten niet sterk afhankelijk is van proteasomale afbraak. De toename in de hoeveelheid 
α-SMA eiwit door st-Ht31 wordt dus niet primair veroorzaakt door een remming van de 
proteasomale activiteit, alhoewel st-Ht31 wel een verhoging van geübiquitinileerde α-SMA 
eiwitten veroorzaakt.
Blootstelling van luchtweggladde spiercellen aan groeifactoren leidt tot fosforylatie en 
activatie van  p70S6 kinase (p70S6K), hetgeen de expressive van cyclines (zoals cycline D1) 
verhoogt. Cycline D1 vormt vervolgens een complex met cycline-afhankelijke kinases (CDK) 
die vervolgens doelwiteitwitten als het retinoblastoma proteïne (Rb) fosforyleren waardoor 
celproliferatie mogelijk wordt gemaakt. Zoals boven beschreven onder fenotypische 
plasticiteit en afhankelijk van de gebruikte stimilus, kunnen luchtweggladde spiercellen een 
proliferatief fenotype of juist een contractiel fenotype hebben. In Hoofdstuk 3 tonen we 
aan dat, behalve het verhogen van contractiele markers, st-Ht31 ook typische proliferatieve 
markers in gekweekte luchtweg gladde spiercellen verhoogt, zoals DNA –synthese, 
fosforylatie van p70s6K en Rb, en de hoeveelheid cycline D1. De st-Ht31 behandelde 
luchtweggladde spierpreparaten hadden niet alleen een toegenomen contractiekracht, 
maar hadden ook een verhoogde expressive van het eiwit proliferating cell nuclear antigen 
(Hoofdstuk 3), hetgeen tot expressie gebracht wordt tijdens de S-fase van de celcyclus. 
Het is van belang dat hoewel er een verhoogde S-fase activiteit werd waargenomen, st-
Ht31 niet tot een toename in cellaantal veroorzaakte (Hoofdstuk 3). Dit suggereert dat 
behandeling met st-Ht31 gelijktijdig een stilstand in de celcyclus veroorzaakt na de S-fase. 
Behandeling met st-Ht31 correleerde met een afname in de hoeveelheid AKAP8 
(Hoofdstuk 3). Van AKAP8 is bekend dat het in de celkern voorkomt en DNA replicatie 
reguleert alsmede de expressive van verscheidende eiwitten die een rol spelen in de 
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celcyclus. Alhoewel het mechanisme waardoor st-Ht31 de AKAP8 expressie verlaagt 
niet door ons is bestudeerd, veronderstellen we dat deze verminderde AKAP8 expressie 
verantwoordelijk is voor de toegenomen S-fase activiteit alsmede de daaropvolgende 
stilstand van de celcyclus in luchtweg gladdespiercellen. Aan de ene kant is van AKAP8 
bekend dat het dezelfde bindingsplaats op CDK4 heeft als cycline D1 en dat AKAP8 en 
cycline D1 dus competeren met betrekking tot hun binding aan CDK4. Een afname van 
AKAP8 zou dus mogelijk leiden tot een verhoogde interactive cycline D1 en CKD4, hetgeen 
de fosforylatie van Rb verhoogt en een stimulatie van de S-fase veroorzaakt. Aan de 
andere kant is bekend dat AKAP8 processen in de M-fase van de celcyclus reguleert, zoals 
condensatie van chromatine, middels een interactie met DNA en andere eiwiten, zoals Eg7 
(een component van het condensincomplex) en histon deacetylase (HDAC)-3 and histone 
deacetylase 3 (HDAC3). Een verminderde AKAP8 expressie zou derhalve een ontregeling 
van de M-fase kunnen veroorzaken waardoor de celcyclus to stilstand komt in de S-fase. 
Concluderend kan gesteld worden dat st-Ht31 een gelijktijdige toename van markers 
van een hypercontractiel fenotype en van markers van een hyperproliferatief fenotype 
induceert in luchtweggladde spieren, zowel in gekweekte cellen als in intacte preparaten. 
Het uiteindelijke functionele effect is een toename in contractiekracht, zonder een effect op 
het celaantal (proliferatie). Wij denken dat onze resultaten belangrijke implicaties hebben 
in hoe we aankijken tegen obstructieve longziekten, zoals COPD, aangezien patiënten met 
deze ziekten vaak gelijktijdig een hypercontractiel en een hyperproliferatief fenotype laten 
zien in hun luchtweggladde spieren. 
Sul-verbindingen als mogelijke nieuwe behandelingsmethode voor 
COPD
Twee belangrijke kenmerken van COPD zijn chronische ontsteking en beperking 
van de luchtstroom. Naast stoppen met roken zijn de aanbevolen medicamenteuze 
behandelingen luchtwegverwijders, zoals  β
2
-agonisten, en ontstekingsremmes, zoals 
glucocorticosteroïden. Aangezien deze medicijnen niet altijd effectief zijn en resistentie 
voor glucorticosteroïden in COPD patienten een groot klinisch probleem is, is onderzoek 
naar nieuwe geneesmiddelen voor de behandeling van COPD nodig.  Met dit als 
doel hebben we de nieuwe Sul-verbindingen, die een antioxidante werking hebben, 
onderzocht op ontstekingsremmende en luchtwegverwijdende eigenschappen,. In 
Hoofdstuk 5 staat beschreven dat van de vier geteste Sul verbindingen, Sul-90 en Sul-121 
de door sigarettenrook veroorzaakte productie van de ontstekingsfactor IL-8 van humane 
luchtweggladde spiercellen bijna volledig remde. Dit geeft aan dat deze verbindingen een 
sterke ontstekingsremmende werking hebben. De andere twee Sul-verbindingen waren 




In dit zelfde Hhodstuk hebben we ook aangetoond dat het ontstekingremmende Sul-90 
als negatieve bijwerking heeft dat het in hogere concentraties celdood veroorzaakt. De 
andere Sul-verbindingen, waaronder het ontstekingsremmende Sul-121, veroorzaakten 
geen celdood in de geteste concentraties.
We hebben tevens onderzocht of de Sul-verbindingen mogelijk een luchtwegverwijdende 
werking hebben (Hoofdstuk 5). Hiertoe werd bestudeerd of de Sul-verbindingen in staat 
waren om de samentrekking van luchtweggladde spierpreparaten, die veroorzaakt wordt 
door methacholine, tegen te gaan. Tevens werd als positieve controle het effect van de 
β-agonist isoprenaline onderzocht. Onze studie toonde aan dat twee van de vier geteste 
Sul-verbindingen, Sul-90 en Sul-121, in staat waren om de luchtweggladde spieren te laten 
relaxeren. De maximale relaxatie die door deze verbindingen veroorzaakt werd was cirda 
70% voor Sul-121 en circa 30% voor Sul-90.
Om te onderzoeken of de relaxerende werking van Sul-121 en Sul-90 veroorzaakt wordt 
door activatie van β
2
-receptoren werd een remmer van β-receptoren  toegediend: 
propranolol. Zoals verwacht was propranolol in staat om de relaxerende werking van de β
2
-
agonist isoprenaline te verminderen, hetgeen zichtbaar is als een rechtsverschuiving van de 
relaxatiecurve van isoprenaline. De relaxerende werking van Sul-121 en Sul-90 werd echter 
niet aangetast door propranolol. Dit toont aan dat de relaxerende werking van Sul-121 en 
Sul-90 onafhankelijk van de β
2
-receptoren optreedt (Hoofdstuk 5).
Aangezien Sul-90 en Sul-121 zowel een ontstekingsremmende als een luchtwegverwijdende 
eigenschappen hebben, zouden deze verbindingen een nieuwe behandelingsmethode 
voor COPD kunnen vormen. Het ontstekingsremmende effect van de Sul-verbindingent is 
van belang aangezien er momenteel geen effectieve ontstekingremmende behandeling is 
voor COPD. Daarnaast zou een mogelijk bronchusverwijdende eigenschap ook bij kunnen 
dragen aan het ontstekingsremmende effect. Van deze twee verbindingen lijkt Sul-121 
de meest veelbelovende kandidaat te zijn, omdat het - in tegenstelling tot Sul-90 – geen 
celdood veroorzaakt en een sterkere relaxatie geeft, terwijl de ontstekingsremmende 
werking vergelijkbaar is met die van Sul-90 (Hoofdstuk 5). 
Het mogelijke werkingsmechanisme van Sul-121
Op grond van de bevindingen in Hoofdstuk 5, hebben we de effecten van Sul-121 onderzocht 
in een caviamodel voor luchtweghyperreactiviteit en neutrofiele ontsteking veroorzaakt 
door LPS. Dit is een diermodel voor deze aspecten van COPD. De bevindingen van deze 
studie staan beschreven in Hoofdstuk 6. Intranasale toediening van LPS veroorzaakt 
luchtweghyperreactiviteit ten opzichte van histamine en verhoogt het aantal neutrofiele 
ontstekingscellen in de longen en in grote en kleine luchtwegen. Voorbehandeling middels 
verneveling en inademing van Sul-121 gaf een dosisafhankelijke bescherming tegen de 
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door LPS veroorzaakte luchtweghyperreactiviteit in vivo. Daarnaast verminderde Sul-
121 ook de neutrofiele ontsteking veroorzaakt door LPS. De beschermende werking met 
betrekking tot de luchtweghyperreactiviteit lijkt op het eerste gezicht verklaard te worden 
door het relaxerende effect van Sul-121 dat we waargenomen hebben in luchtweggladde 
spieren (Hoofdstuk 5). Echter, Sul-121 had geen effect op de basale reactiviteit in dit model. 
Dit sugereert dat Sul-121 geen direct bronchusverwijdend effect had in de concentratie die 
gebruikt is in deze in vivo studie. Dit is aannemelijk omdat de locale Sul-121 concentratie 
in de behandelde dieren waarschijnlijk aanzienlijk lager is dan de concentratie die een 
relaxatie van de luchtweggladde spieren veroorzaakte in Hoofdstuk 5. Vandaar dat het 
ontstekingsremmende effect van Sul-121, zichtbaar al seen sterke remming van de 
door LPS veroorzaakte neutrofiele ontsteking, een meer juiste verklaring geeft voor de 
beschermende werking van Sul-121 met betrekking tot luchtweghyperreactiviteit. Een link 
tussen neutrofiele ontsteking en luchtweghyperreactiviteit is inderdaad aangetoond in 
COPD patiënten. 
Een belangrijke factor voor de recruitering en activatie van neutrofiele ontstekingscellen 
is IL-8. In COPD patiënten en in diermodellen voor COPD is aangetoond dat verhoogde 
concentraties van IL-8 gecorreleerd zijn met toegenomen aantallen neutrofiele 
ontstekingscellen. Blootstelling aan sigarettenrook verhoogd de afgifte van IL-8 door 
ontstekingscellen en door verscheidende celtypes in de longen, waaronder luchtweggladde 
spiercellen. Middels in vitro studies tonen we nu aan dat Sul-121 een dosisafhankelijke 
remming geeft van de door sigarettenrook veroorzaakte afgifte van IL-8 afgifte door 
luchtweggladde spiercellen (Hoofdstuk 5 & 6), hetgeen het remmende effect van Sul-
121 op de neutrofiele ontsteking in het cavia model voor COPD zou kunnen verklaren 
(Hoofdstuk 6).
Aangezien de ontstekingsbevorderende transcriptiefactor NF-κB een belangrijke rol speelt 
in de productie van ontstekingsmediatoren, waaronder de door sigarettenrook veroorzaakte 
afgifte van IL-8 door luchtweggladde spiercellen, hebben we onderzocht of Sul-121 de 
werking van NF-κB remt. Nadat NF-κB geactiveerd is, migreert het p65 deel van NF-κB naar 
de celkern waar het de gentranscriptie reguleert. Sul-121 had een remmend effect op door 
sigarettenrook veroorzaakte activatie van NF-κB activation in luchtweggladde spiercellen, 
hetgeen zichtbaar was al seen afgenomen migratie van NF-κB naar de celkern (Hoofdstuk 6). 
Het beschermende effect van Sul-121 op de neutrofiele ontsteking in het cavia model voor 
COPD wordt waarschijnlijk dus veroorzaakt door een verminderde afgifte van IL-8 als gevolg 
van remming van NF-κB in celtypes als de luchtweggladde spieren (Figuur 1). 
Waterstofsulfide (H
2
S) is een gasvormige signaalmolecuul dat een belangrijke fysiologische 
rol speelt en derhalve interessant is voor de ontwikkeling van nieuwe medicijnen. Hogere 
serumconcentraties van H
2
S zijn gecorreleerd met een toename in lungfuctie en een 
afname in neutrofiele ontstekingscellen in longwassingen. H
2




werking op het ontstekingsproces in luchtwegziekten, waaronder astma en COPD. 
Sigarettenrook kan de e serumconcentraties van H
2
S verminderen, zowel in COPD patiënten 
die een exacerbatie ervaren als in gezonde personen. In Hoofdstuk 6 tonen we aan dat 
ook LPS in staat is om een verlaging van de serumconcentraties van H
2
S te veroorzaken. 
Tevens werd een correlatie waargenomen tussen verlaagde serumconcentraties van 
H
2
S en een toegenomen neutrofiele ontsteking in de longen. Sul-121 gaf echter geen 
significante verhoging van de H
2
S concentraties in het bloed. Oxidatieve stress afkomstig 
van door LPS geactiveerde neutrofiele ontstekingscellen kan H
2
S oxideren. Op basis hiervan 
speculeren we dat Sul-121 de peroxidatieve omzetting van H
2
S beïnvloedt door het proces 
van oxidatieve stress, die waarschijnljik door neutrofiele ontstekingscellen afkomstig is, te 
verlagen. De kleine veranderingen in H
2
S concentraties die we hebben waargenomen na 
Sul-121 behandeling zijn waarschijnlijk een indirect gevolg middels de remming van de 
neutrofiele ontsteking.
Oxidatieve stress speelt een central rol in de ontwikkeling van COPD. De resultaten 
beschreven in Hoofdstuk 6 geven aan dat Sul-121 een remming geeft van de ontsteking 
van de luchtwegen en de luchtweghyperreativiteit die veroorzaakt door zijn door LPS 
door het aanpakken van de oxidatieve stress. Sul-121 gaf inderdaad een verlaging van de 
cellulaire productie van oxidatieve stress die veroorzaakt was door PMA (Hoofdstuk 6). 
Naast een remming van de ontsteking en de hyperreactiviteit gaf Sul-121 ook een verlaging 
van de door LPS veroorzaakte stijging in de concentratie van MDA (malondialdehyde, 
Hoofdstuk 6), een product van peroxidatieve afbraak van poly-onverzadigde vetzuren. 
In vitro studies onderbouwen de antioxidante werking van Sul-121. Nrf2 (nuclear factor 
erythroid 2-related factor 2) is een factor werkzaam in de celkern die de cellulaire antioxidante 
respons reguleert. De Nrf2 activiteit is onderdrukt tijdens de rustfase door Keap1, hetgeen 
de migratie naar de celkern voorkomt. Onder condities van oxidatieve stress ontkoppelt 
Keap1 van Nrf2 waardoor Nrf2 naar de celkern kan migreren waar het de productie van 
antioxidante elementen induceert die de een verlichting van de oxidatieve stressrepons 
geven (Figuur 1). Onze celstudies in luchtweggladde spiercellen (Hoofdstuk 6) toonden 
aan dat sigarettenrook de migratie van Nrf2 naar de celkern verhoogt, hetgeen een 
verhoging van de oxidatieve stress geeft. Dit process werd significant geremd door Sul-121, 
hetgeen aangeeft dat Sul-121 inderdaad een verlaging kan geven van cellulaire oxidatieve 
stress veroorzaakt door sigarettenrook. 
Er zijn momenteel twee belangrijke strategieën om oxidatieve stress aan te pakken: (1) het 
gebruik van antioxidanten die rechtreeks de oxidatieve stress neutralizeren, en (2) stoffen 
die de lichaamseigen antioxidante mechanismen (zoals Nrf2) verhogen. We speculeren 
dat Sul-121 werkt door rechtstreeks de vorming van reactieve oxidatieve stoffen (ROS) 
te neutralizeren. Sul-121 veranderde niet de basale migratie van Nrf2 naar de celkern 
196
Nederlandse Samenvatting
(Hoofdstuk 6), maar verminderde de vorming van ROS veroorzaakt door sigarettenrook 
en door waterstofperoxide onder celvrije condities. ROS speelt een belangrijke rol in de 
pathofysiologie van longaandoeningen en behandeling met antioxidanten in diermodellen 
voor longziekten geven gunstige resultaten. Net als onze huidige studie beschreven in 
Hoofdstuk 6 remt de catalitische antioxidant AEOL 10150 (manganese (III) meso-tetrakis 
(N,N’-diethyl-1,3-imidazolium-2-yl) porphyrin) de neutrofiele ontsteking in de luchtwegen 
van ratten die blootgesteld zijn aan sigarettenrook. Een verbinding met selenium die 
lijkt op de lichaamseigen antioxidant glutathione peroxidase in ook in staat om door LPS 
















Figuur 1. In de rustfase wordt de activiteit van Nrf2 onderdrukt, doordat Keap1 de migratie van Nrf2 
naar de celkern voorkomt. Onder condities van oxidatieve stress ontkoppelt Keap1 van Nrf2, waardoor 
Nrf2 naar de celkern kan migreren. Nrf2 stimuleert vervolgens de transcriptie van antioxidanten die de 
oxidatieve stressrepons verminderen. NF-κB is een transcriptiefactor die uit twee subeenheden (p50 
en p65) bestaat en de transcriptie van diverse ontstekingsmechanismen bevordert. Van ROS is bekend 
dat ze in staat zijn om NF-κB te activeren, waardoor de subeenheid p65 naar de celkern migreert waar 
het de gentranscriptie van diverse ontstekingsmediatoren, waaronder IL-8 – een belangrijke stimulus 
voor neutrofiele ontstekingsprocessen. Sul-121 heeft antioxidante eigenschappen en rechtstreekse 




Oxidatieve stress is gelinked aan een afname in longfunctie en een toegenomen contractiele 
respons van zowel luchtweggladde spiercellen als. Oxidatieve stress is in staat om rechtstreeks 
de contractiekracht van luchtweggladde spiercellen te verhogen. Vandaar dat wij stellen dat 
de antioxidante werking van Sul-121 bijdraagt aan de waargenomen vermindering van de 
luchtweghyperreactiveit in vivo (Hoofdstuk 6). Tevens is oxidatieve stress een belangrijke 
reden voor de afgenomen effectiviteit van glucocorticosteroïden in COPD patiënten, een 
process dat steroïdresistentie wordt genoemd. ROS veroorzaken nitrosylatie and fosforylatie 
– en daardoor inactivatie - van histondeacetylase (HDAC)2, waardoor het effect van 
ontstekingsbevorderende transcriptiefactoren in de celkern minder wordt tegengegaan. 
Dit leidt tot een toename in de transcriptie van ontstekingsbevorderende genen. Het zou 
dus interessant zijn om in de toekomst te onderzoeken of Sul-121 middels zijn antioxidante 
werking in staat is om de steroidresistentie te breken. 
Een ander mechanism dat leidt tot een toename van het aantal neutrofiele ontstekingscellen 
in de luchtwegen in vivo is een vermindering van de epitheliale barrièrefunctie veroorzaakt 
door LPS. In vitro blootstelling aan sigarettenrook en peroxydatieve afbraak van vetzuren 
veroozaken ook een afname van de epitheliale barrièrefunctie. Wij vonden dat een toename 
in de concentratie van het peroxidatieve afbraak product van vetzuren, MDA, correleerde 
met een toename in neutrofiele ontstekingscellen in longwassingen van cavia’s die met 
LPS behandeld zijn (Hoofdstuk 6). Aangezien Sul-121 de MDA-concentraties verlaagt is 
onze hypothese dat Sul-121 een remming geeft van de door LPS veroorzaakte neutrofiele 
ontsteking middels het behouden van de epitheliale barrièrefunctie  door het verminderen 
van de oxidatieve stress. 
. 
Wetenschappelijke toekomstperspectieven 
COPD is wereldwijd de vierde doodsoorzaak en wordt gekenmerkt door een aanhoudende 
beperking van de luchtstroom die gepaard gaat met een toegenomen chronische 
ontstekingsreactie in de luchtwegen en de longen. De toediending van een combinatie 
van ontstekingsremmers en luchtwegverwijdende medicijnen wordt voorgesteld om 
zowel de ontsteking als de voortschrijdende beperking van de luchtstroom te behandelen. 
Het zou dus ideaal zijn voor de behandeling van COPD als een geneesmiddel zowel 
luchtwegverwijdende als ontstekingsremmende eigenschappen bezit. Gebaseerd op onze 
in vitro en in vivo studies tonen we nu aan dat Sul-121 deze beide gunstige eigenschappen 
in een verbinding combineert en dat Sul-121 derhalve een geheel nieuwe behandeling 
voor COPD zou kunnen vormen.
Oxidatieve stress speelt een belangrijke rol in de pathofysiologie van zowel COPD als 
astma. Ontstekingscellen in de luchtwegen van astmatici kunnen een overproductie 
van ROS initiëren die ontstekingsbevorderende transcriptiefactoren, zoals such as NF-κB, 
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kunnen activeren. NF-κB kan vervolgens de transcriptie van ontstekingsbevorderende 
ontstekingsfactoren, zoals IL-4, IL-6, IL-8, TNF-α, verhogen. Daarnaast verminderen ROS ook 
de barrièrefunctie in astma, hetgeen bijdraagt aan de toename van ontstekingscellen in de 
luchtwegen. ROS geven ook een verhoging van de contractie van luchtweggladde spieren 
en faciliteren de ontwikkeling van luchtweghyperreactiviteit. Aangezien Sul-121 zowel 
bronchusverwijdende en ontstekingsremmende eigenschappen bezit en de oxidatieve 
stress verlaagt (Hoofdstuk 5 & 6), verwachten we dat Sul-121 ook een gunstig effect kan 
hebben in de behandeling van astma. 
Twee belangrijke ROS molecule, superoxide anion and waterstofperoxide, worden met 
name geproduceerd door mitochondriën, welke in grote getalen gevonden worden in 
luchtweggladde spiercellen om deze van energie te voorzien die noodzakelijk is voor de 
gladde spiercontractie. Een ontregelde functie van mitochondriën can indirect leiden tot 
een verhoogde cellulaire ROS-productie en oxidatieve stress. Het interessante is dat AKAP1 
(ook bekend als AKAP121) sterk tot expressive komt in mitochondrion en erkent wordt al 
seen essentiële regulator van de mitochondriale werking door een complex te vormen met 
meerdere signaaleiwitten en derhalve PKA aan de buitenmembraan van de mitochondrion 
positioneert. Een studie toonde aan dat ontkoppeling van AKAP1 van de mitochondriën 
door zogenaamde synthetische P
mit
 peptiden een verhoging van de mitochondriale 
ROS productie geeft cardiomyocyten. Deze P
mit
 peptiden zijn de 15–21 of de 10–30 
aminozuurregionen van AKAP1 die een interactie aangaan met mitochondriën en induceren 
een proces van celdood in cardiomyocyten. Muizen die geen AKAP1 tot expressie brengen 
hebben opmerkelijke afwijkingen in de structuur van hun mitochondrion. Tevens hebben 
deze muizen een toegenomen ROS-productie in een muismodel voor een hartinfarct. 
Hoewel de exacte moleculaire signaalroutes die betrokken zijn bij deze overproductie 
van ROS door mitochondrion in deze AKAP1 deficiënte muizen niet bekend is, wordt door 
de auteurs van deze studie voorgesteld dat dit toe te schrijven is aan een verminderde 
activatie van PKA(complexen) aan de buitenmembraan van de mitochondriën. AKAP1 
wordt in vele weefsels en celtypen, waaronder luchtweggladde spiercellen, tot expressive 
gebracht. Vandaar dat wij vermoeden dat het herstel en/of stabilizatie van de interactie 
tussen AKAPs (zoals AKAP1) en PKA een effectieve manier is om oxidatieve stress aan te 
pakken in ziekten als COPD en astma. Het is interessant op te merken dat de stabiliteit van 
AKAP1 gecontroleerd lijkt te worden door een zogenaamd ubiquitine-proteasoomsysteem. 
Onder condities van lage zuurstofbeschikbaarheid (hypoxiaI) in de hersenen bind een 
E3-ubiquitine ligase aan AKAP1, waardoor deze snel afgebroken wordt in het ubiquitine-
proteasoomsysteem. Meerder studies hebben aangetoond dat milde tot matige oxidatieve 
stress de activiteit van dit ubiquitine-proteasoom system – en daarmee de afbraak van 
eiwitten – verhoogt. Wij stellen derhalve dat oxidatieve stress leidt tot de afbraak van AKAP1, 




121 de cellulaire oxidatieve stress kan verminderen door het rechtstreeks neutralizeren 
van ROS bears the property to reduce cellular oxidative stress by directly neutralizing ROS, 
speculeren wij dat Sul-121 een normale mitochondriale werking kan ondersteunen door 
het voorkomen van de afbraak van AKAP1 door oxidatieve stress.
Conclusies 
De belangrijkste conclusies van dit proefschrift zijn:
• Functionele interacties tussen AKAPs en PKA voorkomen de ontwikkeling van een 
hypercontractiel fenotype in luchtweggladde spieren door het remmen van de 
expressie van contractiele eiwitten, zoals α-SMA en calponine (Hoofdstuk 3)
• De regulatie van de expressie van α-SMA en calponine door interacties tussen AKAPs en 
PKA vindt plaats op het post-translationele niveau, waarschijnlijk in een eiwitcomplex 
met proteasomen (Hoofdstuk 3).
• Het verbreken van de interactie tussen AKAPs en PKA leidt tot een toename in markers 
voor een proliferatief fenotype in luchtweggladde spieren. Dit wordt waarschijnlijk 
veroorzaakt door een verlaging in de expressie van AKAP8 waarvan aangetoond is dat 
het de celcyclus reguleert (Hoofdstuk 3 en 4)
• Markers voor een hypercontractiel fenotype (zoals de hoeveelheid contractiele eiwitten) 
en markers voor een hyperproliferatief fenotype (zoals DNA synthese en eiwitten die 
betrokken zijn bij de celcyclus) kunnen gelijktijdig door een enkelvoudige stimulus 
geïnduceerd worden in luchtweggladde spieren (Hoofdstuk 3).
• Sul-90 en Sul-121 remmen de door sigarettenrook veroorzaakte afgifte van IL-8 door 
luchtweg gladdespiercellen en hebben dus een ontstekingsremmend effect in vitro 
(Hoordstuk 5).
• Sul-90 en Sul-121 zijn in staat om onafhankelijk van β
2
-adrenerge receptoren 
luchtweggladde spieren te laten relaxeren (Hoofdstuk 5 en 6).
• Gebasseerd op de resultaten van in vitro studies, is Sul-121 van de vier geteste Sul-
verbindingen de meest veelbelovende kandidaat voor de behandeling van COPD 
(Hoofdstuk 2 en 5).
• Sul-121 neutralizeert ROS die veroorzaakt is door LPS. Dit process gaat gepaard met een 
vermindering van de migratie van Nrf2 naar de celkern (Hoofdstuk 6).
• Sul-121 vermindert de activatie van NF-κB door het rechtstreeks aanpakken van de 
oxidatieve stress. Sul-121 voorkomt hierdoor de afgifte van IL-8 en de daaropvolgende 




• Behandeling met Sul-121 voorkomt de door LPS veroorzaakte luchtweghyperreactiviteit 
in een caviamodel voor COPD. Dit wordt niet veroorzaakt door de bronchusverwijdende 
eigenschappen van Sul-121, maar is zeer waarschijnlijk het gevolg van het remmende 
effect van Sul-121 op de door LPS-geïnduceerde ontsteking (Hoofdstuk 6)
• Vanwege de  combinatie van antioxidante, ontstekingsremmende en 
bronchusverwijdende eigenschappen vormt Sul-121 een mogelijk nieuwe vorm van 
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